Integer (ITGR) 10-K 3 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Jan. 02, 2015	Mar. 03, 2015	Jul. 03, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	GREATBATCH, INC.
Entity Central Index Key	1114483
Document Type	10-K
Document Period End Date	2-Jan-15
Amendment Flag	FALSE
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	-1
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$1,212
Entity Common Stock, Shares Outstanding		25,354,051

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jan. 02, 2015	Jan. 03, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$76,824	$35,465
Accounts receivable, net of allowance for doubtful accounts of $1.4 million in 2014 and $2.0 million in 2013	124,953	113,679
Inventories	129,242	118,358
Refundable income taxes	1,716	2,306
Deferred income taxes	6,168	6,008
Prepaid expenses and other current assets	11,780	6,717
Total current assets	350,683	282,533
Property, plant and equipment, net	144,925	145,773
Amortizing intangible assets, net	65,337	76,122
Indefinite-lived intangible assets	20,288	20,288
Goodwill	354,393	346,656
Deferred income taxes	2,626	2,933
Other assets	17,757	16,398
Total assets	956,009	890,703
Current liabilities:
Current portion of long-term debt	11,250	0
Accounts payable	46,436	46,508
Income taxes payable	2,003	0
Deferred income taxes	588	613
Accrued expenses	48,384	44,681
Total current liabilities	108,661	91,802
Long-term debt	176,250	197,500
Deferred income taxes	53,195	52,012
Other long-term liabilities	4,541	7,334
Total liabilities	342,647	348,648
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding in 2014 or 2013	0	0
Common stock, $0.001 par value, authorized 100,000,000 shares; 25,099,293 shares issued and 25,070,931 shares outstanding in 2014; 24,459,153 shares issued and 24,422,555 shares outstanding in 2013	25	24
Additional paid-in capital	366,073	344,915
Treasury stock, at cost, 28,362 shares in 2014 and 36,598 shares in 2013	-1,307	-1,232
Retained earnings	239,448	183,990
Accumulated other comprehensive income	9,123	14,358
Total stockholders’ equity	613,362	542,055
Total liabilities and stockholders’ equity	$956,009	$890,703

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jan. 02, 2015	Jan. 03, 2014
In Millions, except Share data, unless otherwise specified
Current assets:
Allowance for doubtful accounts	$1.40	$2
Stockholders’ equity:
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	25,099,293	24,459,153
Common stock, shares outstanding	25,070,931	24,422,555
Treasury stock, shares	28,362	36,598

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Income Statement [Abstract]
Sales	$687,787	$663,945	$646,177
Cost of sales	456,389	444,632	444,528
Gross profit	231,398	219,313	201,649
Operating expenses:
Selling, general and administrative expenses	90,602	88,107	80,992
Research, development and engineering costs, net	49,845	54,077	52,490
Other operating expenses, net	15,297	15,790	42,346
Total operating expenses	155,744	157,974	175,828
Operating income	75,654	61,339	25,821
Interest expense	4,252	11,261	18,054
(Gain) loss on cost and equity method investments, net	-4,370	694	106
Other (income) expense, net	-807	546	931
Income before provision for income taxes	76,579	48,838	6,730
Provision for income taxes	21,121	12,571	11,529
Net income (loss)	55,458	36,267	-4,799
Earnings (loss) per share:
Basic (in dollars per share)	$2.23	$1.51	($0.20)
Diluted (in dollars per share)	$2.14	$1.43	($0.20)
Weighted average shares outstanding:
Basic (in shares)	24,825	23,991	23,584
Diluted (in shares)	25,975	25,323	23,584
Comprehensive Income (Loss)
Net income (loss)	55,458	36,267	-4,799
Foreign currency translation gain (loss)	-3,502	1,521	1,905
Net change in cash flow hedges, net of tax	-1,359	-382	428
Defined benefit plan liability adjustment, net of tax	-374	272	1,685
Other comprehensive income (loss)	-5,235	1,411	4,018
Comprehensive income (loss)	$50,223	$37,678	($781)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Cash flows from operating activities:
Net income (loss)	$55,458	$36,267	($4,799)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	37,457	35,966	46,368
Debt related amortization included in interest expense	773	6,366	12,557
Stock-based compensation	13,186	14,101	10,904
(Gain) loss on cost and equity method investments, net	-4,370	694	106
Other non-cash (gains) losses, net	-3,214	255	10,788
Deferred income taxes	531	-29,856	5,733
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	-11,731	7,379	-18,834
Inventories	-6,726	-11,508	-7,481
Prepaid expenses and other assets	-3,281	-353	1,253
Accounts payable	-970	1,307	5,757
Accrued expenses	1,214	-1,176	1,459
Income taxes payable	2,949	-2,687	1,020
Net cash provided by operating activities	81,276	56,755	64,831
Cash flows from investing activities:
Proceeds from sale of orthopaedic product lines	2,655	4,746	0
Acquisition of property, plant and equipment	-24,823	-18,558	-41,069
Proceeds from sale (purchase) of cost and equity method investments, net	2,248	-3,732	-1,887
Acquisitions, net of cash acquired	-16,002	0	-17,224
Other investing activities, net	0	-740	393
Net cash used in investing activities	-35,922	-18,284	-59,787
Cash flows from financing activities:
Principal payments of long-term debt	-10,000	-458,282	-32,000
Proceeds from issuance of long-term debt	0	425,000	10,000
Issuance of common stock	8,278	12,807	1,263
Payment of debt issuance costs	0	-2,802	0
Other financing activities, net	-655	-81	-717
Net cash used in financing activities	-2,377	-23,358	-21,454
Effect of foreign currency exchange rates on cash and cash equivalents	-1,618	68	186
Net increase (decrease) in cash and cash equivalents	41,359	15,181	-16,224
Cash and cash equivalents, beginning of year	35,465	20,284	36,508
Cash and cash equivalents, end of year	$76,824	$35,465	$20,284

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
In Thousands, unless otherwise specified
Balance at Dec. 30, 2011	$467,283	$23	$307,196	($1,387)	$152,522	$8,929
Balance, shares at Dec. 30, 2011		23,466		-60
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	9,019		9,019
Net shares issued under stock incentive plans	687	0	663	24
Net shares issued under stock incentive plans, shares		103		1
Income tax liability from stock options, restricted stock and restricted stock units	-141		-141
Shares contributed to 401(k) Plan	4,793	1	3,881	911
Shares contributed to 401(k) Plan, shares		163		39
Net income (loss)	-4,799				-4,799
Total other comprehensive income (loss)	4,018					4,018
Balance at Dec. 28, 2012	480,860	24	320,618	-452	147,723	12,947
Balance, shares at Dec. 28, 2012		23,732		-20
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	9,333		9,333
Net shares issued under stock incentive plans	11,465	0	12,245	-780
Net shares issued under stock incentive plans, shares		636		-17
Income tax liability from stock options, restricted stock and restricted stock units	242		242
Shares contributed to 401(k) Plan	2,477	0	2,477	0
Shares contributed to 401(k) Plan, shares		91		0
Net income (loss)	36,267				36,267
Total other comprehensive income (loss)	1,411					1,411
Balance at Jan. 03, 2014	542,055	24	344,915	-1,232	183,990	14,358
Balance, shares at Jan. 03, 2014		24,459		-37
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	8,921		8,921
Net shares issued under stock incentive plans	3,465	1	7,754	-4,290
Net shares issued under stock incentive plans, shares		640		-86
Income tax liability from stock options, restricted stock and restricted stock units	4,357		4,357
Shares contributed to 401(k) Plan	4,341	0	126	4,215
Shares contributed to 401(k) Plan, shares		0		95
Net income (loss)	55,458				55,458
Total other comprehensive income (loss)	-5,235					-5,235
Balance at Jan. 02, 2015	$613,362	$25	$366,073	($1,307)	$239,448	$9,123
Balance, shares at Jan. 02, 2015		25,099		-28

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Jan. 02, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	1	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation – The consolidated financial statements include the accounts of Greatbatch, Inc. and its wholly owned subsidiary Greatbatch Ltd. (collectively, the “Company” or “Greatbatch”). All intercompany balances and transactions have been eliminated in consolidation.
	Nature of Operations – The Company has two reportable segments: Greatbatch Medical and QiG Group (“QiG”). Greatbatch Medical designs and manufactures products where Greatbatch either owns the intellectual property or has unique manufacturing and assembly expertise. These products include medical devices and components for the cardiac, neuromodulation, orthopaedics, portable medical, vascular and energy markets among others. The Greatbatch Medical segment also offers value-added assembly and design engineering services for medical devices that utilize its component products.
	QiG focuses on developing medical device systems for some of healthcare’s most pressing challenges and reflects Greatbatch’s strategic evolution of its product offerings in order to raise the growth and profitability profile of the Company. QiG utilizes a disciplined and diversified portfolio approach with three investor modes: new medical device systems commercialization, collaborative programs with original equipment manufacturers (“OEMs”) customers, and strategic equity positions in emerging healthcare companies.
	The Company’s customers include large multi-national OEMs and their affiliated subsidiaries.
	Fiscal Year End – The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. Fiscal years 2014, 2013 and 2012 ended on January 2, 2015, January 3, 2014 and December 28, 2012. Fiscal years 2014 and 2012 each contained fifty-two weeks, while fiscal year 2013 contained fifty-three weeks.
	Fair Value Measurements – Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. the “exit price”) in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:
	Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment.
	Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market.
	Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations.
	The availability of observable inputs can vary and is affected by a wide variety of factors, including, the type of asset/liability, whether the asset/liability is established in the marketplace, and other characteristics particular to the valuation. To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level input that is significant to the fair value measurement in its entirety.
	Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 18 “Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements.
	Cash and Cash Equivalents – Cash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less. The carrying amount of cash and cash equivalents approximated their fair value as of January 2, 2015 and January 3, 2014 based upon the short-term nature of these instruments.
	Concentration of Credit Risk – Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and/or accounts receivable are to four customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19 “Business Segment, Geographic and Concentration Risk Information” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks.
	Allowance for Doubtful Accounts – The Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains an allowance for those customer receivables that it does not expect to collect. The Company accrues its estimated losses from uncollectable accounts receivable to the allowance based upon recent historical experience, the length of time the receivable has been outstanding and other specific information as it becomes available. Provisions to the allowance for doubtful accounts are charged to current operating expenses. Actual losses are charged against this allowance when incurred. The carrying amount of trade receivables approximated their fair value as of January 2, 2015 based upon the short-term nature of these assets.
	Inventories – Inventories are stated at the lower of cost, determined using the first-in first-out method, or market. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held as well as estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory.
	Property, Plant and Equipment (“PP&E”) – PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 7-40 years; machinery and equipment 3-8 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, if less. The cost of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. Note 6 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&E.
	Business Combinations – The Company records its business combinations under the acquisition method of accounting. Under the acquisition method of accounting, the Company allocates the purchase price of each acquisition to the tangible and identifiable intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition. The fair value of identifiable intangible assets is based upon detailed valuations that use various assumptions made by management. Any excess of the purchase price over the fair value of net tangible and identifiable intangible assets acquired is allocated to goodwill. All direct acquisition-related costs are expensed as incurred.
	In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. The Company re-measures this liability each reporting period and records changes in the fair value through Other Operating Expenses, Net. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable contingent consideration. See Note 18 “Fair Value Measurements” and Note 2 “Acquisitions” for additional information on the Company’s contingent consideration and acquisitions, respectively.
	Amortizing Intangible Assets – Amortizing intangible assets consists primarily of purchased technology, patents and customer lists. The Company amortizes its definite-lived intangible assets over their estimated useful lives utilizing an accelerated or straight-line method of amortization, which approximates the projected cash flows used to fair value those intangible assets at the time of acquisition. When the straight-line method of amortization is utilized, the estimated useful life of the intangible asset is shortened to assure that recognition of amortization expense corresponds with the expected cash flows. The amortization period for the Company’s amortizing intangible assets are as follows: purchased technology and patents 5-15 years; customer lists 7-20 years and other intangible assets 1-10 years. See Note 7 “Intangible Assets” for additional information on the Company’s amortizing intangible assets.
	Impairment of Long-Lived Assets – The Company assesses the impairment of definite-lived long-lived assets or asset groups when events or changes in circumstances indicate that the carrying value may not be recoverable. Factors that are considered in deciding when to perform an impairment review include: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which a long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of a long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.
	Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives of assets are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives.
	Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples.
	The Company completed its annual goodwill impairment assessment for 2014 by performing a step zero qualitative analysis. As part of this analysis, the Company evaluated factors including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, share price fluctuations, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. After completing the analysis, the Company determined that it was more likely than not that its reporting units fair values are greater than the reporting units carrying values and the two-step impairment test is not necessary.
	Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach. Note 7 “Intangible Assets” contains additional information on the Company’s long-lived intangible assets.
	Other Long-Term Assets – Other long-term assets includes deferred financing fees incurred in connection with the Company’s issuance of its long-term debt. The fees relating to the Company’s Term Loan are amortized to Interest Expense using the effective interest method over the period from the date of issuance to the put option date (if applicable) or the maturity date, whichever is earlier. Fees relating to the Company’s Revolving Credit Facility are amortized to Interest Expense on a straight-line basis over the contractual term of the credit facility. The amortization of deferred fees is included in Debt Related Amortization Included in Interest Expense in the Consolidated Statements of Cash Flows. Note 9 “Debt” contains additional information on the Company’s deferred financing fees.
	Other long-term assets also include investments in equity securities of entities that are not publicly traded and which do not have readily determinable fair values. The Company accounts for investments in these entities under the cost or equity method depending on the type of ownership interest, as well as the Company’s ability to exercise influence over these entities. Equity method investments are initially recorded at cost, and are subsequently adjusted to reflect the Company’s share of earnings or losses of the investee. Cost method investments are recorded at cost. Each reporting period, management evaluates these cost and equity method investments to determine if there are any events or circumstances that are likely to have a significant effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to: a recent sale or offering of similar shares of the investment at a price below the Company’s cost basis; a significant deterioration in earnings performance; a significant change in the regulatory, economic or technological environment of the investee; or a significant doubt about an investee’s ability to continue as a going concern. If an impairment indicator is identified, management will estimate the fair value of the investment and compare it to its carrying value. The estimation of fair value considers all available financial information related to the investee, including, but not limited to, valuations based on recent third-party equity investments in the investee. If the fair value of the investment is less than its carrying value, the investment is impaired and a determination as to whether the impairment is other-than-temporary is made. Impairment is deemed to be other-than-temporary unless the Company has the ability and intent to hold the investment for a period sufficient for a market recovery up to the carrying value of the investment. Further, evidence must indicate that the carrying value of the investment is recoverable within a reasonable period. For other-than-temporary impairments, an impairment loss is recognized equal to the difference between the investment’s carrying value and its fair value. The Company has determined that these investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant.
	Income Taxes – The consolidated financial statements of the Company have been prepared using the asset and liability approach in accounting for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined that it is more likely than not that the asset will not be realized.
	The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for Income Taxes. Penalties, if incurred, are recognized as a component of Selling, General and Administrative Expenses (“SG&A”).
	The Company and its subsidiary file a consolidated U.S. federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates. See Note 14 “Income Taxes” for additional information.
	Convertible Subordinated Notes (“CSN”) – For convertible debt instruments that may be settled in cash upon conversion, the Company accounts for the liability and equity components of those instruments in a manner that will reflect the entity’s nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods.
	Upon issuance, the Company determined the carrying amount of the liability component of CSN by measuring the fair value of a similar liability that does not have the associated conversion option. The carrying amount of the conversion option was then determined by deducting the fair value of the liability component from the initial proceeds received from the issuance of CSN. The carrying amount of the conversion option was recorded in Additional Paid-In Capital with an offset to Long-Term Debt and was amortized using the effective interest method over the period from the date of issuance to the maturity date. The amortization of discount related to the Company’s convertible debt instruments is included in Debt Related Amortization Included in Interest Expense in the Consolidated Statements of Cash Flows. See Note 9 “Debt” for additional information.
	Derivative Financial Instruments – The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value. Changes in the fair value of derivative instruments are recorded in earnings unless hedge accounting criteria are met. The Company designates its interest rate swaps (See Note 9 “Debt”) and foreign currency contracts (See Note 15 “Commitments and Contingencies”) entered into as cash flow hedges. The effective portion of the changes in fair value of these cash flow hedges is recorded each period, net of tax, in Accumulated Other Comprehensive Income until the related hedged transaction occurs. Any ineffective portion of the changes in fair value of these cash flow hedges is recorded in earnings. In the event the hedged cash flow for forecasted transactions does not occur, or it becomes probable that they will not occur, the Company would reclassify the amount of any gain or loss on the related cash flow hedge to income (expense) at that time. Cash flows related to these derivative financial instruments are included in cash flows from operating activities.
	Revenue Recognition – The Company recognizes revenue when it is realized or realizable and earned. This occurs when persuasive evidence of an arrangement exists, delivery has occurred, the price is fixed or determinable (including any price concessions under long-term agreements), the buyer is obligated to pay us (i.e., not contingent on a future event), the risk of loss is transferred, there is no obligation of future performance, collectability is reasonably assured and the amount of future returns can reasonably be estimated. With regards to the Company’s customers (including distributors), those criteria are met at the time of shipment when title passes. Currently, the revenue recognition policy is the same for both Greatbatch Medical and QiG. In general, for customers with long-term contracts, we have negotiated fixed pricing arrangements. During new contract negotiations, price level decreases (concessions) for future sales may be offered to customers in exchange for volume and/or long-term commitments. Once the new contracts are signed, these prices are fixed and determinable for all future sales. The Company includes shipping and handling fees billed to customers in Sales. Shipping and handling costs associated with inbound and outbound freight are recorded in Cost of Sales. In certain instances the Company obtains component parts for sub-assemblies from its customers that are included in the final product sold back to the same customer. These amounts are excluded from Sales and Cost of Sales recognized by the Company. The cost of these customer supplied component parts amounted to $48.1 million, $45.3 million and $32.6 million in 2014, 2013 and 2012, respectively.
	Product Warranties – The Company allows customers to return defective or damaged products for credit, replacement, or exchange. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon recent historical experience and other specific information as it becomes available. Note 15 “Commitments and Contingencies” contains additional information on the Company’s product warranties.
	Research, Development and Engineering Costs, Net (“RD&E”) – RD&E costs are expensed as incurred. The primary costs are salary and benefits for personnel, material costs used in development projects and subcontracting costs. Cost reimbursements for engineering services from customers for whom the Company designs products are recorded as an offset to engineering costs upon achieving development milestones specified in the contracts. These reimbursements do not cover the complete cost of the development projects. Additionally, the technology developed under these cost reimbursement projects is owned by the Company and is utilized for future products developed for other customers.
	In-process research and development (“IPR&D”) represents research projects acquired in a business combination which are expected to generate cash flows but have not yet reached technological feasibility. The primary basis for determining the technological feasibility of these projects is whether or not regulatory approval has been obtained. The Company classifies IPR&D acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated projects. Upon completion, the Company would determine the useful life of the IPR&D and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, the remaining carrying amount of the associated IPR&D would be written-off. The Company tests the IPR&D acquired for impairment at least annually, and more frequently if events or changes in circumstances indicate that the assets may be impaired. The impairment test consists of a comparison of the fair value of the intangible assets with their carrying amount. If the carrying amount exceeds its fair value, the Company would record an impairment loss in an amount equal to the excess.
	Note 12 “Research, Development and Engineering Costs, Net” contains additional information on the Company’s RD&E activities.
	Stock-Based Compensation – The Company records compensation costs related to stock-based awards granted to employees based upon their estimated fair value on the grant date. Compensation cost for service-based awards is recognized ratably over the applicable vesting period. Compensation cost for nonmarket-based performance awards is reassessed each period and recognized based upon the probability that the performance targets will be achieved. Compensation cost for market-based performance awards is expensed ratably over the applicable vesting period and is recognized each period whether the performance metrics are achieved or not.
	The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options granted. For service-based and nonmarket-based performance restricted stock and restricted stock unit awards, the fair market value of the award is determined based upon the closing value of the Company’s stock price on the grant date. For market-based performance restricted stock unit awards, the fair market value of the award is determined utilizing a Monte Carlo simulation model, which projects the value of the Company’s stock under numerous scenarios and determines the value of the award based upon the present value of those projected outcomes.
	The amount of stock-based compensation expense recognized is based on the portion of the awards that are ultimately expected to vest. The Company estimates pre-vesting forfeitures at the time of grant by analyzing historical data and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The total expense recognized over the vesting period will only be for those awards that ultimately vest, excluding market and nonmarket performance award considerations. Note 11 “Stock-Based Compensation” contains additional information on the Company’s stock-based compensation.
	Foreign Currency Translation – The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translates income and expenses at the average exchange rates in effect during the period. The net effect of this translation is recorded in the consolidated financial statements as Accumulated Other Comprehensive Income. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in the Company’s foreign subsidiaries.
	Net foreign currency transaction gains and losses are included in Other (Income) Expense, Net and amounted to a gain of $1.3 million for 2014, a loss of $0.1 million for 2013 and a loss of $0.3 million for 2012.
	Defined Benefit Plans – The Company recognizes in its balance sheet as an asset or liability the overfunded or underfunded status of its defined benefit plans provided to its employees located in Mexico, Switzerland and France. This asset or liability is measured as the difference between the fair value of plan assets and the benefit obligation of those plans. For these plans, the benefit obligation is the projected benefit obligation, which is calculated based on actuarial computations of current and future benefits for employees. Actuarial gains or losses and prior service costs or credits that arise during the period, but are not included as components of net periodic benefit expense, are recognized as a component of Accumulated Other Comprehensive Income. Defined benefit expenses are charged to Cost of Sales, SG&A and RD&E expenses as applicable. Note 10 “Benefit Plans” contains additional information on these costs.
	Earnings (Loss) Per Share (“EPS”) – Basic EPS is calculated by dividing Net Income (Loss) by the weighted average number of shares outstanding during the period. Diluted EPS is calculated by adjusting the weighted average number of shares outstanding for potential common shares, which consist of stock options, unvested restricted stock and restricted stock units and, if applicable, contingently convertible instruments such as convertible debt. Note 16 “Earnings (Loss) Per Share” contains additional information on the computation of the Company’s EPS.
	Comprehensive Income (Loss) – The Company’s comprehensive income (loss) as reported in the Consolidated Statements of Operations and Comprehensive Income (Loss) includes net income (loss), foreign currency translation adjustments, the net change in cash flow hedges, and defined benefit plan liability adjustments. The Consolidated Statements of Operations and Comprehensive Income (Loss) and Note 17 “Accumulated Other Comprehensive Income” contains additional information on the computation of the Company’s comprehensive income (loss).
	Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting period. Actual results could differ materially from those estimates.
	Recently Issued Accounting Pronouncements – In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements.
	In November 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-17, “Business Combinations (Topic 805): Pushdown Accounting (a Consensus of the FASB Emerging Issues Task Force).” The amendments in this ASU provide an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. The amendments in this ASU are effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. This ASU did not impact the Company’s Consolidated Financial Statements.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract and recognizing revenue when the entity satisfies the performance obligations. This ASU supersedes existing revenue recognition guidance and is effective for annual reporting periods beginning after December 15, 2016 with early application not permitted. This ASU allows two methods of adoption; a full retrospective approach where three years of financial information are presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. The Company is currently assessing the financial impact of adopting the new standard and the methods of adoption; however, given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected.
	In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” which amends the definition of a discontinued operation and requires entities to provide additional disclosures about disposal transactions that do not meet the discontinued operations criteria. The revised guidance changes how entities identify and disclose information about disposal transactions under U.S. GAAP. This ASU is effective prospectively for all disposals (except disposals classified as held for sale before the adoption date) or components initially classified as held for sale in periods beginning on or after December 15, 2014, with early adoption permitted. This ASU will be applicable for disposal transactions, if any, that the Company enters into after the adoption date.
	In July 2013, the FASB issued ASU No. 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This ASU requires that entities present an unrecognized tax benefit, or portion of an unrecognized tax benefit, as a reduction to a deferred tax asset in the financial statements for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions. This ASU was adopted during the first quarter of 2014 and did not impact the Company’s Consolidated Financial Statements as the Company does not have any net operating loss carryforward deferred tax assets that are eligible to be reduced by an unrecognized tax benefit as required by the ASU.

Acquisitions

Acquisitions	12 Months Ended
	Jan. 02, 2015
Business Combinations [Abstract]
ACQUISITIONS
	2		ACQUISITIONS
	Centro de Construcción de Cardioestimuladores del Uruguay
	On August 12, 2014 the Company purchased all of the outstanding common stock of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”), headquartered in Montevideo, Uruguay. CCC is an active implantable neuromodulation medical device systems developer and manufacturer that produces a range of medical devices including implantable pulse generators, programmer systems, battery chargers, patient wands and leads. This acquisition allows the Company to more broadly partner with medical device companies, complements the Company’s core discrete technology offerings and enhances the Company’s medical device innovation efforts.
	This transaction was accounted for under the acquisition method of accounting. Accordingly, the operating results of CCC have been included in the Company’s QiG segment from the date of acquisition. For 2014, CCC added approximately $5.8 million to the Company’s revenue and increased the Company’s net income by $1.2 million. The aggregate purchase price of $19.8 million was funded with cash on hand.
	The cost of the acquisition was preliminarily allocated to the assets acquired and liabilities assumed from CCC based on their fair values as of the closing date of the acquisition, with the amount exceeding the fair value of the net assets acquired being recorded as goodwill. The value assigned to certain assets and liabilities are preliminary and are subject to adjustment as additional information is obtained, including, but not limited to, the finalization of pre-acquisition tax positions. The valuation is expected to be finalized in 2015. When the valuation is finalized, any changes to the preliminary valuation of assets acquired or liabilities assumed may result in material adjustments to the fair value of the intangible assets acquired, as well as goodwill.
	The following table summarizes the preliminary allocation of the CCC purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):
	Assets acquired
	Current assets	$	10,670
	Property, plant and equipment	1,131
	Amortizing intangible assets	6,100
	Goodwill	8,296
	Total assets acquired	26,197
	Liabilities assumed
	Current liabilities	4,842
	Deferred income taxes	1,590
	Total liabilities assumed	6,432
	Net assets acquired	$	19,765
	The preliminary fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations.
	The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions.
	Current assets and liabilities – The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities.
	The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the market approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $0.3 million.
	Intangible assets – The purchase price was allocated to intangible assets as follows (dollars in thousands):
	Amortizing Intangible Assets		Fair			Weighted		Weighted
			Value			Average		Average
			Assigned			Amortization		Discount
						Period (Years)		Rate
	Technology		$	1,400		10		18%
	Customer lists		4,600			10		18%
	Trademarks and tradenames		100			2		18%
			$	6,100		10		18%
	Technology – Technology consists of technical processes, unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by CCC and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate of 3%. The weighted average amortization period of the technology is based upon management’s estimate of the product life cycle associated with technology before they will be replaced by new technologies.
	Customer lists – Customer lists represent the estimated fair value of non-contractual customer relationships CCC has as of the acquisition date. The primary customers of CCC include medical device companies in various geographic locations around the world. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The weighted average amortization period of the existing customer base was based upon the historical customer annual attrition rate of 15%, as well as management’s understanding of the industry and product life cycles.
	Trademarks and tradenames – Trademarks and tradenames represent the estimated fair value of corporate and product names acquired from CCC. These tradenames were valued separately from goodwill at the amount that an independent third party would be willing to pay for use of these names. The fair value of the trademarks and tradenames was determined by utilizing the relief from royalty method, a form of the income approach, with a 0.5% royalty rate.
	Goodwill – The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including: the value of CCC’s highly trained assembled work force and management team; the incremental value that CCC’s technology will bring to QiG’s medical devices; and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the CCC acquisition was allocated to the QiG business segment and is not deductible for tax purposes.
	NeuroNexus Technologies, Inc.
	On February 16, 2012, the Company purchased all of the outstanding common stock of NeuroNexus Technologies, Inc. (“NeuroNexus”) headquartered in Ann Arbor, MI. NeuroNexus is an active implantable medical device design firm specializing in developing and commercializing neural interface technology, components and systems for neuroscience and clinical markets. NeuroNexus has an extensive intellectual property portfolio, core technologies and capabilities to support the development and manufacturing of neural interface devices across a wide range of applications including neuromodulation, sensing, optical stimulation and targeted drug delivery.
	This transaction was accounted for under the acquisition method of accounting. Accordingly, the operating results of NeuroNexus have been included in the Company’s QiG segment from the date of acquisition. For 2012, NeuroNexus added approximately $2.5 million to the Company’s revenue and decreased the Company’s net loss by $0.2 million. The purchase price of NeuroNexus consisted of cash payments of $11.7 million and potential future payments of up to an additional $2 million. These future payments were contingent upon the achievement of certain financial and development-based milestones and had an estimated fair value of $1.5 million as of the acquisition date.
	The cost of the acquisition was allocated to the assets acquired and liabilities assumed from NeuroNexus based on their fair values as of the close of the acquisition, with the amount exceeding the fair value of the net assets acquired being recorded as goodwill. The valuation of the assets acquired and liabilities assumed from NeuroNexus was finalized during 2013 and did not result in a material adjustment to the original valuation of net assets acquired, including goodwill and therefore was not reflected as a retrospective adjustment of the historical financial statements.
	The following table summarizes the allocation of the NeuroNexus purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):
	Assets acquired
	Current assets	$	618
	Property, plant and equipment	35
	Amortizing intangible assets	2,927
	Indefinite-lived intangible assets	540
	Goodwill	8,924
	Other assets	1,576
	Total assets acquired	14,620
	Liabilities assumed
	Current liabilities	420
	Deferred income taxes	989
	Total liabilities assumed	1,409
	Net assets acquired	$	13,211
	The fair values of the assets acquired were determined using one of three valuation approaches: market, income and cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations.
	Current assets and liabilities – The fair value of current assets and liabilities was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities.
	Intangible assets – The purchase price was allocated to identifiable intangible assets as follows (dollars in thousands):
		Fair			Weighted		Estimated		Weighted
		Value			Average		Useful		Average
		Assigned			Amortization		Life (Years)		Discount
					Period (Years)				Rate
	Amortizing Intangible Assets
	Technology and patents	$	1,058		6		10		14	%
	Customer lists	1,869			7		15		13	%
		$	2,927		7		13		13	%
Indefinite-lived Intangible Assets
In-process research and development	$	540		N/A		12		26	%
The weighted average amortization period is less than the estimated useful life due to the Company using an accelerated amortization method, which approximates the projected cash flows used to determine the fair value of those intangible assets.
Technology and patents – Technology and patents consists of technical processes, patented and unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by NeuroNexus and that will be leveraged in current and future products. The fair value of technology and patents acquired was determined utilizing the relief from royalty method, a form of the income approach, with royalty rates that ranged from 2% to 6%. The estimated useful life of the technology and patents is based upon management’s estimate of the product life cycle associated with technology and patents before they will be replaced by new technologies.
Customer lists – Customer lists represent the estimated fair value of non-contractual customer relationships NeuroNexus has as of the acquisition date. The primary customers of NeuroNexus include numerous scientists and researchers from various geographic locations around the world. These relationships were valued separately from goodwill at the amount which an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The estimated useful life of the existing customer list was based upon historical customer attrition as well as management’s understanding of the industry and product life cycles.
IPR&D – IPR&D represents research projects which are expected to generate cash flows but have not yet reached technological feasibility. The Company used the income approach to determine the fair value of the IPR&D acquired. In arriving at the value of the IPR&D, management considered, among other factors: the projects’ stage of completion; the complexity of the work to be completed as of the acquisition date; the projected costs to complete the projects; the contribution of other acquired assets; and the estimated useful life of the technology. The Company applied a market-participant risk-adjusted discount rate to arrive at a present value as of the date of acquisition. The value assigned to IPR&D related to the development of micro-electrodes for deep brain mapping and electrocorticography. For purposes of valuing the IPR&D, the Company estimated total costs to complete the projects to be approximately $1.5 million.
Goodwill – The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including: the value of NeuroNexus’s highly trained assembled work force and management team; the incremental value that NeuroNexus’s technology will bring to the Company’s neuromodulation platform currently in development; and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the NeuroNexus acquisition was allocated to the QiG business segment and is not deductible for tax purposes.
Pro Forma Results (Unaudited) – The following unaudited pro forma information presents the consolidated results of operations of the Company, CCC, and NeuroNexus as if those acquisitions occurred as of the beginning of fiscal years 2013 (CCC) and 2011 (NeuroNexus) (in thousands, except per share amounts):
	Year Ended
	January 2,			January 3,				December 28,
	2015			2014				2012
Sales	$	696,357		$	677,657			$	646,617
Net income (loss)	56,453			37,612				(4,973		)
Earnings (loss) per share:
Basic	$	2.27		$	1.57			$	(0.21	)
Diluted	$	2.17		$	1.49			$	(0.21	)
The unaudited pro forma information presents the combined operating results of Greatbatch, CCC, and NeuroNexus, with the results prior to the acquisition date adjusted to include the pro forma impact of the amortization of acquired intangible assets, the adjustment to interest expense reflecting the amount borrowed in connection with the acquisitions at Greatbatch’s interest rate, and the impact of income taxes on the pro forma adjustments utilizing the applicable statutory tax rate. The unaudited pro forma consolidated basic and diluted earnings (loss) per share calculations are based on the consolidated basic and diluted weighted average shares of Greatbatch. The unaudited pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings, and any related integration costs. Certain costs savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These pro forma results do not purport to be indicative of the results that would have been obtained, or to be a projection of results that may be obtained in the future.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	12 Months Ended
	Jan. 02, 2015
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION
	3		SUPPLEMENTAL CASH FLOW INFORMATION
		Year Ended
		January 2,		January 3,		December 28,
		2015		2014		2012
	(in thousands)
	Noncash investing and financing activities:
	Common stock contributed to 401(k) Plan	$	4,341	$	2,477	$	4,793
	Property, plant and equipment purchases included in accounts payable	2,926		2,103		2,522
	Cash paid during the year for:
	Interest	3,521		4,989		6,230
	Income taxes	13,565		44,165		4,909
	Acquisition of noncash assets	22,434		—		14,396
	Liabilities assumed	6,432		—		1,244

Inventories

Inventories	12 Months Ended
	Jan. 02, 2015
Inventory Disclosure [Abstract]
INVENTORIES
	4		INVENTORIES
	Inventories are comprised of the following (in thousands):
		At
		January 2,		January 3,
		2015		2014
	Raw materials	$	73,354	$	67,939
	Work-in-process	38,930		36,670
	Finished goods	16,958		13,749
	Total	$	129,242	$	118,358

Assets_Held_For_Sale

Assets Held For Sale	12 Months Ended
	Jan. 02, 2015
Discontinued Operations and Disposal Groups [Abstract]
ASSETS HELD FOR SALE
	5	ASSETS HELD FOR SALE
	Assets held for sale included in Prepaid Expenses and Other Current Assets, is comprised of the following (in thousands):
			At
	Asset	Business	January 2,		January 3,
		Segment	2015		2014
	Building and building improvements	Greatbatch Medical	$	1,635	$	—
	During 2014, the Company transferred $2.1 million of assets relating to the Company’s Orvin, Switzerland property to held for sale and recognized a $0.4 million impairment charge that was recorded in Other Operating Expenses, Net. See Note 13 “Other Operating Expenses, Net,” for additional information regarding this transaction and Note 18 “Fair Value Measurements,” for information regarding the fair value of the assets.

Property_Plant_and_Equipment_N

Property, Plant and Equipment, Net	12 Months Ended
	Jan. 02, 2015
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET
	6		PROPERTY, PLANT AND EQUIPMENT, NET
	Property, plant and equipment are comprised of the following (in thousands):
		At
		January 2,			January 3,
		2015			2014
	Manufacturing machinery and equipment	$	167,173		$	159,542
	Buildings and building improvements	89,258			87,359
	Information technology hardware and software	31,725			28,010
	Leasehold improvements	31,170			31,522
	Furniture and fixtures	14,045			13,889
	Land and land improvements	10,816			13,016
	Construction work in process	14,129			7,886
	Other	629			633
		358,945			341,857
	Accumulated depreciation	(214,020		)	(196,084		)
	Total	$	144,925		$	145,773
	Depreciation expense for property, plant and equipment was as follows (in thousands):
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	Depreciation expense	$	23,320		$	22,799		$	31,575
	Construction work in process at January 2, 2015 primarily relates to the Company’s 2014 investment in capacity and capabilities initiative. See Note 13 “Other Operating Expenses, Net” for a description of the Company’s significant capital investment projects. Construction work in process at January 3, 2014 primarily relates to routine purchases of machinery, equipment, and information technology assets to support normal recurring operations.

Intangible_Assets

Intangible Assets	12 Months Ended
	Jan. 02, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS
	7		INTANGIBLE ASSETS
	Amortizing intangible assets, net are comprised of the following (in thousands):
		Gross			Accumulated			Foreign			Net
		Carrying			Amortization			Currency			Carrying
		Amount						Translation			Amount
	At January 2, 2015
	Purchased technology and patents	$	95,776		$	(75,894	)	$	1,966		$	21,848
	Customer lists	72,857			(31,460		)	1,374			42,771
	Other	4,534			(4,619		)	803			718
	Total amortizing intangible assets	$	173,167		$	(111,973	)	$	4,143		$	65,337
	At January 3, 2014
	Purchased technology and patents	$	97,376		$	(69,026	)	$	1,980		$	30,330
	Customer lists	68,257			(24,671		)	1,367			44,953
	Other	4,434			(4,399		)	804			839
	Total amortizing intangible assets	$	170,067		$	(98,096	)	$	4,151		$	76,122
	Aggregate intangible asset amortization expense is comprised of the following (in thousands):
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	Cost of sales	$	6,201		$	6,822		$	7,489
	SG&A	7,009			5,800			6,227
	RD&E	667			545			545
	Total intangible asset amortization expense	$	13,877		$	13,167		$	14,261
	Estimated future intangible asset amortization expense based upon the current carrying value is as follows (in thousands):
		Estimated
		Amortization
		Expense
	2015	$	12,988
	2016	10,676
	2017	9,520
	2018	7,232
	2019	5,431
	Thereafter	19,490
	Total estimated amortization expense	$	65,337
	As of January 3, 2014, the Company had recorded in Other Long-Term Liabilities $4.0 million of contingent liabilities incurred in connection with technology purchases made in previous years. During 2014, the Company reversed $3.0 million of these contingent liabilities as a result of certain performance targets not being achieved, which reduced the technology asset recorded at the time of the asset purchase.
	The change in indefinite-lived assets during 2014 is as follows (in thousands)
		Trademarks
		and
		Tradenames
	At January 3, 2014	$	20,288
	At January 2, 2015	$	20,288
	The change in goodwill during 2014 is as follows (in thousands):
		Greatbatch			QiG			Total
		Medical
	At January 3, 2014	$	304,856		$	41,800		$	346,656
	Goodwill acquired (Note 2)	—			8,296			8,296
	Foreign currency translation	(559		)	—			(559		)
	At January 2, 2015	$	304,297		$	50,096		$	354,393
	As of January 2, 2015, no accumulated impairment loss has been recognized for the goodwill allocated to the Company’s Greatbatch Medical or QiG segments.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Jan. 02, 2015
Accounts Payable and Accrued Liabilities [Abstract]
ACCRUED EXPENSES
	8		ACCRUED EXPENSES
	Accrued expenses are comprised of the following (in thousands):
		At
		January 2,		January 3,
		2015		2014
	Salaries and benefits	$	20,770	$	16,311
	Profit sharing and bonuses	18,524		19,808
	Warranty	660		1,819
	Other	8,430		6,743
	Total	$	48,384	$	44,681

Debt

Debt	12 Months Ended
	Jan. 02, 2015
Debt Disclosure [Abstract]
DEBT
	9		DEBT
	Long-term debt is comprised of the following (in thousands):
		At
		January 2,				3-Jan-14
		2015
	Variable rate term loan	$	187,500			$	197,500
	Revolving line of credit	—				—
	Total debt	187,500				197,500
	Less current portion of long-term debt	11,250				—
	Total long-term debt	$	176,250			$	197,500
	Credit Facility – In September 2013, the Company amended and extended its credit facility (the “Credit Facility”). The Credit Facility provides a $300 million revolving credit facility (the “Revolving Credit Facility”), a $200 million term loan (the “Term Loan”), a $15 million letter of credit subfacility, and a $15 million swingline subfacility. The Revolving Credit Facility can be increased by $200 million upon the Company’s request and approval by the lenders. The Revolving Credit Facility has a maturity date of September 20, 2018, which may be extended to September 20, 2019 upon notice by the Company and subject to certain conditions. The principal of the Term Loan is payable in quarterly installments as specified in the Credit Facility until its maturity date of September 20, 2019 when the unpaid balance is due in full.
	The Credit Facility is secured by the Company’s non-realty assets including cash, accounts receivable and inventories. Interest rates on the Revolving Credit Facility and Term Loan are, at the Company’s option either at: (i) the prime rate plus the applicable margin, which ranges between 0.0% and 0.75%, based on the Company’s total leverage ratio or (ii) the applicable LIBOR rate plus the applicable margin, which ranges between 1.375% and 2.75%, based on the Company’s total leverage ratio. Loans under the swingline subfacility will bear interest at the prime rate plus the applicable margin, which ranges between 0.0% and 0.75%, based on the Company’s total leverage ratio. The Company is also required to pay a commitment fee, which varies between 0.175% and 0.25% depending on the Company’s total leverage ratio.
	The Credit Facility contains limitations on the incurrence of indebtedness, liens and licensing of intellectual property, investments and certain payments. The Credit Facility permits the Company to engage in the following activities up to an aggregate amount of $300 million: 1) permitted acquisitions in the aggregate not to exceed $250 million; 2) other investments in the aggregate not to exceed $100 million; 3) stock repurchases and dividends not to exceed $150 million in the aggregate; and 4) investments in foreign subsidiaries not to exceed $20 million in the aggregate. At any time that the total leverage ratio of the Company for the two most recently ended fiscal quarters is less than 2.75 to 1.0, the Company may make an election to reset each of the amounts specified above. Additionally, these limitations can be waived upon the Company’s request and approval of a majority of the lenders. As of January 2, 2015, the Company had available to it 100% of the above limits except for the aggregate limit, acquisitions limit, and other investments limit which are now $277 million, $230 million, and $97 million, respectively.
	The Credit Facility requires the Company to maintain a rolling four quarter ratio of adjusted EBITDA to interest expense of at least 3.0 to 1.0, and a total leverage ratio of not greater than 4.5 to 1.0 decreasing to not greater than 4.25 to 1.0 after January 2, 2016. The calculation of adjusted EBITDA and total leverage ratio excludes non-cash charges, extraordinary, unusual, or non-recurring expenses or losses, non-cash stock-based compensation, and non-recurring expenses or charges incurred in connection with permitted acquisitions. As of January 2, 2015, the Company was in compliance with all covenants under the Credit Facility.
	The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable.
	As of January 2, 2015, the weighted average interest rate on borrowings under the Credit Facility, which does not take into account the impact of the Company’s interest rate swap, was 1.57%. As of January 2, 2015, the Company had $300 million of borrowing capacity available under the Credit Facility. This borrowing capacity may vary from period to period based upon the debt and EBITDA levels of the Company, which impacts the covenant calculations described above.
	Interest Rate Swaps – From time to time, the Company enters into interest rate swap agreements in order to hedge against potential changes in cash flows on the outstanding borrowings on the Credit Facility. The variable rate received on the interest rate swaps and the variable rate paid on the debt have the same rate of interest, excluding the credit spread, indexed to the one-month LIBOR rate and reset and pay interest on the same date. During 2012, the Company entered into a three-year $150 million interest rate swap, which amortizes $50 million per year. During 2014, the Company entered into an additional interest rate swap. The first $45 million of notional amount of the swap is effective February 20, 2015 and the second $45 million of notional amount is effective February 22, 2016. The notional amount of the swap amortizes $10 million per year beginning on February 21, 2017 with the remaining settled on the termination date of the swap agreement on September 20, 2019. These swaps are being accounted for as cash flow hedges.
	Information regarding the Company’s outstanding interest rate swaps as of January 2, 2015 is as follows (dollars in thousands):
	Instrument		Type of		Notional			Start		End	Pay		Current		Fair			Balance
			Hedge		Amount			Date		Date	Fixed		Receive		Value			Sheet Location
											Rate		Floating		2-Jan-15
													Rate
	Interest rate swap		Cash flow		$	100,000		13-Feb		16-Feb	0.573	%	0.155	%	$	(125	)	Other Long-Term Liabilities
	Interest rate swap		Cash flow		$	90,000		15-Feb		19-Sep	1.921	%	N/A		$	(865	)	Other Long-Term Liabilities
	The estimated fair value of the interest rate swap agreements represents the amount the Company expects to receive (pay) to terminate the contract. No portion of the change in fair value of the Company’s interest rate swaps during 2014, 2013, or 2012 was considered ineffective. The amount recorded as Interest Expense during 2014, 2013, and 2012 related to the Company’s interest rate swaps was $0.5 million, $0.5 million and $0.0 million, respectively.
	The expected future minimum principal payments under the Credit Facility as of January 2, 2015 are as follows (in thousands):
	2015	$	11,250
	2016	16,250
	2017	20,000
	2018	20,000
	2019	120,000
	Total	187,500
	Convertible Subordinated Notes – In March 2007, the Company issued $197.8 million of CSN at a 5% discount. CSN accrued interest at 2.25% per annum. The effective interest rate of CSN, which took into consideration the amortization of the discount and deferred fees related to the issuance of these notes, was 8.5%. On February 20, 2013, the Company redeemed all outstanding CSN. The contractual interest and discount amortization for CSN were as follows (in thousands):
		Year Ended
		January 2,				January 3,			December 28,
		2015				2014			2012
	Contractual interest	$	—			$	634		$	4,450
	Discount amortization	—				5,368			11,464
	Deferred Financing Fees - The change in deferred financing fees is as follows (in thousands):
	At December 28, 2012	$	2,056
	Financing costs deferred	2,802
	Write-off during the period	(156		)
	Amortization during the period	(842		)
	At January 3, 2014	3,860
	Amortization during the period	(773		)
	At January 2, 2015	$	3,087

Benefit_Plans

Benefit Plans	12 Months Ended
	Jan. 02, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
BENEFIT PLANS
	10		BENEFIT PLANS
	Savings Plan – The Company sponsors a defined contribution 401(k) plan, for its U.S. based employees. The plan provides for the deferral of employee compensation under Section 401(k) and a discretionary Company match. In 2014, 2013, and 2012, this match was 35% per dollar of participant deferral, up to 6% of the total compensation for each participant. Net costs related to this defined contribution plan were $2.2 million in 2014 and $2.0 million in 2013 and 2012.
	In addition to the above, under the terms of the 401(k) plan document there is an annual discretionary defined contribution of up to 4% of each employee’s eligible compensation based upon the achievement of certain performance targets. This amount is contributed to the 401(k) plan in the form of Company stock. Compensation cost recognized related to the defined contribution plan was $4.2 million, $4.8 million, $1.9 million in 2014, 2013, and 2012, respectively. As of January 2, 2015, the 401(k) Plan held 602,604 shares of Company stock.
	Education Assistance Program – The Company reimburses tuition, textbooks and laboratory fees for college or other job related programs for all of its U.S. based employees. The Company also reimburses college tuition for the dependent children of certain full-time U.S. based employees hired prior to 2012, which vests on a straight-line basis over ten years, up to the applicable local state university tuition rate. For certain employees and executives, the dependent children benefit is not limited. Minimum academic achievement is required in order to receive reimbursement under both programs. Aggregate expenses under the programs were $1.9 million, $2.0 million, and $2.2 million in 2014, 2013 and 2012, respectively.
	Defined Benefit Plans – The Company is required to provide its employees located in Switzerland, Mexico, and France certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico and France are unfunded and noncontributory. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees.
	During 2012, the Company transferred most major functions performed at its facilities in Switzerland into other existing facilities. As a result, the Company curtailed its defined benefit plan provided to employees at those Swiss facilities during 2012. In accordance with ASC 715, this gain was recognized in Other Operating Expenses, Net as the related employees were terminated. Since Swiss plan assets were sufficient to cover all plan liabilities, during 2012 the plan assets were transferred into cash. During 2013, the plan assets that remained after settlement payments were made were transferred to an AA- rated insurance carrier who bears the pension risk and longevity risk, and will be used to cover the pension liability for the remaining retirees of the Swiss plan, as well as the remaining employees at that location.
	Information relating to the funding position of the Company’s defined benefit plans as of the plans measurement date of January 2, 2015 and January 3, 2014 were as follows (in thousands):
		Year Ended
		January 2,				January 3,
		2015				2014
	Change in projected benefit obligation:
	Projected benefit obligation at beginning of year	$	2,422			$	16,215
	Service cost	203				236
	Interest cost	75				138
	Prior service cost and plan amendments	—				(45		)
	Plan participants’ contribution	36				134
	Actuarial (gain) loss	630				(2		)
	Benefits transferred in, net	155				434
	Settlement/curtailment gain	(337		)		(14,539		)
	Foreign currency translation	(341		)		(149		)
	Projected benefit obligation at end of year	2,843				2,422
	Change in fair value of plan assets:
	Fair value of plan assets at beginning of year	731				12,269
	Employer contributions (refund)	(39		)		150
	Plan participants’ contributions	36				134
	Actual loss on plan assets	(101		)		(26		)
	Benefits transferred in, net	198				138
	Settlements	(337		)		(11,780		)
	Foreign currency translation	(51		)		(154		)
	Fair value of plan assets at end of year	437				731
	Projected benefit obligation in excess of plan assets at end of year	$	2,406			$	1,691
	Defined benefit liability classified as other current liabilities	$	25			$	25
	Defined benefit liability classified as long-term liabilities	$	2,381			$	1,666
	Accumulated benefit obligation at end of year	$	1,938			$	1,684
	Amounts recognized in Accumulated Other Comprehensive Income are as follows (in thousands):
		Year Ended
		January 2,				January 3,
		2015				2014
	Net loss occurring during the year	$	736			$	25
	Amortization of losses	(138		)		(722		)
	Prior service cost	(2		)		150
	Amortization of prior service cost	(11		)		33
	Foreign currency translation	(76		)		224
	Pre-tax adjustment	509				(290		)
	Taxes	(135		)		18
	Net (gain) loss	$	374			$	(272	)
	The amortization of amounts in Accumulated Other Comprehensive Income expected to be recognized as components of net periodic benefit expense during 2015 are as follows (in thousands):
	Amortization of net prior service cost	$	11
	Amortization of net loss	45
	Net pension cost (income) is comprised of the following (in thousands):
		Year Ended
		2-Jan-15				3-Jan-14
	Service cost	$	203			$	236
	Interest cost	75				138
	Settlements loss	105				—
	Expected return on assets	(3		)		—
	Recognized net actuarial loss (gain)	45				(1,929		)
	Net pension cost (income)	$	425			$	(1,555	)
	The weighted-average rates used in the actuarial valuations were as follows:
		Projected Benefit Obligation						Net Pension Cost
		January 2,			January 3,			2014			2013		2012
		2015			2014
	Discount rate	2.3	%		3.4	%		3.4	%		2.1	%	2.5	%
Salary growth	3	%		3.1	%		3.1	%		2.4	%	2.3	%
Expected rate of return on assets	2.3	%		2.5	%		2.5	%		—	%	3.5	%
The discount rate used is based on the yields of AA bonds with a duration matching the duration of the liabilities plus approximately 50 basis points to reflect the risk of investing in corporate bonds. The expected rate of return on plan assets reflects earnings expectations on existing plan assets.
Plan assets were comprised of the following (in thousands):
					Fair Value Measurements Using
	2-Jan-15				Quoted				Significant			Significant
					Prices in				Other			Unobservable
					Active				Observable			Inputs
					Markets for				Inputs			(Level 3)
					Identical				(Level 2)
					Assets
					(Level 1)
Insurance contract	$	437			$	—			$	437		$	—
Total	$	437			$	—			$	437		$	—
					Fair Value Measurements Using
	January 3,				Quoted				Significant			Significant
	2014				Prices in				Other			Unobservable
					Active				Observable			Inputs
					Markets for				Inputs			(Level 3)
					Identical				(Level 2)
					Assets
					(Level 1)
Insurance contract	$	731			$	—			$	731		$	—
Total	$	731			$	—			$	731		$	—
The fair value of Level 2 plan assets are obtained from quoted market prices in inactive markets or valuation models with observable market data inputs to estimate fair value. These observable market data inputs include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and reference data.
Estimated benefit payments over the next ten years are as follows (in thousands):
2015	$	47
2016	67
2017	124
2018	113
2019	177
2020-2024	866

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Jan. 02, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION
	11		STOCK-BASED COMPENSATION
	The components and classification of stock-based compensation expense were as follows (in thousands):
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Stock options	$	2,523			$	3,490			$	2,786
	Restricted stock and units	6,417				5,843				6,233
	401(k) stock contribution	4,246				4,768				1,885
	Total stock-based compensation expense	$	13,186			$	14,101			$	10,904
	Cost of sales	$	3,530			$	3,864			$	2,620
	Selling, general and administrative expenses	7,923				7,907				7,684
	Research, development and engineering costs, net	1,440				1,194				600
	Other operating expenses, net (Note 13)	293				1,136				—
	Total stock-based compensation expense	$	13,186			$	14,101			$	10,904
	During 2014 and 2013, the Company recorded within Other Operating Expenses, Net stock modification expense related to employee separation costs incurred during 2014 and 2013 in connection with realignment initiatives, which are discussed in Note 13 “Other Operating Expenses, Net.”
	Summary of Plans
	The Company’s 1998 Stock Option Plan and Non-Employee Directors Stock Plan have been frozen to any new award issuances. Stock options remain outstanding under these plans.
	The Company’s 2005 Stock Incentive Plan (“2005 Plan”), as amended, authorizes the issuance of up to 2,450,000 shares of equity incentive awards including nonqualified and incentive stock options, restricted stock, restricted stock units, stock bonuses and stock appreciation rights subject to the terms of the 2005 Plan. The 2005 Plan limits the amount of restricted stock, restricted stock units and stock bonuses that may be awarded in the aggregate to 850,000 shares of the 2,450,000 shares authorized by the 2005 Plan.
	The Company’s 2009 Stock Incentive Plan (“2009 Plan”) authorizes the issuance of up to 1,350,000 shares of equity incentive awards including nonqualified and incentive stock options, restricted stock, restricted stock units, stock bonuses and stock appreciation rights subject to the terms of the 2009 Plan. The 2009 Plan limits the amount of restricted stock, restricted stock units and stock bonuses that may be awarded in the aggregate to 200,000 shares of the 1,350,000 shares authorized.
	The Company’s 2011 Stock Incentive Plan (“2011 Plan”), as amended, authorizes the issuance of up to 1,350,000 shares of equity incentive awards including nonqualified and incentive stock options, restricted stock, restricted stock units, stock bonuses and stock appreciation rights, subject to the terms of the 2011 Plan. The 2011 Plan does not limit the amount of restricted stock, restricted stock units or stock bonuses that may be awarded.
	As of January 2, 2015, there were 575,451, 316,695, and 16,799 shares available for future grants under the 2011 Plan, 2009 Plan and 2005 Plan, respectively. Due to plan sub-limits, of the shares available for grant, only 26,594 shares and 3,625 shares may be awarded under the 2009 Plan and the 2005 Plan, respectively, in the form of restricted stock, restricted stock units or stock bonuses.
	Stock Options
	Stock options granted generally vest over a three year period, expire 10 years from the date of grant, and are granted at exercise prices equal to or greater than the fair value of the Company’s common stock on the date of grant. Performance-based stock options have not been granted since 2010.
	The Company utilizes the Black-Scholes option pricing model to determine the fair value of stock options. Management is required to make certain assumptions with respect to selected model inputs. Expected volatility is based on the historical volatility of the Company’s stock over the most recent period commensurate with the estimated expected life of the stock options. The expected life of stock options, which represents the period of time that the stock options are expected to be outstanding, is based on historical data. The expected dividend yield is based on the Company’s history and expectation of future dividend payouts. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a period commensurate with the estimated expected life. If factors change and result in different assumptions, the stock option expense that the Company records for future grants may differ significantly from what the Company recorded in the current period. Stock-based compensation expense is only recorded for those awards that are expected to vest. Pre-vesting forfeiture estimates for determining appropriate stock-based compensation expense are estimated at the time of grant based on historical experience. Revisions are made to those estimates in subsequent periods if actual forfeitures differ from estimated forfeitures.
	The weighted-average fair value and assumptions used are as follows:
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Weighted average grant date fair value	$	16.43			$	8.38			$	8.2
	Risk-free interest rate	1.73		%		0.73		%		0.83		%
	Expected volatility	39		%		39		%		40		%
	Expected life (in years)	5.3				5.3				5.3
	Expected dividend yield	0		%		0		%		0		%
	Annual prevesting forfeiture rate	9		%		9		%		9		%
	The following table summarizes time-vested stock option activity:
		Number of			Weighted				Weighted		Aggregate
		Time-Vested			Average				Average		Intrinsic
		Stock			Exercise				Remaining		Value
		Options			Price				Contractual		(In Millions)
									Life
									(In Years)
	Outstanding at December 30, 2011	1,558,771			$	23.42
	Granted	395,978			22.19
	Exercised	(52,683	)		20.77
	Forfeited or expired	(126,219	)		24.21
	Outstanding at December 28, 2012	1,775,847			23.17
	Granted	372,676			23.33
	Exercised	(443,428	)		23.24
	Forfeited or expired	(88,686	)		28.05
	Outstanding at January 3, 2014	1,616,409			22.92
	Granted	183,571			43.84
	Exercised	(295,203	)		23.42
	Forfeited or expired	(33,279	)		27.82
	Outstanding at January 2, 2015	1,471,498			$	25.32			6.1		$	34.3
	Expected to vest at January 2, 2015	1,447,519			$	25.1			6.1		$	34.1
	Exercisable at January 2, 2015	1,278,765			$	23.88			5.8		$	31.7
	The following table summarizes performance-vested stock option activity:
		Number of			Weighted				Weighted		Aggregate
		Performance-			Average				Average		Intrinsic
		Vested Stock			Exercise				Remaining		Value
		Options			Price				Contractual		(In Millions)
									Life
									(In Years)
Outstanding at December 30, 2011	478,364			$	24.44
Exercised	(7,657	)		22.04
Forfeited or expired	(185,782	)		26.35
Outstanding at December 28, 2012	284,925			23.26
Exercised	(107,664	)		23.23
Forfeited or expired	—			—
Outstanding at January 3, 2014	177,261			23.27
Exercised	(58,422	)		23.35
Forfeited or expired	—			—
Outstanding at January 2, 2015	118,839			$	23.24			3		$	3
Expected to vest at January 2, 2015	118,839			$	23.24			3		$	3
Exercisable at January 2, 2015	118,839			$	23.24			3		$	3
Intrinsic value is calculated for in-the-money options (exercise price less than market price) as the difference between the market price of the Company’s common shares as of January 2, 2015 ($48.66) and the weighted average exercise price of the underlying stock options, multiplied by the number of options outstanding and/or exercisable. As of January 2, 2015, $2.1 million of unrecognized compensation cost related to non-vested stock options is expected to be recognized over a weighted-average period of approximately 2 years. Shares are distributed from the Company’s authorized but unissued reserve upon the exercise of stock options or treasury stock if available. The Company does not intend to purchase treasury shares to fund the future exercises of stock options.
Proceeds from the exercise of stock options are credited to common stock at par value and the excess is credited to additional paid-in capital. A portion of the options outstanding qualify as incentive stock options (“ISO”) for income tax purposes. As such, a tax benefit is not recorded at the time the compensation cost related to the stock options is recorded for book purposes due to the fact that an ISO does not ordinarily result in a tax benefit unless there is a disqualifying disposition. Stock option grants of non-qualified stock options result in the creation of a deferred tax asset, which is a temporary difference, until the time that the option is exercised.
The following table provides certain information relating to the exercise of stock options (in thousands):
	Year Ended
	January 2,				January 3,				December 28,
	2015				2014				2012
Intrinsic value	$	7,997			$	6,807			$	148
Cash received	8,278				12,807				1,263
Tax benefit (expense) realized	1,704				727				(132		)
Restricted Stock and Restricted Stock Units
Time-vested restricted stock and restricted stock unit awards granted typically vest in equal annual installments over a three or four year period. The fair value of time-based as well as nonmarket-based performance restricted stock and restricted stock unit awards is equal to the fair value of the Company’s stock on the date of grant. The following table summarizes time-vested restricted stock and unit activity:
	Time-Vested			Weighted
	Activity			Average
				Fair Value
Nonvested at December 30, 2011	69,942			$	22.69
Granted	92,265			23.49
Vested	(74,901	)		22.83
Forfeited	(7,037	)		22.56
Nonvested at December 28, 2012	80,269			23.48
Granted	67,230			26.76
Vested	(74,062	)		23.93
Forfeited	(5,862	)		22.26
Nonvested at January 3, 2014	67,575			26.37
Granted	63,817			44.78
Vested	(53,568	)		34.16
Forfeited	(9,992	)		35.3
Nonvested at January 2, 2015	67,832			$	36.22
Performance-based restricted stock units granted only vest if certain market-based performance metrics are achieved. The amount of shares that ultimately vest range from 0 shares to 716,163 shares based upon the total shareholder return of the Company relative to the Company’s compensation peer group over a three year performance period beginning in the year of grant. The fair value of the restricted stock units was determined by utilizing a Monte Carlo simulation model, which projects the value of Greatbatch stock versus the peer group under numerous scenarios and determines the value of the award based upon the present value of these projected outcomes. The following table summarizes performance-vested restricted stock and stock unit activity related to the Company’s plans:
	Performance-			Weighted
	Vested			Average
	Activity			Fair Value
Nonvested at December 30, 2011	529,743			$	16.68
Granted	332,918			15.3
Vested	(15,500	)		24.64
Forfeited	(64,715	)		15.72
Nonvested at December 28, 2012	782,446			16.02
Granted	318,169			15.86
Vested	(49,139	)		14.68
Forfeited	(271,798	)		14.94
Nonvested at January 3, 2014	779,678			16.41
Granted	186,825			31.33
Vested	(221,470	)		18.51
Forfeited	(28,870	)		18.42
Nonvested at January 2, 2015	716,163			$	19.57
The realized tax benefit (expense) from the vesting of restricted stock and restricted stock units was $2.3 million, $(0.4) million and $(0.02) million for 2014, 2013, 2012, respectively. As of January 2, 2015, there was $7.7 million of total unrecognized compensation cost related to the restricted stock and restricted stock unit awards. That cost is expected to be recognized over a weighted-average period of approximately 2 years. The fair value of shares vested in 2014, 2013, 2012 was $12.5 million, $4.0 million and $1.5 million, respectively.

Research_Development_and_Engin

Research, Development and Engineering Costs	12 Months Ended
	Jan. 02, 2015
Research and Development Expense [Abstract]
RESEARCH, DEVELOPMENT AND ENGINEERING COSTS, NET
	12		RESEARCH, DEVELOPMENT AND ENGINEERING COSTS, NET
	Research, Development and Engineering Costs, Net are comprised of the following (in thousands):
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	Research, development and engineering costs	$	58,974		$	62,652		$	62,848
	Less: cost reimbursements	(9,129		)	(8,575		)	(10,358		)
	Total research, development and engineering costs, net	$	49,845		$	54,077		$	52,490

Other_Operating_Expenses_Net

Other Operating Expenses, Net	12 Months Ended
	Jan. 02, 2015
Other Income and Expenses [Abstract]
OTHER OPERATING EXPENSES, NET
	13		OTHER OPERATING EXPENSES, NET
	Other Operating Expenses, Net is comprised of the following (in thousands):
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	2014 investments in capacity and capabilities	$	8,925		$	—		$	—
	2013 operating unit realignment	1,017			5,625			—
	Orthopaedic facilities optimization	1,317			8,038			32,482
	Medical device facility optimization	11			312			1,525
	ERP system upgrade (income) costs	(82		)	783			5,041
	Acquisition and integration (income) costs	3			(502		)	1,460
	Asset dispositions, severance and other	4,106			1,534			1,838
	Total other operating expenses, net	$	15,297		$	15,790		$	42,346
	2014 investments in capacity and capabilities. In 2014, the Company announced several initiatives to invest in capacity and capabilities and to better align its resources to meet its customers’ needs and drive organic growth and profitability. These included the following:
	•	Functions currently performed at the Company’s facility in Plymouth, MN to manufacture catheters and introducers will transfer into the Company’s existing facility in Tijuana, Mexico by the first half of 2016.
	•	Functions currently performed at the Company’s facilities in Beaverton, OR and Raynham, MA to manufacture products for the portable medical market will transfer to a new facility in Tijuana, Mexico by the end of 2015. Products currently manufactured at the Beaverton facility, which do not serve the portable medical market, are planned to transfer to the Company’s Raynham facility.
	•	Establishing a R&D hub in the Minneapolis/St. Paul, MN area for the Company’s Global R&D QiG - Medical Device Systems team, which will serve as the technical center of expertise for active implantable medical device development, implantable leads design, system level design verification testing, and continuation engineering. As part of this initiative, the design engineering responsibilities previously performed at the Company’s Cleveland, OH facility was transferred to the new R&D hub in 2014.
	•	Establishing a commercial operations hub at the Company’s global headquarters in Frisco, Texas. This initiative will build upon the investment the Company has made in its global sales and marketing function and is expected to be completed during the first half of 2015.
	The total capital investment expected for these initiatives is between $25.0 million and $27.0 million, of which $4.0 million has been expended to date. Total restructuring charges expected to be incurred in connection with this realignment are between $29.0 million and $34.0 million, of which $8.9 million has been incurred to date. Expenses related to this initiative are recorded within the applicable segment and corporate cost centers that the expenditures relate to and include the following:
	•	Severance and retention: $7.0 million - $9.0 million;
	•	Accelerated depreciation and asset write-offs: $2.0 million - $3.0 million; and
	•	Other: $20.0 million - $22.0 million
	Other costs primarily consist of costs to relocate certain equipment and other personnel, duplicate personnel costs, disposal and travel expenditures. All expenses are cash expenditures, except accelerated depreciation and asset write-offs.
	The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands):
		Severance and Retention			Accelerated			Other			Total
					Depreciation/
					Asset Write-offs
	At January 3, 2014	$	—		$	—		$	—		$	—
	Restructuring charges	2,209			33			6,683			8,925
	Write-offs	—			(33		)	—			(33		)
	Cash payments	(1,046		)	—			(5,617		)	(6,663		)
	At January 2, 2015	$	1,163		$	—		$	1,066		$	2,229
	2013 operating unit realignment. In 2013, the Company initiated a plan to realign its operating structure in order to optimize its continued focus on profitable growth. As part of this initiative, the sales and marketing and operations groups of its former Implantable Medical and Electrochem reportable segments were combined into one sales and marketing and one operations group serving the entire Company. This initiative was completed during 2014. Total restructuring charges incurred in connection with this realignment were $6.6 million. Expenses related to this initiative were recorded within the applicable segment that the expenditures relate to and included the following:
	•	Severance and retention: $5.0 million; and
	•	Other: $1.6 million.
	Other costs primarily consist of relocation, recruitment and travel expenditures. The change in accrued liabilities related to the 2013 operating unit realignment is as follows (in thousands):
		Severance and Retention			Other			Total
	At January 3, 2014	$	465		$	746		$	1,211
	Restructuring charges	849			168			1,017
	Cash payments	(1,314		)	(914		)	(2,228		)
	At January 2, 2015	$	—		$	—		$	—
	Orthopaedic facilities optimization. In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities and reduce dependence on outside suppliers. This initiative was completed in 2011.
	In 2011, the Company began construction of an orthopaedic manufacturing facility in Fort Wayne, IN and transferred manufacturing operations being performed at its Columbia City, IN location into this new facility. This initiative was completed in 2012.
	During 2012, the Company transferred manufacturing and development operations performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico. In connection with this consolidation, the Company curtailed its defined benefit plan provided to its Swiss employees and recognized a $1.9 million pension gain in 2013. See Note 10 “Benefit Plans” for additional information. Also in connection with this consolidation, in 2012, the Company entered into an agreement to sell assets related to certain non-core Swiss orthopaedic product lines to an independent third party. In connection with the transfer of these orthopaedic product lines to held for sale, the Company recognized a $3.6 million impairment charge in 2012 based upon the contractual sales price to the third party. This transaction closed during 2013 upon which the Company received payments totaling $4.7 million and the third party assumed $2.4 million of severance liabilities. The purchase agreement provided the Company with an earn out payment based upon the amount of inventory consumed by the purchaser within one year after the close of the transaction. As a result of this earn out, a gain of $2.7 million was recorded in Other Operating Expenses, Net during 2014. During 2014, the Company transferred $2.1 million of assets relating to the Company’s Orvin, Switzerland property to held for sale and recognized a $0.4 million impairment charge. See Note 5 “Assets Held For Sale” for additional information.
	During 2013, the Company began a project to expand its Chaumont, France facility in order to enhance its capabilities and fulfill larger volume customer supply agreements. This initiative is expected to be completed over the next two years.
	The total capital investment expected to be incurred for these initiatives is between $30 million and $35 million, of which $24.8 million has been expended to date. Total expense expected to be incurred for these initiatives is between $43 million and $48 million, of which $42.5 million has been incurred to date. All expenses have been and will be recorded within the Greatbatch Medical segment and are expected to include the following:
	•Severance and retention: $11 million;
	•Accelerated depreciation and asset write-offs: $13 million;
	•Other: $19 million - $24 million.
	Other costs include production inefficiencies, moving, revalidation, personnel, training and travel costs associated with these consolidation projects. All expenses are cash expenditures, except accelerated depreciation and asset write-offs. The change in accrued liabilities related to the orthopaedic facilities optimizations is as follows (in thousands):
		Severance			Accelerated			Other			Total
		and			Depreciation/
		Retention			Asset Write-offs
	At January 3, 2014	$	—		$	—		$	857		$	857
	Restructuring charges (income), net	—			(2,255		)	3,572			1,317
	Write-offs	—			(400		)	—			(400		)
	Cash receipts (payments)	—			2,655			(4,142		)	(1,487		)
	At January 2, 2015	$	—		$	—		$	287		$	287
	Medical device facility optimization. Near the end of 2011, the Company initiated plans to upgrade and expand its manufacturing infrastructure in order to support its medical device strategy. This includes the transfer of certain product lines to create additional capacity for the manufacture of medical devices, expansion of two existing facilities, as well as the purchase of equipment to enable the production of medical devices. These initiatives were completed in 2014. Total capital investment under these initiatives was $12.5 million. Total expenses incurred on these projects was $1.8 million. All expenses were recorded within the Greatbatch Medical segment and included the following:
	•Production inefficiencies, moving and revalidation: $0.7 million;
	•Personnel: $0.6 million; and
	•Other: approximately $0.5 million.
	The change in accrued liabilities related to the medical device facility optimization is as follows (in thousands):
	Production			Personnel			Other			Total
	Inefficiencies,
	Moving and
	Revalidation
At January 3, 2014	$	—		$	—		$	—		$	—
Restructuring charges	—			1			10			11
Cash payments	—			(1		)	(10		)	(11		)
At January 2, 2015	$	—		$	—		$	—		$	—
ERP system upgrade (income) costs. In 2011, the Company initiated plans to upgrade its existing global ERP system. This initiative was completed in 2014. Total capital investment expended under this initiative was $4.0 million. Total expenses incurred on this initiative were $5.7 million. Expenses related to this initiative were recorded within the applicable segment and corporate cost centers that the expenditures related to and included the following:
•Training and consulting costs: $3.2 million; and
•Accelerated depreciation and asset write-offs: $2.5 million.
The change in accrued liabilities related to the ERP system upgrade is as follows (in thousands):
	Training &			Accelerated			Total
	Consulting			Depreciation/
	Costs			Asset Write-offs
At January 3, 2014	$	—		$	—		$	—
Restructuring income	(82		)	—			(82		)
Cash receipts	82			—			82
At January 2, 2015	$	—		$	—		$	—
Acquisition and integration (income) costs. During 2014, 2013, and 2012, the Company incurred costs (income) related to the integration of CCC, NeuroNexus, and Micro Power Electronics, Inc. These expenses were primarily for retention bonuses, travel cost in connection with integration efforts, training, severance, and the change in fair value of the contingent consideration recorded in connection with these acquisitions. See Note 18 “Fair Value Measurements” for additional information on the Company’s contingent consideration, which resulted in a gain of $0.8 million and $0.7 million in 2014, and 2013, respectively.
Asset dispositions, severance and other. During 2014, 2013, and 2012, the Company recorded losses in connection with various asset disposals and/or write-downs. During 2014, the Company incurred $0.9 million of expense related to the separation of the Company’s Senior Vice President, Human Resources. Additionally, during 2014, the Company recorded charges in connection with its business reorganization to align its contract manufacturing operations. Costs incurred primarily related to consulting and IT development and were completed in 2014.
During 2013, Greatbatch Medical recorded a $0.9 million write-off related to its wireless sensing product line and QiG recorded a $0.5 million write-off of IPR&D. See Note 18, “Fair Value Measurements” for additional information.
During 2012, the Company incurred $1.2 million of costs related to the relocation of its global headquarters to Frisco, Texas.

Income_Taxes

Income Taxes	12 Months Ended
	Jan. 02, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES
	14		INCOME TAXES
	The U.S. and international components of income before provision for income taxes were as follows (in thousands):
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	U.S.	$	56,801			$	42,392			$	36,057
	International	19,778				6,446				(29,327		)
	Total income before provision for income taxes	$	76,579			$	48,838			$	6,730
	The provision for income taxes was comprised of the following (in thousands):
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Current:
	Federal	$	16,293			$	39,353			$	4,747
	State	1,299				1,604				381
	International	2,998				1,470				668
		20,590				42,427				5,796
	Deferred:
	Federal	1,211				(28,678		)		6,615
	State	(310		)		427				175
	International	(370		)		(1,605		)		(1,057		)
		531				(29,856		)		5,733
	Total provision for income taxes	$	21,121			$	12,571			$	11,529
	The provision for income taxes differs from the U.S. statutory rate due to the following:
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	Statutory rate	35	%		35	%		35	%
	Federal tax credits	(2.1	)		(7.5	)		—
	Foreign rate differential	(4.3	)		(0.7	)		50.7
	Uncertain tax positions	0.6			1.7			(10.1	)
	State taxes, net of federal benefit	0.7			2.3			4.9
	Change in tax rate - loss of Swiss tax holiday	—			—			25.6
	Change in foreign tax rates	(0.6	)		(3.7	)		—
	Valuation allowance	(0.4	)		0.4			67.6
	Other	(1.3	)		(1.8	)		(2.4	)
	Effective tax rate	27.6	%		25.7	%		171.3	%
	Deferred tax assets (liabilities) consist of the following (in thousands):
		At
		January 2,				January 3,
		2015				2014
	Tax credits	$	5,828			$	6,624
	Net operating loss carryforwards	6,721				9,161
	Inventories	3,335				4,202
	Accrued expenses	4,338				4,303
	Stock-based compensation	9,341				9,194
	Other	1,659				573
	Gross deferred tax assets	31,222				34,057
	Less valuation allowance	(10,709		)		(11,661		)
	Net deferred tax assets	20,513				22,396
	Property, plant and equipment	(2,646		)		(2,254		)
	Intangible assets	(57,850		)		(57,648		)
	Convertible subordinated notes	(5,006		)		(6,178		)
	Gross deferred tax liabilities	(65,502		)		(66,080		)
	Net deferred tax liability	$	(44,989	)		$	(43,684	)
	Presented as follows:
	Current deferred tax asset	$	6,168			$	6,008
	Current deferred tax liability	(588		)		(613		)
	Noncurrent deferred tax asset	2,626				2,933
	Noncurrent deferred tax liability	(53,195		)		(52,012		)
	Net deferred tax liability	$	(44,989	)		$	(43,684	)
	As of January 2, 2015, the Company has the following carryforwards available:
	Jurisdiction	Tax		Amount				Begin to
Attribute		(in millions)		Expire
International	Net Operating Loss		48		-1		2015
State	Net Operating Loss		37.6		-1		Various
U.S. and State	R&D Tax Credit		0.7		-1		Various
State	Investment Tax Credit		5.3				Various
(1) The utilization of certain net operating losses and credits is subject to an annual limitation under Internal Revenue Code Section 382.
Certain federal tax credits reported on filed income tax returns included uncertain tax positions taken in prior years. Due to the application of the accounting for uncertain tax positions, the actual tax attributes are larger than the tax credits for which a deferred tax asset is recognized for financial statement purposes.
In assessing the realizability of deferred tax assets, management considers, within each taxing jurisdiction, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the consideration of the weight of both positive and negative evidence, management has determined that a portion of the deferred tax assets as of January 2, 2015 and January 3, 2014 related to certain state investment tax credits and net operating losses will not be realized.
The Company files annual income tax returns in the U.S., various state and local jurisdictions, and in various foreign jurisdictions. A number of years may elapse before an uncertain tax position, for which the Company has unrecognized tax benefits, is examined and finally settled. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its unrecognized tax benefits reflect the most probable outcome. The Company adjusts these unrecognized tax benefits, as well as the related interest, in light of changing facts and circumstances. The resolution of a matter could be recognized as an adjustment to the Provision for Income Taxes and the effective tax rate in the period of resolution.
Below is a summary of changes to the unrecognized tax benefit (in thousands):
	Year Ended
	January 2,				January 3,				December 28,
	2015				2014				2012
Balance, beginning of year	$	1,858			$	970			$	1,580
Additions based upon tax positions related to the current year	268				325				—
Additions related to prior period tax positions	510				651				210
Reductions relating to settlements with tax authorities	(225		)		(88		)		(522		)
Reductions as a result of a lapse of applicable statute of limitations	—				—				(298		)
Balance, end of year	$	2,411			$	1,858			$	970
The tax years that remain open and subject to tax audits varies depending on the tax jurisdiction. An audit of the consolidated federal 2012 and 2013 tax returns were completed in the first quarter of 2015. It is reasonably possible that a reduction of approximately $1.0 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of the lapse of the statute of limitations and/or audit settlements. As of January 2, 2015, approximately $2.1 million of unrecognized tax benefits would favorably impact the effective tax rate (net of federal impact on state issues), if recognized.

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Jan. 02, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
	15		COMMITMENTS AND CONTINGENCIES
	Litigation – On December 21, 2012, the Company and several other unaffiliated parties were named as defendants in a personal injury and wrongful death action filed in the 113th Judicial District Court of Harris County, Texas. The complaint seeks damages alleging marketing and product defects and failure to warn, negligence and gross negligence relating to a product the Company manufactured and sold to a customer, one of the other named defendants. The Company’s customer, in turn, incorporated the Greatbatch product into its own product which it sold to a third party, another named defendant. On December 3, 2014, the District Court granted the Company’s motion for summary judgment and dismissed all claims against the Company. The ruling is subject to appeal by the plaintiffs.
	The Company is indemnified by its customer against any loss in this matter, including costs of defense, which obligation is supported by its customer’s product liability insurance coverage in the amount of $5 million. The Company also has its own product liability insurance coverage, subject to a $10 million retention. In January 2015, Greatbatch’s customer reached a tentative, confidential settlement with the plaintiffs which, if approved by the Court, is expected to result in a release of all claims, including appeal rights, against the Company and its customer. The Company has not recorded a reserve in connection with this matter since any potential loss is not probable.
	The Company is a party to various other legal actions arising in the normal course of business. While the Company does not expect that the ultimate resolution of any of these pending actions will have a material effect on its consolidated results of operations, financial position, or cash flows, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, does not become material in the future.
	License agreements – The Company is a party to various license agreements for technology that is utilized in certain of its products. The most significant of these agreements are the licenses for basic technology used in the production of wet tantalum capacitors, filtered feedthroughs and MRI compatible lead systems. Expenses related to license agreements were $3.3 million, $3.5 million and $3.1 million, for 2014, 2013 and 2012, respectively, and are included in Cost of Sales.
	Product Warranties – The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in product warranty liability was comprised of the following (in thousands):
		Year Ended
		January 2,				January 3,
		2015				2014
	Beginning balance	$	1,819			$	2,626
	Additions to warranty reserve	953				1,624
	Warranty claims paid	(2,112		)		(2,431		)
	Ending balance	$	660			$	1,819
	Operating Leases – The Company is a party to various operating lease agreements for buildings, machinery, equipment and software. The Company primarily leases buildings, which accounts for the majority of the future lease payments. Lease expense includes the effect of escalation clauses and leasehold improvement incentives which are accounted for ratably over the lease term. Operating lease expense was as follows (in thousands):
		Year Ended
		January 2,				January 3,			December 28,
		2015				2014			2012
	Operating lease expense	$	4,281			$	4,379		$	4,024
	Minimum future estimated annual operating lease expenses are as follows (in thousands):
	2015	$	5,797
	2016	5,952
	2017	3,908
	2018	3,489
	2019	3,418
	Thereafter	13,938
	Total estimated operating lease expense	$	36,502
	Self-Insured Medical Plan – The Company self-funds the medical insurance coverage provided to its U.S. based employees. The Company had specific stop loss coverage per associate for claims incurred during 2014 exceeding $225 thousand per associate with no annual maximum aggregate stop loss coverage. As of January 2, 2015 and January 3, 2014, the Company had $1.8 million and $1.6 million accrued related to the self-insurance of its medical plan, respectively. This accrual is recorded in Accrued Expenses in the Consolidated Balance Sheet, and is primarily based upon claim history.
	Purchase Commitments – Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing needs and are fulfilled by its vendors within short time horizons. The Company enters into blanket orders with vendors that have preferred pricing and terms, however these orders are normally cancelable by us without penalty. As of January 2, 2015, the total contractual obligation related to such expenditures is approximately $36.4 million and will primarily be financed by existing cash and cash equivalents, cash generated from operations, or the Credit Facility. The Company also enters into contracts for outsourced services; however, the obligations under these contracts were not significant and the contracts generally contain clauses allowing for cancellation without significant penalty.
	Foreign Currency Contracts – The Company has entered into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with the operations at its Tijuana, Mexico facility. The impact to the Company’s results of operations from these forward contracts was as follows (in thousands):
		Year Ended
		January 2,				January 3,			December 28,
		2015				2014			2012
	Reduction in Cost of Sales	$	(168	)		$	(1,154	)	$	(79	)
	Ineffective portion of change in fair value	—				—			—
	Information regarding outstanding foreign currency contracts as of January 2, 2015 is as follows (dollars in thousands):
	Instrument	Type of		Aggregate				Start	End		$/Peso	Fair			Balance Sheet
		Hedge		Notional				Date	Date			Value			Location
				Amount
	FX Contract	Cash flow		$	16,880			15-Jan	15-Dec		0.0734	$	(1,568	)	Accrued Expenses
	Workers’ Compensation Trust – The Company was a member of a group self-insurance trust that provided workers’ compensation benefits to employees of the Company in Western New York (the “Trust”). Under the Trust agreement, each participating organization has joint and several liability for Trust obligations if the assets of the Trust are not sufficient to cover those obligations. During 2011, the Company was notified by the Trust of its intentions to cease operations at the end of 2011 and was assessed a pro-rata share of future costs related to the Trust. Based on actual experience, the Company could receive a refund or be assessed additional contributions for workers’ compensation claims insured by the Trust. Since 2011, the Company has utilized a traditional insurance provider for workers’ compensation coverage.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	12 Months Ended
	Jan. 02, 2015
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE
	16		EARNINGS (LOSS) PER SHARE
	The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts):
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	Numerator for basic EPS:
	Net income (loss)	$	55,458		$	36,267		$	(4,799	)
	Denominator for basic EPS:
	Weighted average shares outstanding	24,825			23,991			23,584
	Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,150			1,332			—
	Denominator for diluted EPS	25,975			25,323			23,584
	Basic EPS	$	2.23		$	1.51		$	(0.20	)
	Diluted EPS	$	2.14		$	1.43		$	(0.20	)
	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met:
		Year Ended
		January 2,		January 3,			December 28,
		2015		2014			2012
	Time-vested stock options, restricted stock and restricted stock units	175,549		18,480			2,142,000
	Performance-vested stock options and restricted stock units	—		—			781,000
	For the 2013 and 2012 periods, no shares related to CSN were included in the diluted EPS calculations as the average share price of the Company’s common stock for those periods did not exceed CSN’s conversion price per share.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	12 Months Ended
	Jan. 02, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME
	17		ACCUMULATED OTHER COMPREHENSIVE INCOME
	Accumulated Other Comprehensive Income is comprised of the following (in thousands):
		Defined			Cash			Foreign			Total			Tax			Net-of-Tax
		Benefit			Flow			Currency			Pre-Tax						Amount
		Plan			Hedges			Translation			Amount
		Liability						Adjustment
	At January 3, 2014	$	(672	)	$	(468	)	$	14,952		$	13,812		$	546		$	14,358
	Unrealized loss on cash flow hedges	—			(2,372		)	—			(2,372		)	829			(1,543		)
	Realized gain on foreign currency hedges	—			(168		)	—			(168		)	59			(109		)
	Realized loss on interest rate swap hedges	—			450			—			450			(157		)	293
	Net defined benefit plan liability adjustments	(509		)	—			—			(509		)	135			(374		)
	Foreign currency translation loss	—			—			(3,502		)	(3,502		)	—			(3,502		)
	At January 2, 2015	$	(1,181	)	$	(2,558	)	$	11,450		$	7,711		$	1,412		$	9,123
		Defined			Cash			Foreign			Total			Tax			Net-of-Tax
		Benefit			Flow			Currency			Pre-Tax						Amount
		Plan			Hedges			Translation			Amount
		Liability						Adjustment
	At December 28, 2012	$	(962	)	$	120		$	13,431		$	12,589		$	358		$	12,947
	Unrealized gain on cash flow hedges	—			58			—			58			(20		)	38
	Realized gain on foreign currency hedges	—			(1,154		)	—			(1,154		)	404			(750		)
	Realized loss on interest rate swap hedges	—			508			—			508			(178		)	330
	Net defined benefit plan liability adjustments	290			—			—			290			(18		)	272
	Foreign currency translation gain	—			—			1,521			1,521			—			1,521
	At January 3, 2014	$	(672	)	$	(468	)	$	14,952		$	13,812		$	546		$	14,358
	The realized (gain) loss relating to the Company’s foreign currency and interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales and Interest Expense, respectively, in the Consolidated Statements of Operations. See Note 10 “Benefit Plans” for details on the change in defined benefit plan liability adjustments.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Jan. 02, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS
	18		FAIR VALUE MEASUREMENTS
	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and accrued contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis.
	Foreign currency contracts – The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. In addition to the above, the Company received fair value estimates from the foreign currency contract counterparty to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Cost of Sales as the inventory, which the contracts are hedging the cash flows to produce, is sold, of which approximately $1.6 million is expected to be realized within the next twelve months.
	Interest rate swaps – The fair value of the Company’s interest rate swaps outstanding at January 2, 2015 was determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition to the above, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company’s estimate. This fair value calculation was categorized in Level 2 of the fair value hierarchy.
	Accrued contingent consideration – The fair value of accrued contingent consideration recorded by the Company represents the estimated fair value of the contingent consideration the Company expects to pay to the former shareholders of NeuroNexus based upon the achievement of certain financial and development-based milestones. The fair value of the contingent consideration liability was estimated by discounting to present value, the probability weighted contingent payments expected to be made utilizing a risk adjusted discount rate. During the first quarter of 2014, the financial milestone expired unachieved and as a result, was determined to have a fair value of zero. During the fourth quarter of 2014, the Company determined that the development milestone will expire unachieved, and as a result, was determined to have a fair value of zero. Changes in the fair value of accrued contingent consideration were recorded in Other Operating Expenses, Net. The Company’s accrued contingent consideration is categorized in Level 3 of the fair value hierarchy. Changes in accrued contingent consideration were as follows (in thousands):
	At December 28, 2012	$	1,530
	Fair value adjustments	(690		)
	At January 3, 2014	840
	Fair value adjustments	(840		)
	At January 2, 2015	$	—
	The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):
		Fair Value Measurements Using
	Description	At January 2, 2015			Quoted		Significant		Significant
					Prices in		Other		Unobservable
					Active Markets		Observable		Inputs
					for Identical		Inputs		(Level 3)
					Assets		(Level 2)
					(Level 1)
	Liabilities
	Foreign currency contracts (Note 15)	$	1,568		$	—	$	1,568	$	—
	Interest rate swaps (Note 9)	990			—		990		—
		Fair Value Measurements Using
	Description	At January 3,			Quoted		Significant		Significant
		2014			Prices in		Other		Unobservable
					Active Markets		Observable		Inputs
					for Identical		Inputs		(Level 3)
					Assets		(Level 2)
					(Level 1)
	Liabilities
	Foreign currency contracts	$	140		$	—	$	140	$	—
	Accrued contingent consideration	840			—		—		840
	Interest rate swap	328			—		328		—
	Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
	Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, accrued expenses and current portion of long-term debt approximate fair value because of the short-term nature of these items. As of January 2, 2015, the fair value of the Company’s variable rate long-term debt approximates its carrying value and is categorized in Level 2 of the fair value hierarchy.
	A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows:
	Cost and equity method investments – The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other (Income) Expense, Net, unless separately stated. The aggregate recorded amount of cost and equity method investments at January 2, 2015 and January 3, 2014 was $14.5 million and $12.3 million, respectively. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. This fund accounts for its investments at fair value with the unrealized change in fair value of these investments recorded as income or loss to the fund in the period of change. As of January 2, 2015, the Company owned 7.4% of this fund.
	During 2014, 2013 and 2012, the Company recognized impairment charges related to its cost method investments of $0.0 million, $0.5 million and $0.1 million, respectively. The fair value of these investments was determined by reference to recent sales data of similar shares to independent parties in an inactive market. This fair value calculation was categorized in Level 2 of the fair value hierarchy. During 2014, the Company sold one of its cost method investments, which resulted in a pre-tax gain of $3.2 million. During 2014, 2013, and 2012, the Company recognized a net gain (loss) on equity method investments of $1.2 million, $(0.2) million, and $(0.3) million, respectively.
	Long-lived assets – The Company reviews the carrying amount of its long-lived assets to be held and used for potential impairment whenever certain indicators are present as described in Note 1 “Summary of Significant Accounting Policies.” During 2014, the Company recorded a $0.4 million impairment charge related to its Orvin, Switzerland property held for sale. The fair value of these assets were determined based upon recent sales data of similar assets and discussions with potential buyers, and was categorized in Level 2 of the fair value hierarchy. During 2013, the Company wrote off $0.5 million of IPR&D allocated to its QiG segment as these projects were discontinued prior to reaching technological feasibility. Additionally, during 2013, the Company wrote off $0.9 million of inventory and technology related to Greatbatch Medical’s wireless sensing product line held for sale, as an agreement could not be reached with potential buyers. During 2012, the Company recognized a $3.6 million impairment charge in connection with the sale of certain non-core Swiss orthopaedic product lines to an independent third party. The above impairment charges were recorded in Other Operating Expenses, Net. See Note 13 “Other Operating Expenses, Net” for further discussion.
	The following table provides information regarding assets and liabilities recorded at fair value on a nonrecurring basis as of January 2, 2015. There were no such assets or liabilities as of January 3, 2014 (in thousands):
		Fair Value Measurements Using
	Description	At January 2, 2015			Quoted		Significant		Significant
					Prices in		Other		Unobservable
					Active Markets		Observable		Inputs
					for Identical		Inputs		(Level 3)
					Assets		(Level 2)
					(Level 1)
	Assets
	Assets Held for Sale (Note 5)	$	1,635		$	—	$	1,635	$	—
	Fair Value of Other Financial Instruments
	Pension plan assets – The fair value of the Company’s pension plan assets disclosed in Note 10 “Benefit Plans” are determined based upon quoted market prices in inactive markets or valuation models with observable market data inputs to estimate fair value. These observable market data inputs include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and reference data. The Company’s pension plan assets are categorized Level 2 of the fair value hierarchy.

Business_Segment_Geographic_an

Business Segment, Geographic and Concentration Risk Information	12 Months Ended
	Jan. 02, 2015
Segment Reporting [Abstract]
BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION
	19		BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION
	The Company has two reportable segments: Greatbatch Medical and QiG. Greatbatch Medical designs and manufactures medical devices and components where Greatbatch either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical provides medical devices and components to the following markets:
	•	Cardiac/Neuromodulation: Products include batteries, capacitors, filtered and unfiltered feed-throughs, engineered components, implantable stimulation leads, and enclosures used in implantable medical devices.
	•	Orthopaedics: Products include implants, instruments and delivery systems for large joint, spine, extremity and trauma procedures.
	•	Portable Medical: Products include life-saving and life-enhancing applications comprising automated external defibrillators, portable oxygen concentrators, ventilators, and powered surgical tools.
	•	Vascular: Products include introducers, steerable sheaths, and catheters that deliver therapies for various markets such as coronary and neurovascular disease, peripheral vascular disease, interventional radiology, vascular access, atrial fibrillation, and interventional cardiology, plus products for medical imaging and pharmaceutical delivery.
	•	Energy, Military, Environmental: Products include primary and rechargeable batteries and battery packs for demanding applications such as down hole drilling tools.
	Greatbatch Medical also offers value-added assembly and design engineering services for medical devices that utilize its component products.
	QiG focuses on developing medical device systems for some of healthcare’s most pressing challenges and reflects Greatbatch’s strategic evolution of its product offerings in order to raise the growth and profitability profile of the Company. QiG utilizes a disciplined and diversified portfolio approach with three investment modes: new medical device systems commercialization, collaborative programs with OEM customers, and strategic equity positions in emerging healthcare companies. The development of certain new medical device systems are facilitated through the establishment of limited liability companies (“LLCs”). These LLCs do not own, but have the exclusive right to use the technology of Greatbatch in certain, specific fields of use and have an exclusive manufacturing agreement with Greatbatch Medical. QiG currently owns 89% - 100% of three LLCs. Minority interest in these LLCs are held by key opinion leaders, clinicians and strategic partners. Under the agreements governing these LLCs, QiG is responsible to fund 100% of the expenses incurred by the LLC. However, no distributions are made to the minority holders until QiG is reimbursed for all expenses paid. Once QiG has been fully reimbursed, all future distributions are made based upon the respective LLCs ownership percentages. One of the LLCs established by QiG is for the Company’s Algovita spinal cord stimulator to treat chronic intractable pain of the trunk and/or limbs. This product was submitted for premarket approval (“PMA”) to the United States Food & Drug Administration (“FDA”) in December 2013 and in January 2014 documentation for European CE Mark was submitted to the notified body, TÜV SÜD America. CE Mark approval was obtained on June 17, 2014.
	QiG revenue includes sales of neural interface technology, components and systems to the neuroscience and clinical markets. As further discussed in Note 2 “Acquisitions,” during 2014, the Company acquired CCC, a neuromodulation medical device developer and manufacturer. As a result of this transaction, QiG revenue also includes sales of various medical device products such as implantable pulse generators, programmer systems, battery chargers, patient wands and leads to medical device companies. Future income of QiG is expected to come from various sources including investment gains from the sales of its LLC ownership interests, technology licensing fees, royalty revenue, and/or the sales of medical device systems.
	An analysis and reconciliation of the Company’s business segment, product line and geographic information to the respective information in the Consolidated Financial Statements follows. Intersegment sales between Greatbatch Medical and QiG were not material for 2014, 2013 or 2012. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped to (in thousands):
		Year Ended
	Sales:	January 2,				January 3,				December 28,
		2015				2014				2012
	Greatbatch Medical
	Cardiac/Neuromodulation	$	321,419			$	325,412			$	306,669
	Orthopaedics	147,296				130,247				122,061
	Portable Medical	69,043				78,743				81,659
	Vascular	58,770				48,357				51,980
	Energy, Military, Environmental	81,757				78,143				81,353
	Total Greatbatch Medical	678,285				660,902				643,722
	QiG	9,502				3,043				2,455
	Total sales	$	687,787			$	663,945			$	646,177
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Segment income (loss) from operations:
	Greatbatch Medical	$	126,312			$	111,805			$	79,093
	QiG	(23,256		)		(30,484		)		(32,554		)
	Total segment income from operations	103,056				81,321				46,539
	Unallocated operating expenses	(27,402		)		(19,982		)		(20,718		)
	Operating income as reported	75,654				61,339				25,821
	Unallocated other income (expense), net	925				(12,501		)		(19,091		)
	Income before provision for income taxes as reported	$	76,579			$	48,838			$	6,730
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Depreciation and Amortization:
	Greatbatch Medical	$	31,906			$	31,112			$	39,820
	QiG	2,101				1,539				630
	Total depreciation and amortization included in segment income from operations	34,007				32,651				40,450
	Unallocated depreciation and amortization	4,223				9,681				18,475
	Total depreciation and amortization	$	38,230			$	42,332			$	58,925
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Expenditures for tangible long-lived assets, excluding acquisitions:
	Greatbatch Medical	$	19,006			$	13,242			$	33,249
	QiG	1,453				2,134				3,208
	Total reportable segments	20,459				15,376				36,457
	Unallocated long-lived tangible assets	5,187				2,798				4,709
	Total expenditures	$	25,646			$	18,174			$	41,166
		At
		January 2,				January 3,				December 28,
		2015				2014				2012
	Identifiable assets:
	Greatbatch Medical	$	761,225			$	758,369			$	779,890
	QiG	76,529				56,245				57,750
	Total reportable segments	837,754				814,614				837,640
	Unallocated assets	118,255				76,089				52,235
	Total assets	$	956,009			$	890,703			$	889,875
		Year Ended
		January 2,				January 3,				December 28,
2015			2014			2012
Sales by geographic area:
United States	$	312,539			$	325,090			$	330,537
Non-Domestic locations:
Puerto Rico	127,702				117,961				105,731
Belgium	65,308				67,155				58,043
Rest of world	182,238				153,739				151,866
Total sales	$	687,787			$	663,945			$	646,177
	At
	January 2,				January 3,				December 28,
	2015				2014				2012
Long-lived tangible assets:
United States	$	113,851			$	116,484			$	123,104
Rest of world	31,074				29,289				27,789
Total	$	144,925			$	145,773			$	150,893
A significant portion of the Company’s sales and accounts receivable were to four customers as follows:
	Sales									Accounts Receivable
	Year Ended									At
	January 2,			January 3,			December 28,			January 2,		January 3,
	2015			2014			2012			2015		2014
Customer A	18	%		20	%		19	%		4	%	8	%
Customer B	18	%		16	%		16	%		23	%	19	%
Customer C	12	%		13	%		11	%		8	%	8	%
Customer D	6	%		7	%		6	%		12	%	11	%
	54	%		56	%		52	%		47	%	46	%

Quarterly_Sales_and_Earnings_D

Quarterly Sales and Earnings Data - Unaudited	12 Months Ended
	Jan. 02, 2015
Quarterly Financial Information Disclosure [Abstract]
QUARTERLY SALES AND EARNINGS DATA - UNAUDITED
	20		QUARTERLY SALES AND EARNINGS DATA—UNAUDITED
		4th Qtr.		3rd Qtr.		2nd Qtr.		1st Qtr.
		(in thousands, except per share data)
	2014
	Sales	$	169,726	$	171,699	$	172,081	$	174,281
	Gross profit	57,214		58,118		58,470		57,596
	Net income	14,176		14,012		12,348		14,922
	EPS—basic	0.57		0.56		0.5		0.61
	EPS—diluted	0.54		0.54		0.48		0.58
	2013
	Sales	$	176,619	$	167,730	$	171,331	$	148,265
	Gross profit	57,385		55,877		57,302		48,749
	Net income	9,781		11,071		9,752		5,663
	EPS—basic	0.4		0.46		0.41		0.24
	EPS—diluted	0.38		0.44		0.39		0.23
	Fourth quarter results for 2013 includes an additional week of operations in comparison to the same period of 2014 as the Company utilizes a fifty-two, fifty-three week fiscal year, which ends on the Friday nearest December 31st. Although this additional week of operations may have impacted certain financial statement line items, management believes that, when combined with the additional holiday and weather related shutdowns, this additional week did not materially impact the Company’s net operating results.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts	12 Months Ended
	Jan. 02, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts Disclosure	Schedule II—Valuation and Qualifying Accounts
				Col. C—Additions
	Col. A	Col. B Balance at Beginning		Charged to Costs &				Charged to Other Accounts- Describe				Col. D Deductions				Col. E Balance at End of
	Description	of Period		Expenses								- Describe				Period
	2-Jan-15
	Allowance for doubtful accounts	$	2,001	$	98			$	14		(3)(4)	$	(702	)	(2)	$	1,411
	Valuation allowance for deferred income tax assets	$	11,661	$	(729	)	(1)	$	—		(4)	$	(223	)	(1)(5)	$	10,709
	3-Jan-14
	Allowance for doubtful accounts	$	2,372	$	(93	)		$	(15	)	(4)	$	(263	)	(2)	$	2,001
	Valuation allowance for deferred income tax assets	$	12,768	$	(1,263	)	(1)	$	32		(4)	$	124		(1)	$	11,661
	28-Dec-12
	Allowance for doubtful accounts	$	1,930	$	484			$	71		(3)(4)	$	(113	)	(2)	$	2,372
	Valuation allowance for deferred income tax assets	$	7,775	$	5,145		(1)	$	124		(4)	$	(276	)	(5)	$	12,768
	(1)	Valuation allowance recorded in the provision for income taxes for certain net operating losses and tax credits. The net decrease in allowance in 2014 and 2013 primarily relates to the use of net operating loss carryforwards.
	(2)	Accounts written off.
	(3)	Balance recorded as a part of our 2014 acquisition of Centro de Construcción de Cardioestimuladores del Uruguay and our 2012 acquisition of NeuroNexus Technologies, Inc.
	(4)	Includes foreign currency translation effect.
	(5)	Primarily relates to return to provision adjustments for prior years.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jan. 02, 2015
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation – The consolidated financial statements include the accounts of Greatbatch, Inc. and its wholly owned subsidiary Greatbatch Ltd. (collectively, the “Company” or “Greatbatch”). All intercompany balances and transactions have been eliminated in consolidation.
Fair Value Measurements	Fair Value Measurements – Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. the “exit price”) in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:
	Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment.
	Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market.
	Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations.
	The availability of observable inputs can vary and is affected by a wide variety of factors, including, the type of asset/liability, whether the asset/liability is established in the marketplace, and other characteristics particular to the valuation. To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level input that is significant to the fair value measurement in its entirety.
	Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 18 “Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements.
Cash and Cash Equivalents	Cash and Cash Equivalents – Cash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less. The carrying amount of cash and cash equivalents approximated their fair value as of January 2, 2015 and January 3, 2014 based upon the short-term nature of these instruments.
Concentration of Credit Risk	Concentration of Credit Risk – Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and/or accounts receivable are to four customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19 “Business Segment, Geographic and Concentration Risk Information” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts – The Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains an allowance for those customer receivables that it does not expect to collect. The Company accrues its estimated losses from uncollectable accounts receivable to the allowance based upon recent historical experience, the length of time the receivable has been outstanding and other specific information as it becomes available. Provisions to the allowance for doubtful accounts are charged to current operating expenses. Actual losses are charged against this allowance when incurred. The carrying amount of trade receivables approximated their fair value as of January 2, 2015 based upon the short-term nature of these assets.
Inventories	Inventories – Inventories are stated at the lower of cost, determined using the first-in first-out method, or market. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held as well as estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory.
Property, Plant and Equipment	Property, Plant and Equipment (“PP&E”) – PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 7-40 years; machinery and equipment 3-8 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, if less. The cost of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. Note 6 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&E.
Business Combinations	Business Combinations – The Company records its business combinations under the acquisition method of accounting. Under the acquisition method of accounting, the Company allocates the purchase price of each acquisition to the tangible and identifiable intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition. The fair value of identifiable intangible assets is based upon detailed valuations that use various assumptions made by management. Any excess of the purchase price over the fair value of net tangible and identifiable intangible assets acquired is allocated to goodwill. All direct acquisition-related costs are expensed as incurred.
	In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. The Company re-measures this liability each reporting period and records changes in the fair value through Other Operating Expenses, Net. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable contingent consideration. See Note 18 “Fair Value Measurements” and Note 2 “Acquisitions” for additional information on the Company’s contingent consideration and acquisitions, respectively.
Amortizing Intangible Assets	Amortizing Intangible Assets – Amortizing intangible assets consists primarily of purchased technology, patents and customer lists. The Company amortizes its definite-lived intangible assets over their estimated useful lives utilizing an accelerated or straight-line method of amortization, which approximates the projected cash flows used to fair value those intangible assets at the time of acquisition. When the straight-line method of amortization is utilized, the estimated useful life of the intangible asset is shortened to assure that recognition of amortization expense corresponds with the expected cash flows. The amortization period for the Company’s amortizing intangible assets are as follows: purchased technology and patents 5-15 years; customer lists 7-20 years and other intangible assets 1-10 years. See Note 7 “Intangible Assets” for additional information on the Company’s amortizing intangible assets.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets – The Company assesses the impairment of definite-lived long-lived assets or asset groups when events or changes in circumstances indicate that the carrying value may not be recoverable. Factors that are considered in deciding when to perform an impairment review include: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which a long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of a long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.
	Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives of assets are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives.
Goodwill and Intangible Assets	Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples.
	The Company completed its annual goodwill impairment assessment for 2014 by performing a step zero qualitative analysis. As part of this analysis, the Company evaluated factors including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, share price fluctuations, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. After completing the analysis, the Company determined that it was more likely than not that its reporting units fair values are greater than the reporting units carrying values and the two-step impairment test is not necessary.
	Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach. Note 7 “Intangible Assets” contains additional information on the Company’s long-lived intangible assets.
Other Long-Term Assets	Other Long-Term Assets – Other long-term assets includes deferred financing fees incurred in connection with the Company’s issuance of its long-term debt. The fees relating to the Company’s Term Loan are amortized to Interest Expense using the effective interest method over the period from the date of issuance to the put option date (if applicable) or the maturity date, whichever is earlier. Fees relating to the Company’s Revolving Credit Facility are amortized to Interest Expense on a straight-line basis over the contractual term of the credit facility. The amortization of deferred fees is included in Debt Related Amortization Included in Interest Expense in the Consolidated Statements of Cash Flows. Note 9 “Debt” contains additional information on the Company’s deferred financing fees.
Cost And Equity Method Investments	Other long-term assets also include investments in equity securities of entities that are not publicly traded and which do not have readily determinable fair values. The Company accounts for investments in these entities under the cost or equity method depending on the type of ownership interest, as well as the Company’s ability to exercise influence over these entities. Equity method investments are initially recorded at cost, and are subsequently adjusted to reflect the Company’s share of earnings or losses of the investee. Cost method investments are recorded at cost. Each reporting period, management evaluates these cost and equity method investments to determine if there are any events or circumstances that are likely to have a significant effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to: a recent sale or offering of similar shares of the investment at a price below the Company’s cost basis; a significant deterioration in earnings performance; a significant change in the regulatory, economic or technological environment of the investee; or a significant doubt about an investee’s ability to continue as a going concern. If an impairment indicator is identified, management will estimate the fair value of the investment and compare it to its carrying value. The estimation of fair value considers all available financial information related to the investee, including, but not limited to, valuations based on recent third-party equity investments in the investee. If the fair value of the investment is less than its carrying value, the investment is impaired and a determination as to whether the impairment is other-than-temporary is made. Impairment is deemed to be other-than-temporary unless the Company has the ability and intent to hold the investment for a period sufficient for a market recovery up to the carrying value of the investment. Further, evidence must indicate that the carrying value of the investment is recoverable within a reasonable period. For other-than-temporary impairments, an impairment loss is recognized equal to the difference between the investment’s carrying value and its fair value. The Company has determined that these investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant.
Income Taxes	Income Taxes – The consolidated financial statements of the Company have been prepared using the asset and liability approach in accounting for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined that it is more likely than not that the asset will not be realized.
	The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for Income Taxes. Penalties, if incurred, are recognized as a component of Selling, General and Administrative Expenses (“SG&A”).
	The Company and its subsidiary file a consolidated U.S. federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates. See Note 14 “Income Taxes” for additional information.
Convertible Subordinated Notes	Convertible Subordinated Notes (“CSN”) – For convertible debt instruments that may be settled in cash upon conversion, the Company accounts for the liability and equity components of those instruments in a manner that will reflect the entity’s nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods.
	Upon issuance, the Company determined the carrying amount of the liability component of CSN by measuring the fair value of a similar liability that does not have the associated conversion option. The carrying amount of the conversion option was then determined by deducting the fair value of the liability component from the initial proceeds received from the issuance of CSN. The carrying amount of the conversion option was recorded in Additional Paid-In Capital with an offset to Long-Term Debt and was amortized using the effective interest method over the period from the date of issuance to the maturity date. The amortization of discount related to the Company’s convertible debt instruments is included in Debt Related Amortization Included in Interest Expense in the Consolidated Statements of Cash Flows. See Note 9 “Debt” for additional information.
Derivative Financial Instruments	Derivative Financial Instruments – The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value. Changes in the fair value of derivative instruments are recorded in earnings unless hedge accounting criteria are met. The Company designates its interest rate swaps (See Note 9 “Debt”) and foreign currency contracts (See Note 15 “Commitments and Contingencies”) entered into as cash flow hedges. The effective portion of the changes in fair value of these cash flow hedges is recorded each period, net of tax, in Accumulated Other Comprehensive Income until the related hedged transaction occurs. Any ineffective portion of the changes in fair value of these cash flow hedges is recorded in earnings. In the event the hedged cash flow for forecasted transactions does not occur, or it becomes probable that they will not occur, the Company would reclassify the amount of any gain or loss on the related cash flow hedge to income (expense) at that time. Cash flows related to these derivative financial instruments are included in cash flows from operating activities.
Revenue Recognition	Revenue Recognition – The Company recognizes revenue when it is realized or realizable and earned. This occurs when persuasive evidence of an arrangement exists, delivery has occurred, the price is fixed or determinable (including any price concessions under long-term agreements), the buyer is obligated to pay us (i.e., not contingent on a future event), the risk of loss is transferred, there is no obligation of future performance, collectability is reasonably assured and the amount of future returns can reasonably be estimated. With regards to the Company’s customers (including distributors), those criteria are met at the time of shipment when title passes. Currently, the revenue recognition policy is the same for both Greatbatch Medical and QiG. In general, for customers with long-term contracts, we have negotiated fixed pricing arrangements. During new contract negotiations, price level decreases (concessions) for future sales may be offered to customers in exchange for volume and/or long-term commitments. Once the new contracts are signed, these prices are fixed and determinable for all future sales. The Company includes shipping and handling fees billed to customers in Sales. Shipping and handling costs associated with inbound and outbound freight are recorded in Cost of Sales. In certain instances the Company obtains component parts for sub-assemblies from its customers that are included in the final product sold back to the same customer. These amounts are excluded from Sales and Cost of Sales recognized by the Company.
Product Warranties	Product Warranties – The Company allows customers to return defective or damaged products for credit, replacement, or exchange. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon recent historical experience and other specific information as it becomes available. Note 15 “Commitments and Contingencies” contains additional information on the Company’s product warranties.
Research, Development and Engineering Costs, Net	Research, Development and Engineering Costs, Net (“RD&E”) – RD&E costs are expensed as incurred. The primary costs are salary and benefits for personnel, material costs used in development projects and subcontracting costs. Cost reimbursements for engineering services from customers for whom the Company designs products are recorded as an offset to engineering costs upon achieving development milestones specified in the contracts. These reimbursements do not cover the complete cost of the development projects. Additionally, the technology developed under these cost reimbursement projects is owned by the Company and is utilized for future products developed for other customers.
	In-process research and development (“IPR&D”) represents research projects acquired in a business combination which are expected to generate cash flows but have not yet reached technological feasibility. The primary basis for determining the technological feasibility of these projects is whether or not regulatory approval has been obtained. The Company classifies IPR&D acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated projects. Upon completion, the Company would determine the useful life of the IPR&D and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, the remaining carrying amount of the associated IPR&D would be written-off. The Company tests the IPR&D acquired for impairment at least annually, and more frequently if events or changes in circumstances indicate that the assets may be impaired. The impairment test consists of a comparison of the fair value of the intangible assets with their carrying amount. If the carrying amount exceeds its fair value, the Company would record an impairment loss in an amount equal to the excess.
	Note 12 “Research, Development and Engineering Costs, Net” contains additional information on the Company’s RD&E activities.
Stock-Based Compensation	Stock-Based Compensation – The Company records compensation costs related to stock-based awards granted to employees based upon their estimated fair value on the grant date. Compensation cost for service-based awards is recognized ratably over the applicable vesting period. Compensation cost for nonmarket-based performance awards is reassessed each period and recognized based upon the probability that the performance targets will be achieved. Compensation cost for market-based performance awards is expensed ratably over the applicable vesting period and is recognized each period whether the performance metrics are achieved or not.
	The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options granted. For service-based and nonmarket-based performance restricted stock and restricted stock unit awards, the fair market value of the award is determined based upon the closing value of the Company’s stock price on the grant date. For market-based performance restricted stock unit awards, the fair market value of the award is determined utilizing a Monte Carlo simulation model, which projects the value of the Company’s stock under numerous scenarios and determines the value of the award based upon the present value of those projected outcomes.
	The amount of stock-based compensation expense recognized is based on the portion of the awards that are ultimately expected to vest. The Company estimates pre-vesting forfeitures at the time of grant by analyzing historical data and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The total expense recognized over the vesting period will only be for those awards that ultimately vest, excluding market and nonmarket performance award considerations. Note 11 “Stock-Based Compensation” contains additional information on the Company’s stock-based compensation.
Foreign Currency Translation	Foreign Currency Translation – The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translates income and expenses at the average exchange rates in effect during the period. The net effect of this translation is recorded in the consolidated financial statements as Accumulated Other Comprehensive Income. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in the Company’s foreign subsidiaries.
Defined Benefit Plans	Defined Benefit Plans – The Company recognizes in its balance sheet as an asset or liability the overfunded or underfunded status of its defined benefit plans provided to its employees located in Mexico, Switzerland and France. This asset or liability is measured as the difference between the fair value of plan assets and the benefit obligation of those plans. For these plans, the benefit obligation is the projected benefit obligation, which is calculated based on actuarial computations of current and future benefits for employees. Actuarial gains or losses and prior service costs or credits that arise during the period, but are not included as components of net periodic benefit expense, are recognized as a component of Accumulated Other Comprehensive Income. Defined benefit expenses are charged to Cost of Sales, SG&A and RD&E expenses as applicable. Note 10 “Benefit Plans” contains additional information on these costs.
Earnings (Loss) Per Share	Earnings (Loss) Per Share (“EPS”) – Basic EPS is calculated by dividing Net Income (Loss) by the weighted average number of shares outstanding during the period. Diluted EPS is calculated by adjusting the weighted average number of shares outstanding for potential common shares, which consist of stock options, unvested restricted stock and restricted stock units and, if applicable, contingently convertible instruments such as convertible debt. Note 16 “Earnings (Loss) Per Share” contains additional information on the computation of the Company’s EPS.
Comprehensive Income (Loss)	Comprehensive Income (Loss) – The Company’s comprehensive income (loss) as reported in the Consolidated Statements of Operations and Comprehensive Income (Loss) includes net income (loss), foreign currency translation adjustments, the net change in cash flow hedges, and defined benefit plan liability adjustments. The Consolidated Statements of Operations and Comprehensive Income (Loss) and Note 17 “Accumulated Other Comprehensive Income” contains additional information on the computation of the Company’s comprehensive income (loss).
Use of Estimates	Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting period. Actual results could differ materially from those estimates.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements – In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements.
	In November 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-17, “Business Combinations (Topic 805): Pushdown Accounting (a Consensus of the FASB Emerging Issues Task Force).” The amendments in this ASU provide an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. The amendments in this ASU are effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. This ASU did not impact the Company’s Consolidated Financial Statements.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract and recognizing revenue when the entity satisfies the performance obligations. This ASU supersedes existing revenue recognition guidance and is effective for annual reporting periods beginning after December 15, 2016 with early application not permitted. This ASU allows two methods of adoption; a full retrospective approach where three years of financial information are presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. The Company is currently assessing the financial impact of adopting the new standard and the methods of adoption; however, given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected.
	In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” which amends the definition of a discontinued operation and requires entities to provide additional disclosures about disposal transactions that do not meet the discontinued operations criteria. The revised guidance changes how entities identify and disclose information about disposal transactions under U.S. GAAP. This ASU is effective prospectively for all disposals (except disposals classified as held for sale before the adoption date) or components initially classified as held for sale in periods beginning on or after December 15, 2014, with early adoption permitted. This ASU will be applicable for disposal transactions, if any, that the Company enters into after the adoption date.
	In July 2013, the FASB issued ASU No. 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This ASU requires that entities present an unrecognized tax benefit, or portion of an unrecognized tax benefit, as a reduction to a deferred tax asset in the financial statements for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions. This ASU was adopted during the first quarter of 2014 and did not impact the Company’s Consolidated Financial Statements as the Company does not have any net operating loss carryforward deferred tax assets that are eligible to be reduced by an unrecognized tax benefit as required by the ASU.

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Jan. 02, 2015
Business Acquisition [Line Items]
Schedule of Pro Forma Information	The following unaudited pro forma information presents the consolidated results of operations of the Company, CCC, and NeuroNexus as if those acquisitions occurred as of the beginning of fiscal years 2013 (CCC) and 2011 (NeuroNexus) (in thousands, except per share amounts):
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Sales	$	696,357			$	677,657			$	646,617
	Net income (loss)	56,453				37,612				(4,973		)
	Earnings (loss) per share:
	Basic	$	2.27			$	1.57			$	(0.21	)
	Diluted	$	2.17			$	1.49			$	(0.21	)
Centro De Construccion De Cardioestimuladores Del Uruguay [Member]
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition	The following table summarizes the preliminary allocation of the CCC purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):
	Assets acquired
	Current assets	$	10,670
	Property, plant and equipment	1,131
	Amortizing intangible assets	6,100
	Goodwill	8,296
	Total assets acquired	26,197
	Liabilities assumed
	Current liabilities	4,842
	Deferred income taxes	1,590
	Total liabilities assumed	6,432
	Net assets acquired	$	19,765
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	Intangible assets – The purchase price was allocated to intangible assets as follows (dollars in thousands):
	Amortizing Intangible Assets		Fair				Weighted		Weighted
			Value				Average		Average
			Assigned				Amortization		Discount
							Period (Years)		Rate
	Technology		$	1,400			10		18%
	Customer lists		4,600				10		18%
	Trademarks and tradenames		100				2		18%
			$	6,100			10		18%
Neuro Nexus Technologies Inc [Member]
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition	The following table summarizes the allocation of the NeuroNexus purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):
	Assets acquired
	Current assets	$	618
	Property, plant and equipment	35
	Amortizing intangible assets	2,927
	Indefinite-lived intangible assets	540
	Goodwill	8,924
	Other assets	1,576
	Total assets acquired	14,620
	Liabilities assumed
	Current liabilities	420
	Deferred income taxes	989
	Total liabilities assumed	1,409
	Net assets acquired	$	13,211
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	The purchase price was allocated to identifiable intangible assets as follows (dollars in thousands):
		Fair				Weighted		Estimated		Weighted
		Value				Average		Useful		Average
		Assigned				Amortization		Life (Years)		Discount
						Period (Years)				Rate
	Amortizing Intangible Assets
	Technology and patents	$	1,058			6		10		14	%
	Customer lists	1,869				7		15		13	%
		$	2,927			7		13		13	%
	Indefinite-lived Intangible Assets
	In-process research and development	$	540			N/A		12		26	%
Schedule of Acquired Indefinite-lived Intangible Assets by Major Class
	Indefinite-lived Intangible Assets
	In-process research and development	540			N/A		12		26	%

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Jan. 02, 2015
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow
		Year Ended
		January 2,		January 3,		December 28,
		2015		2014		2012
	(in thousands)
	Noncash investing and financing activities:
	Common stock contributed to 401(k) Plan	$	4,341	$	2,477	$	4,793
	Property, plant and equipment purchases included in accounts payable	2,926		2,103		2,522
	Cash paid during the year for:
	Interest	3,521		4,989		6,230
	Income taxes	13,565		44,165		4,909
	Acquisition of noncash assets	22,434		—		14,396
	Liabilities assumed	6,432		—		1,244

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Jan. 02, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories are comprised of the following (in thousands):
		At
		January 2,		January 3,
		2015		2014
	Raw materials	$	73,354	$	67,939
	Work-in-process	38,930		36,670
	Finished goods	16,958		13,749
	Total	$	129,242	$	118,358

Assets_Held_For_Sale_Tables

Assets Held For Sale (Tables)	12 Months Ended
	Jan. 02, 2015
Discontinued Operations and Disposal Groups [Abstract]
Disclosure of Long Lived Assets Held-for-sale	Assets held for sale included in Prepaid Expenses and Other Current Assets, is comprised of the following (in thousands):
			At
	Asset	Business	January 2,		January 3,
		Segment	2015		2014
	Building and building improvements	Greatbatch Medical	$	1,635	$	—

Property_Plant_and_Equipment_N1

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Jan. 02, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment are comprised of the following (in thousands):
		At
		January 2,			January 3,
		2015			2014
	Manufacturing machinery and equipment	$	167,173		$	159,542
	Buildings and building improvements	89,258			87,359
	Information technology hardware and software	31,725			28,010
	Leasehold improvements	31,170			31,522
	Furniture and fixtures	14,045			13,889
	Land and land improvements	10,816			13,016
	Construction work in process	14,129			7,886
	Other	629			633
		358,945			341,857
	Accumulated depreciation	(214,020		)	(196,084		)
	Total	$	144,925		$	145,773
Depreciation Expense Disclosure	Depreciation expense for property, plant and equipment was as follows (in thousands):
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	Depreciation expense	$	23,320		$	22,799		$	31,575

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Jan. 02, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Amortizing intangible assets, net are comprised of the following (in thousands):
		Gross			Accumulated			Foreign			Net
		Carrying			Amortization			Currency			Carrying
		Amount						Translation			Amount
	At January 2, 2015
	Purchased technology and patents	$	95,776		$	(75,894	)	$	1,966		$	21,848
	Customer lists	72,857			(31,460		)	1,374			42,771
	Other	4,534			(4,619		)	803			718
	Total amortizing intangible assets	$	173,167		$	(111,973	)	$	4,143		$	65,337
	At January 3, 2014
	Purchased technology and patents	$	97,376		$	(69,026	)	$	1,980		$	30,330
	Customer lists	68,257			(24,671		)	1,367			44,953
	Other	4,434			(4,399		)	804			839
	Total amortizing intangible assets	$	170,067		$	(98,096	)	$	4,151		$	76,122
Schedule of Finite-Lived Intangible Assets, Amortization Expense	Aggregate intangible asset amortization expense is comprised of the following (in thousands):
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	Cost of sales	$	6,201		$	6,822		$	7,489
	SG&A	7,009			5,800			6,227
	RD&E	667			545			545
	Total intangible asset amortization expense	$	13,877		$	13,167		$	14,261
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future intangible asset amortization expense based upon the current carrying value is as follows (in thousands):
		Estimated
		Amortization
		Expense
	2015	$	12,988
	2016	10,676
	2017	9,520
	2018	7,232
	2019	5,431
	Thereafter	19,490
	Total estimated amortization expense	$	65,337
Schedule of Indefinite-Lived Intangible Assets	The change in indefinite-lived assets during 2014 is as follows (in thousands)
		Trademarks
		and
		Tradenames
	At January 3, 2014	$	20,288
	At January 2, 2015	$	20,288
Schedule of Goodwill	The change in goodwill during 2014 is as follows (in thousands):
		Greatbatch			QiG			Total
		Medical
	At January 3, 2014	$	304,856		$	41,800		$	346,656
	Goodwill acquired (Note 2)	—			8,296			8,296
	Foreign currency translation	(559		)	—			(559		)
	At January 2, 2015	$	304,297		$	50,096		$	354,393

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Jan. 02, 2015
Accounts Payable and Accrued Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued expenses are comprised of the following (in thousands):
		At
		January 2,		January 3,
		2015		2014
	Salaries and benefits	$	20,770	$	16,311
	Profit sharing and bonuses	18,524		19,808
	Warranty	660		1,819
	Other	8,430		6,743
	Total	$	48,384	$	44,681

Debt_Tables

Debt (Tables)	12 Months Ended
	Jan. 02, 2015
Debt Disclosure [Abstract]
Schedule of Debt	Long-term debt is comprised of the following (in thousands):
		At
		January 2,				3-Jan-14
		2015
	Variable rate term loan	$	187,500			$	197,500
	Revolving line of credit	—				—
	Total debt	187,500				197,500
	Less current portion of long-term debt	11,250				—
	Total long-term debt	$	176,250			$	197,500
Schedule of Interest Rate Derivatives	Information regarding the Company’s outstanding interest rate swaps as of January 2, 2015 is as follows (dollars in thousands):
	Instrument		Type of		Notional			Start		End	Pay		Current		Fair			Balance
			Hedge		Amount			Date		Date	Fixed		Receive		Value			Sheet Location
											Rate		Floating		2-Jan-15
													Rate
	Interest rate swap		Cash flow		$	100,000		13-Feb		16-Feb	0.573	%	0.155	%	$	(125	)	Other Long-Term Liabilities
	Interest rate swap		Cash flow		$	90,000		15-Feb		19-Sep	1.921	%	N/A		$	(865	)	Other Long-Term Liabilities
Schedule of Maturities of Long-term Debt	The expected future minimum principal payments under the Credit Facility as of January 2, 2015 are as follows (in thousands):
	2015	$	11,250
	2016	16,250
	2017	20,000
	2018	20,000
	2019	120,000
	Total	187,500
Schedule of Interest	The contractual interest and discount amortization for CSN were as follows (in thousands):
		Year Ended
		January 2,				January 3,			December 28,
		2015				2014			2012
	Contractual interest	$	—			$	634		$	4,450
	Discount amortization	—				5,368			11,464
Schedule of Deferred Financing Costs	The change in deferred financing fees is as follows (in thousands):
	At December 28, 2012	$	2,056
	Financing costs deferred	2,802
	Write-off during the period	(156		)
	Amortization during the period	(842		)
	At January 3, 2014	3,860
	Amortization during the period	(773		)
	At January 2, 2015	$	3,087

Benefit_Plans_Tables

Benefit Plans (Tables)	12 Months Ended
	Jan. 02, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule of Changes in Projected Benefit Obligations
		Year Ended
		January 2,				January 3,
		2015				2014
	Change in projected benefit obligation:
	Projected benefit obligation at beginning of year	$	2,422			$	16,215
	Service cost	203				236
	Interest cost	75				138
	Prior service cost and plan amendments	—				(45		)
	Plan participants’ contribution	36				134
	Actuarial (gain) loss	630				(2		)
	Benefits transferred in, net	155				434
	Settlement/curtailment gain	(337		)		(14,539		)
	Foreign currency translation	(341		)		(149		)
	Projected benefit obligation at end of year	2,843				2,422
Schedule of Changes in Fair Value of Plan Assets
		January 2,				January 3,
		2015				2014
	Change in fair value of plan assets:
	Fair value of plan assets at beginning of year	731				12,269
	Employer contributions (refund)	(39		)		150
	Plan participants’ contributions	36				134
	Actual loss on plan assets	(101		)		(26		)
	Benefits transferred in, net	198				138
	Settlements	(337		)		(11,780		)
	Foreign currency translation	(51		)		(154		)
	Fair value of plan assets at end of year	437				731
	Projected benefit obligation in excess of plan assets at end of year	$	2,406			$	1,691
	Defined benefit liability classified as other current liabilities	$	25			$	25
	Defined benefit liability classified as long-term liabilities	$	2,381			$	1,666
	Accumulated benefit obligation at end of year	$	1,938			$	1,684
Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)	Amounts recognized in Accumulated Other Comprehensive Income are as follows (in thousands):
		Year Ended
		January 2,				January 3,
		2015				2014
	Net loss occurring during the year	$	736			$	25
	Amortization of losses	(138		)		(722		)
	Prior service cost	(2		)		150
	Amortization of prior service cost	(11		)		33
	Foreign currency translation	(76		)		224
	Pre-tax adjustment	509				(290		)
	Taxes	(135		)		18
	Net (gain) loss	$	374			$	(272	)
Schedule of Amounts in Accumulated Other Comprehensive Income (Loss) to be Recognized over Next Fiscal Year	The amortization of amounts in Accumulated Other Comprehensive Income expected to be recognized as components of net periodic benefit expense during 2015 are as follows (in thousands):
	Amortization of net prior service cost	$	11
	Amortization of net loss	45
Schedule of Net Benefit Costs	Net pension cost (income) is comprised of the following (in thousands):
		Year Ended
		2-Jan-15				3-Jan-14
	Service cost	$	203			$	236
	Interest cost	75				138
	Settlements loss	105				—
	Expected return on assets	(3		)		—
	Recognized net actuarial loss (gain)	45				(1,929		)
	Net pension cost (income)	$	425			$	(1,555	)
Schedule of Assumptions Used	The weighted-average rates used in the actuarial valuations were as follows:
		Projected Benefit Obligation						Net Pension Cost
		January 2,			January 3,			2014			2013		2012
		2015			2014
	Discount rate	2.3	%		3.4	%		3.4	%		2.1	%	2.5	%
	Salary growth	3	%		3.1	%		3.1	%		2.4	%	2.3	%
	Expected rate of return on assets	2.3	%		2.5	%		2.5	%		—	%	3.5	%
Schedule of Allocation of Plan Assets	Plan assets were comprised of the following (in thousands):
						Fair Value Measurements Using
		2-Jan-15				Quoted				Significant			Significant
						Prices in				Other			Unobservable
						Active				Observable			Inputs
						Markets for				Inputs			(Level 3)
						Identical				(Level 2)
						Assets
						(Level 1)
	Insurance contract	$	437			$	—			$	437		$	—
	Total	$	437			$	—			$	437		$	—
						Fair Value Measurements Using
		January 3,				Quoted				Significant			Significant
		2014				Prices in				Other			Unobservable
						Active				Observable			Inputs
						Markets for				Inputs			(Level 3)
						Identical				(Level 2)
						Assets
						(Level 1)
	Insurance contract	$	731			$	—			$	731		$	—
	Total	$	731			$	—			$	731		$	—
Schedule of Expected Benefit Payments	Estimated benefit payments over the next ten years are as follows (in thousands):
	2015	$	47
	2016	67
	2017	124
	2018	113
	2019	177
	2020-2024	866

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Jan. 02, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The components and classification of stock-based compensation expense were as follows (in thousands):
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Stock options	$	2,523			$	3,490			$	2,786
	Restricted stock and units	6,417				5,843				6,233
	401(k) stock contribution	4,246				4,768				1,885
	Total stock-based compensation expense	$	13,186			$	14,101			$	10,904
	Cost of sales	$	3,530			$	3,864			$	2,620
	Selling, general and administrative expenses	7,923				7,907				7,684
	Research, development and engineering costs, net	1,440				1,194				600
	Other operating expenses, net (Note 13)	293				1,136				—
	Total stock-based compensation expense	$	13,186			$	14,101			$	10,904
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted-average fair value and assumptions used are as follows:
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Weighted average grant date fair value	$	16.43			$	8.38			$	8.2
	Risk-free interest rate	1.73		%		0.73		%		0.83		%
	Expected volatility	39		%		39		%		40		%
	Expected life (in years)	5.3				5.3				5.3
	Expected dividend yield	0		%		0		%		0		%
	Annual prevesting forfeiture rate	9		%		9		%		9		%
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes time-vested stock option activity:
		Number of			Weighted				Weighted		Aggregate
		Time-Vested			Average				Average		Intrinsic
		Stock			Exercise				Remaining		Value
		Options			Price				Contractual		(In Millions)
									Life
									(In Years)
	Outstanding at December 30, 2011	1,558,771			$	23.42
	Granted	395,978			22.19
	Exercised	(52,683	)		20.77
	Forfeited or expired	(126,219	)		24.21
	Outstanding at December 28, 2012	1,775,847			23.17
	Granted	372,676			23.33
	Exercised	(443,428	)		23.24
	Forfeited or expired	(88,686	)		28.05
	Outstanding at January 3, 2014	1,616,409			22.92
	Granted	183,571			43.84
	Exercised	(295,203	)		23.42
	Forfeited or expired	(33,279	)		27.82
	Outstanding at January 2, 2015	1,471,498			$	25.32			6.1		$	34.3
	Expected to vest at January 2, 2015	1,447,519			$	25.1			6.1		$	34.1
	Exercisable at January 2, 2015	1,278,765			$	23.88			5.8		$	31.7
	The following table summarizes performance-vested stock option activity:
		Number of			Weighted				Weighted		Aggregate
		Performance-			Average				Average		Intrinsic
		Vested Stock			Exercise				Remaining		Value
		Options			Price				Contractual		(In Millions)
									Life
									(In Years)
	Outstanding at December 30, 2011	478,364			$	24.44
	Exercised	(7,657	)		22.04
	Forfeited or expired	(185,782	)		26.35
	Outstanding at December 28, 2012	284,925			23.26
	Exercised	(107,664	)		23.23
	Forfeited or expired	—			—
	Outstanding at January 3, 2014	177,261			23.27
	Exercised	(58,422	)		23.35
	Forfeited or expired	—			—
	Outstanding at January 2, 2015	118,839			$	23.24			3		$	3
	Expected to vest at January 2, 2015	118,839			$	23.24			3		$	3
	Exercisable at January 2, 2015	118,839			$	23.24			3		$	3
Schedule Of Stock Option Exercise Information	The following table provides certain information relating to the exercise of stock options (in thousands):
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Intrinsic value	$	7,997			$	6,807			$	148
	Cash received	8,278				12,807				1,263
	Tax benefit (expense) realized	1,704				727				(132		)
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes performance-vested restricted stock and stock unit activity related to the Company’s plans:
		Performance-			Weighted
		Vested			Average
		Activity			Fair Value
	Nonvested at December 30, 2011	529,743			$	16.68
	Granted	332,918			15.3
	Vested	(15,500	)		24.64
	Forfeited	(64,715	)		15.72
	Nonvested at December 28, 2012	782,446			16.02
	Granted	318,169			15.86
	Vested	(49,139	)		14.68
	Forfeited	(271,798	)		14.94
	Nonvested at January 3, 2014	779,678			16.41
	Granted	186,825			31.33
	Vested	(221,470	)		18.51
	Forfeited	(28,870	)		18.42
	Nonvested at January 2, 2015	716,163			$	19.57
	The following table summarizes time-vested restricted stock and unit activity:
		Time-Vested			Weighted
		Activity			Average
					Fair Value
	Nonvested at December 30, 2011	69,942			$	22.69
	Granted	92,265			23.49
	Vested	(74,901	)		22.83
	Forfeited	(7,037	)		22.56
	Nonvested at December 28, 2012	80,269			23.48
	Granted	67,230			26.76
	Vested	(74,062	)		23.93
	Forfeited	(5,862	)		22.26
	Nonvested at January 3, 2014	67,575			26.37
	Granted	63,817			44.78
	Vested	(53,568	)		34.16
	Forfeited	(9,992	)		35.3
	Nonvested at January 2, 2015	67,832			$	36.22

Research_Development_and_Engin1

Research, Development and Engineering Costs (Tables)	12 Months Ended
	Jan. 02, 2015
Research and Development Expense [Abstract]
Schedule Of Research And Development Expense Details	Research, Development and Engineering Costs, Net are comprised of the following (in thousands):
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	Research, development and engineering costs	$	58,974		$	62,652		$	62,848
	Less: cost reimbursements	(9,129		)	(8,575		)	(10,358		)
	Total research, development and engineering costs, net	$	49,845		$	54,077		$	52,490

Other_Operating_Expenses_Net_T

Other Operating Expenses, Net (Tables)	12 Months Ended
	Jan. 02, 2015
Restructuring Cost and Reserve [Line Items]
Schedule of Other Operating Cost and Expense, by Component	Other Operating Expenses, Net is comprised of the following (in thousands):
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	2014 investments in capacity and capabilities	$	8,925		$	—		$	—
	2013 operating unit realignment	1,017			5,625			—
	Orthopaedic facilities optimization	1,317			8,038			32,482
	Medical device facility optimization	11			312			1,525
	ERP system upgrade (income) costs	(82		)	783			5,041
	Acquisition and integration (income) costs	3			(502		)	1,460
	Asset dispositions, severance and other	4,106			1,534			1,838
	Total other operating expenses, net	$	15,297		$	15,790		$	42,346
Investments in Capacity and Capabilities [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost	The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands):
		Severance and Retention			Accelerated			Other			Total
					Depreciation/
					Asset Write-offs
	At January 3, 2014	$	—		$	—		$	—		$	—
	Restructuring charges	2,209			33			6,683			8,925
	Write-offs	—			(33		)	—			(33		)
	Cash payments	(1,046		)	—			(5,617		)	(6,663		)
	At January 2, 2015	$	1,163		$	—		$	1,066		$	2,229
Operating Unit Realignment [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost	Other costs primarily consist of relocation, recruitment and travel expenditures. The change in accrued liabilities related to the 2013 operating unit realignment is as follows (in thousands):
		Severance and Retention			Other			Total
	At January 3, 2014	$	465		$	746		$	1,211
	Restructuring charges	849			168			1,017
	Cash payments	(1,314		)	(914		)	(2,228		)
	At January 2, 2015	$	—		$	—		$	—
Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost	The change in accrued liabilities related to the orthopaedic facilities optimizations is as follows (in thousands):
		Severance			Accelerated			Other			Total
		and			Depreciation/
		Retention			Asset Write-offs
	At January 3, 2014	$	—		$	—		$	857		$	857
	Restructuring charges (income), net	—			(2,255		)	3,572			1,317
	Write-offs	—			(400		)	—			(400		)
	Cash receipts (payments)	—			2,655			(4,142		)	(1,487		)
	At January 2, 2015	$	—		$	—		$	287		$	287
Medical Device Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost	The change in accrued liabilities related to the medical device facility optimization is as follows (in thousands):
		Production			Personnel			Other			Total
		Inefficiencies,
		Moving and
		Revalidation
	At January 3, 2014	$	—		$	—		$	—		$	—
	Restructuring charges	—			1			10			11
	Cash payments	—			(1		)	(10		)	(11		)
	At January 2, 2015	$	—		$	—		$	—		$	—
ERP System Upgrade [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost	The change in accrued liabilities related to the ERP system upgrade is as follows (in thousands):
		Training &			Accelerated			Total
		Consulting			Depreciation/
		Costs			Asset Write-offs
	At January 3, 2014	$	—		$	—		$	—
	Restructuring income	(82		)	—			(82		)
	Cash receipts	82			—			82
	At January 2, 2015	$	—		$	—		$	—

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jan. 02, 2015
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	The U.S. and international components of income before provision for income taxes were as follows (in thousands):
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	U.S.	$	56,801			$	42,392			$	36,057
	International	19,778				6,446				(29,327		)
	Total income before provision for income taxes	$	76,579			$	48,838			$	6,730
Schedule of Components of Income Tax Expense (Benefit)	The provision for income taxes was comprised of the following (in thousands):
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Current:
	Federal	$	16,293			$	39,353			$	4,747
	State	1,299				1,604				381
	International	2,998				1,470				668
		20,590				42,427				5,796
	Deferred:
	Federal	1,211				(28,678		)		6,615
	State	(310		)		427				175
	International	(370		)		(1,605		)		(1,057		)
		531				(29,856		)		5,733
	Total provision for income taxes	$	21,121			$	12,571			$	11,529
Schedule of Effective Income Tax Rate Reconciliation	The provision for income taxes differs from the U.S. statutory rate due to the following:
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	Statutory rate	35	%		35	%		35	%
	Federal tax credits	(2.1	)		(7.5	)		—
	Foreign rate differential	(4.3	)		(0.7	)		50.7
	Uncertain tax positions	0.6			1.7			(10.1	)
	State taxes, net of federal benefit	0.7			2.3			4.9
	Change in tax rate - loss of Swiss tax holiday	—			—			25.6
	Change in foreign tax rates	(0.6	)		(3.7	)		—
	Valuation allowance	(0.4	)		0.4			67.6
	Other	(1.3	)		(1.8	)		(2.4	)
	Effective tax rate	27.6	%		25.7	%		171.3	%
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets (liabilities) consist of the following (in thousands):
		At
		January 2,				January 3,
		2015				2014
	Tax credits	$	5,828			$	6,624
	Net operating loss carryforwards	6,721				9,161
	Inventories	3,335				4,202
	Accrued expenses	4,338				4,303
	Stock-based compensation	9,341				9,194
	Other	1,659				573
	Gross deferred tax assets	31,222				34,057
	Less valuation allowance	(10,709		)		(11,661		)
	Net deferred tax assets	20,513				22,396
	Property, plant and equipment	(2,646		)		(2,254		)
	Intangible assets	(57,850		)		(57,648		)
	Convertible subordinated notes	(5,006		)		(6,178		)
	Gross deferred tax liabilities	(65,502		)		(66,080		)
	Net deferred tax liability	$	(44,989	)		$	(43,684	)
	Presented as follows:
	Current deferred tax asset	$	6,168			$	6,008
	Current deferred tax liability	(588		)		(613		)
	Noncurrent deferred tax asset	2,626				2,933
	Noncurrent deferred tax liability	(53,195		)		(52,012		)
	Net deferred tax liability	$	(44,989	)		$	(43,684	)
Summary of Operating Loss and Tax Credit Carryforwards	As of January 2, 2015, the Company has the following carryforwards available:
	Jurisdiction	Tax		Amount				Begin to
		Attribute		(in millions)				Expire
	International	Net Operating Loss		48		-1		2015
	State	Net Operating Loss		37.6		-1		Various
	U.S. and State	R&D Tax Credit		0.7		-1		Various
	State	Investment Tax Credit		5.3				Various
	(1) The utilization of certain net operating losses and credits is subject to an annual limitation under Internal Revenue Code Section 382.
Summary of Income Tax Contingencies	Below is a summary of changes to the unrecognized tax benefit (in thousands):
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Balance, beginning of year	$	1,858			$	970			$	1,580
	Additions based upon tax positions related to the current year	268				325				—
	Additions related to prior period tax positions	510				651				210
	Reductions relating to settlements with tax authorities	(225		)		(88		)		(522		)
	Reductions as a result of a lapse of applicable statute of limitations	—				—				(298		)
	Balance, end of year	$	2,411			$	1,858			$	970

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Jan. 02, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranty Liability	The change in product warranty liability was comprised of the following (in thousands):
		Year Ended
		January 2,				January 3,
		2015				2014
	Beginning balance	$	1,819			$	2,626
	Additions to warranty reserve	953				1,624
	Warranty claims paid	(2,112		)		(2,431		)
	Ending balance	$	660			$	1,819
Operating Leases of Lessee Disclosure	Operating lease expense was as follows (in thousands):
		Year Ended
		January 2,				January 3,			December 28,
		2015				2014			2012
	Operating lease expense	$	4,281			$	4,379		$	4,024
Schedule of Future Minimum Rental Payments for Operating Leases	Minimum future estimated annual operating lease expenses are as follows (in thousands):
	2015	$	5,797
	2016	5,952
	2017	3,908
	2018	3,489
	2019	3,418
	Thereafter	13,938
	Total estimated operating lease expense	$	36,502
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The impact to the Company’s results of operations from these forward contracts was as follows (in thousands):
		Year Ended
		January 2,				January 3,			December 28,
		2015				2014			2012
	Reduction in Cost of Sales	$	(168	)		$	(1,154	)	$	(79	)
	Ineffective portion of change in fair value	—				—			—
Schedule of Foreign Exchange Contracts, Statement of Financial Position	Information regarding outstanding foreign currency contracts as of January 2, 2015 is as follows (dollars in thousands):
	Instrument	Type of		Aggregate				Start	End		$/Peso	Fair			Balance Sheet
		Hedge		Notional				Date	Date			Value			Location
				Amount
	FX Contract	Cash flow		$	16,880			15-Jan	15-Dec		0.0734	$	(1,568	)	Accrued Expenses

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Jan. 02, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts):
		Year Ended
		January 2,			January 3,			December 28,
		2015			2014			2012
	Numerator for basic EPS:
	Net income (loss)	$	55,458		$	36,267		$	(4,799	)
	Denominator for basic EPS:
	Weighted average shares outstanding	24,825			23,991			23,584
	Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,150			1,332			—
	Denominator for diluted EPS	25,975			25,323			23,584
	Basic EPS	$	2.23		$	1.51		$	(0.20	)
	Diluted EPS	$	2.14		$	1.43		$	(0.20	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met:
		Year Ended
		January 2,		January 3,			December 28,
		2015		2014			2012
	Time-vested stock options, restricted stock and restricted stock units	175,549		18,480			2,142,000
	Performance-vested stock options and restricted stock units	—		—			781,000

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Jan. 02, 2015																			Jan. 03, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income is comprised of the following (in thousands):
																					Defined			Cash			Foreign		Total			Tax			Net-of-Tax
		Defined			Cash			Foreign			Total			Tax			Net-of-Tax				Benefit			Flow			Currency		Pre-Tax						Amount
		Benefit			Flow			Currency			Pre-Tax						Amount				Plan			Hedges			Translation		Amount
		Plan			Hedges			Translation			Amount										Liability						Adjustment
		Liability						Adjustment												At December 28, 2012	$	(962	)	$	120		$	13,431	$	12,589		$	358		$	12,947
	At January 3, 2014	$	(672	)	$	(468	)	$	14,952		$	13,812		$	546		$	14,358
																				Unrealized gain on cash flow hedges	—			58			—		58			(20		)	38
	Unrealized loss on cash flow hedges	—			(2,372		)	—			(2,372		)	829			(1,543		)
																				Realized gain on foreign currency hedges	—			(1,154		)	—		(1,154		)	404			(750		)
	Realized gain on foreign currency hedges	—			(168		)	—			(168		)	59			(109		)
																				Realized loss on interest rate swap hedges	—			508			—		508			(178		)	330
	Realized loss on interest rate swap hedges	—			450			—			450			(157		)	293
																				Net defined benefit plan liability adjustments	290			—			—		290			(18		)	272
	Net defined benefit plan liability adjustments	(509		)	—			—			(509		)	135			(374		)
																				Foreign currency translation gain	—			—			1,521		1,521			—			1,521
	Foreign currency translation loss	—			—			(3,502		)	(3,502		)	—			(3,502		)
																				At January 3, 2014	$	(672	)	$	(468	)	$	14,952	$	13,812		$	546		$	14,358
	At January 2, 2015	$	(1,181	)	$	(2,558	)	$	11,450		$	7,711		$	1,412		$	9,123

Fair_Value_Tables

Fair Value (Tables)	12 Months Ended
	Jan. 02, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	Changes in accrued contingent consideration were as follows (in thousands):
	At December 28, 2012	$	1,530
	Fair value adjustments	(690		)
	At January 3, 2014	840
	Fair value adjustments	(840		)
	At January 2, 2015	$	—
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):
		Fair Value Measurements Using
	Description	At January 2, 2015			Quoted		Significant		Significant
					Prices in		Other		Unobservable
					Active Markets		Observable		Inputs
					for Identical		Inputs		(Level 3)
					Assets		(Level 2)
					(Level 1)
	Liabilities
	Foreign currency contracts (Note 15)	$	1,568		$	—	$	1,568	$	—
	Interest rate swaps (Note 9)	990			—		990		—
		Fair Value Measurements Using
	Description	At January 3,			Quoted		Significant		Significant
		2014			Prices in		Other		Unobservable
					Active Markets		Observable		Inputs
					for Identical		Inputs		(Level 3)
					Assets		(Level 2)
					(Level 1)
	Liabilities
	Foreign currency contracts	$	140		$	—	$	140	$	—
	Accrued contingent consideration	840			—		—		840
	Interest rate swap	328			—		328		—
Fair Value Measurements, Nonrecurring	The following table provides information regarding assets and liabilities recorded at fair value on a nonrecurring basis as of January 2, 2015. There were no such assets or liabilities as of January 3, 2014 (in thousands):
		Fair Value Measurements Using
	Description	At January 2, 2015			Quoted		Significant		Significant
					Prices in		Other		Unobservable
					Active Markets		Observable		Inputs
					for Identical		Inputs		(Level 3)
					Assets		(Level 2)
					(Level 1)
	Assets
	Assets Held for Sale (Note 5)	$	1,635		$	—	$	1,635	$	—

Business_Segment_Geographic_an1

Business Segment, Geographic and Concentration Risk Information (Tables)	12 Months Ended
	Jan. 02, 2015
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped to (in thousands):
		Year Ended
	Sales:	January 2,				January 3,				December 28,
		2015				2014				2012
	Greatbatch Medical
	Cardiac/Neuromodulation	$	321,419			$	325,412			$	306,669
	Orthopaedics	147,296				130,247				122,061
	Portable Medical	69,043				78,743				81,659
	Vascular	58,770				48,357				51,980
	Energy, Military, Environmental	81,757				78,143				81,353
	Total Greatbatch Medical	678,285				660,902				643,722
	QiG	9,502				3,043				2,455
	Total sales	$	687,787			$	663,945			$	646,177
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Segment income (loss) from operations:
	Greatbatch Medical	$	126,312			$	111,805			$	79,093
	QiG	(23,256		)		(30,484		)		(32,554		)
	Total segment income from operations	103,056				81,321				46,539
	Unallocated operating expenses	(27,402		)		(19,982		)		(20,718		)
	Operating income as reported	75,654				61,339				25,821
	Unallocated other income (expense), net	925				(12,501		)		(19,091		)
	Income before provision for income taxes as reported	$	76,579			$	48,838			$	6,730
Reconciliation Of Depreciation And Amortization By Reportable Segment To Consolidated
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Depreciation and Amortization:
	Greatbatch Medical	$	31,906			$	31,112			$	39,820
	QiG	2,101				1,539				630
	Total depreciation and amortization included in segment income from operations	34,007				32,651				40,450
	Unallocated depreciation and amortization	4,223				9,681				18,475
	Total depreciation and amortization	$	38,230			$	42,332			$	58,925
Schedule Of Expenditures For Tangible Long-Lived Assets By Segment
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Expenditures for tangible long-lived assets, excluding acquisitions:
	Greatbatch Medical	$	19,006			$	13,242			$	33,249
	QiG	1,453				2,134				3,208
	Total reportable segments	20,459				15,376				36,457
	Unallocated long-lived tangible assets	5,187				2,798				4,709
	Total expenditures	$	25,646			$	18,174			$	41,166
Reconciliation of Assets from Segment to Consolidated
		At
		January 2,				January 3,				December 28,
		2015				2014				2012
	Identifiable assets:
	Greatbatch Medical	$	761,225			$	758,369			$	779,890
	QiG	76,529				56,245				57,750
	Total reportable segments	837,754				814,614				837,640
	Unallocated assets	118,255				76,089				52,235
	Total assets	$	956,009			$	890,703			$	889,875
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
		Year Ended
		January 2,				January 3,				December 28,
		2015				2014				2012
	Sales by geographic area:
	United States	$	312,539			$	325,090			$	330,537
	Non-Domestic locations:
	Puerto Rico	127,702				117,961				105,731
	Belgium	65,308				67,155				58,043
	Rest of world	182,238				153,739				151,866
	Total sales	$	687,787			$	663,945			$	646,177
		At
		January 2,				January 3,				December 28,
		2015				2014				2012
	Long-lived tangible assets:
	United States	$	113,851			$	116,484			$	123,104
	Rest of world	31,074				29,289				27,789
	Total	$	144,925			$	145,773			$	150,893
Schedule of Revenue by Major Customers by Reporting Segments	A significant portion of the Company’s sales and accounts receivable were to four customers as follows:
		Sales									Accounts Receivable
		Year Ended									At
		January 2,			January 3,			December 28,			January 2,		January 3,
		2015			2014			2012			2015		2014
	Customer A	18	%		20	%		19	%		4	%	8	%
	Customer B	18	%		16	%		16	%		23	%	19	%
	Customer C	12	%		13	%		11	%		8	%	8	%
	Customer D	6	%		7	%		6	%		12	%	11	%
		54	%		56	%		52	%		47	%	46	%

Quarterly_Sales_and_Earnings_D1

Quarterly Sales and Earnings Data - Unaudited (Tables)	12 Months Ended
	Jan. 02, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information
		4th Qtr.		3rd Qtr.		2nd Qtr.		1st Qtr.
		(in thousands, except per share data)
	2014
	Sales	$	169,726	$	171,699	$	172,081	$	174,281
	Gross profit	57,214		58,118		58,470		57,596
	Net income	14,176		14,012		12,348		14,922
	EPS—basic	0.57		0.56		0.5		0.61
	EPS—diluted	0.54		0.54		0.48		0.58
	2013
	Sales	$	176,619	$	167,730	$	171,331	$	148,265
	Gross profit	57,385		55,877		57,302		48,749
	Net income	9,781		11,071		9,752		5,663
	EPS—basic	0.4		0.46		0.41		0.24
	EPS—diluted	0.38		0.44		0.39		0.23

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Basis of Presentation) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
	customer
	Segment
Schedule of Assets Useful Life [Line Items]
Number of Reportable Segments	2
Number of Customers	4
Weeks In Reporting Period	Fifty-two	Fifty-three	Fifty-two
Customer Supplied Components Excluded From Revenue	$48.10	$45.30	$32.60
Foreign Currency Transaction Gain (Loss), Realized	$1.30	($0.10)	($0.30)
Patented Technology [Member] | Minimum [Member]
Schedule of Assets Useful Life [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Patented Technology [Member] | Maximum [Member]
Schedule of Assets Useful Life [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Customer Lists [Member] | Minimum [Member]
Schedule of Assets Useful Life [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years
Customer Lists [Member] | Maximum [Member]
Schedule of Assets Useful Life [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Other Intangible Assets [Member] | Minimum [Member]
Schedule of Assets Useful Life [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Other Intangible Assets [Member] | Maximum [Member]
Schedule of Assets Useful Life [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Building and Building Improvements [Member] | Minimum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Building and Building Improvements [Member] | Maximum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Machinery and Equipment [Member] | Minimum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	8 years
Office Equipment [Member] | Minimum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Acquisitions_Narrative_Details

Acquisitions (Narrative) (Details) (USD $)	0 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended
	Aug. 12, 2014	Jan. 02, 2015	Feb. 16, 2012	Dec. 28, 2012	Jan. 03, 2014
Business Acquisition [Line Items]
Contingent consideration liability		$0		$1,530,000	$840,000
Centro De Construccion De Cardioestimuladores Del Uruguay [Member]
Business Acquisition [Line Items]
Effective date of acquisition	12-Aug-14
Name of acquired entity	Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”)
Description of acquired entity	CCC is an active implantable neuromodulation medical device systems developer and manufacturer that produces a range of medical devices including implantable pulse generators, programmer systems, battery chargers, patient wands and leads.
Reason for acquisition	This acquisition allows the Company to more broadly partner with medical device companies, complements the Company’s core discrete technology offerings and enhances the Company’s medical device innovation efforts.
Total revenue included from the acquired entity		5,800,000
Total net income included from the acquired entity		1,200,000
Cash paid	19,800,000
Increase in inventory	300,000
Centro De Construccion De Cardioestimuladores Del Uruguay [Member] | Technology-Based Intangible Assets [Member]
Business Acquisition [Line Items]
Royalty rate	3.00%
Centro De Construccion De Cardioestimuladores Del Uruguay [Member] | Customer Lists [Member]
Business Acquisition [Line Items]
Customer annual attrition rate	15.00%
Centro De Construccion De Cardioestimuladores Del Uruguay [Member] | Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Royalty rate	0.50%
Neuro Nexus Technologies Inc [Member]
Business Acquisition [Line Items]
Effective date of acquisition			16-Feb-12
Name of acquired entity			NeuroNexus Technologies, Inc.
Description of acquired entity			NeuroNexus is an active implantable medical device design firm specializing in developing and commercializing neural interface technology, components and systems for neuroscience and clinical markets.
Reason for acquisition			NeuroNexus has an extensive intellectual property portfolio, core technologies and capabilities to support the development and manufacturing of neural interface devices across a wide range of applications including neuromodulation, sensing, optical stimulation and targeted drug delivery.
Total revenue included from the acquired entity				2,500,000
Total net income included from the acquired entity				-200,000
Cash paid			11,700,000
Potential future payments (maximum)			2,000,000
Contingent consideration liability			1,500,000
Neuro Nexus Technologies Inc [Member] | Patented Technology [Member]
Business Acquisition [Line Items]
Minimum royalty rate assumed, acquired finite lived intangible assets			2.00%
Maximum royalty rate assumed, acquired finite lived intangible assets			6.00%
Neuro Nexus Technologies Inc [Member] | In Process Research And Development [Member]
Business Acquisition [Line Items]
Estimated cost to complete in process research and development programs acquired			$1,500,000

Acquisitions_Details_1

Acquisitions (Details 1) (USD $)	Jan. 02, 2015	Jan. 03, 2014	Aug. 12, 2014	Feb. 16, 2012
In Thousands, unless otherwise specified
Assets acquired
Goodwill	$354,393	$346,656
Centro De Construccion De Cardioestimuladores Del Uruguay [Member]
Assets acquired
Current assets			10,670
Property, plant and equipment			1,131
Amortizing intangible assets			6,100
Goodwill			8,296
Total assets acquired			26,197
Liabilities assumed
Current liabilities			4,842
Deferred income taxes			1,590
Total liabilities assumed			6,432
Net assets acquired			19,765
Neuro Nexus Technologies Inc [Member]
Assets acquired
Current assets				618
Property, plant and equipment				35
Amortizing intangible assets				2,927
Indefinite-lived intangible assets				540
Goodwill				8,924
Other assets				1,576
Total assets acquired				14,620
Liabilities assumed
Current liabilities				420
Deferred income taxes				989
Total liabilities assumed				1,409
Net assets acquired				$13,211

Acquisitions_Details_2

Acquisitions (Details 2) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Aug. 12, 2014	Feb. 16, 2012
Centro De Construccion De Cardioestimuladores Del Uruguay [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortizing intangible assets	$6,100
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Neuro Nexus Technologies Inc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortizing intangible assets		2,927
Weighted Average Amortization Period (Years)		7 years
Weighted Average Useful Life (Years)		13 years
Weighted Average Discount Rate		13.00%
Patented Technology [Member] | Centro De Construccion De Cardioestimuladores Del Uruguay [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortizing intangible assets	1,400
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Patented Technology [Member] | Neuro Nexus Technologies Inc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortizing intangible assets		1,058
Weighted Average Amortization Period (Years)		6 years
Weighted Average Useful Life (Years)		10 years
Weighted Average Discount Rate		14.00%
Customer Lists [Member] | Centro De Construccion De Cardioestimuladores Del Uruguay [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortizing intangible assets	4,600
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Customer Lists [Member] | Neuro Nexus Technologies Inc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortizing intangible assets		1,869
Weighted Average Amortization Period (Years)		7 years
Weighted Average Useful Life (Years)		15 years
Weighted Average Discount Rate		13.00%
Trademarks and Trade Names [Member] | Centro De Construccion De Cardioestimuladores Del Uruguay [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortizing intangible assets	$100
Weighted Average Amortization Period (Years)	2 years
Weighted Average Discount Rate	18.00%

Acquisitions_Acquired_Indefini

Acquisitions (Acquired Indefinite-lived Intangible Assets) (Details) (Neuro Nexus Technologies Inc [Member], In Process Research And Development [Member], USD $)	0 Months Ended
In Thousands, unless otherwise specified	Feb. 16, 2012
Neuro Nexus Technologies Inc [Member] | In Process Research And Development [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived assets acquired	$540
Weighted Average Useful Life (Years)	12 years
Weighted Average Discount Rate	26.00%

Acquisitions_Pro_Forma_Informa

Acquisitions (Pro Forma Information) (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Business Acquisition, Pro Forma Information [Abstract]
Sales	$696,357	$677,657	$646,617
Net income (loss)	$56,453	$37,612	($4,973)
Basic earnings per share (in dollars per share)	$2.27	$1.57	($0.21)
Diluted earnings per share (in dollars per share)	$2.17	$1.49	($0.21)

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Noncash investing and financing activities:
Common stock contributed to 401(k) Plan	$4,341	$2,477	$4,793
Property, plant and equipment purchases included in accounts payable	2,926	2,103	2,522
Cash paid during the year for:
Interest	3,521	4,989	6,230
Income taxes	13,565	44,165	4,909
Acquisition of noncash assets	22,434	0	14,396
Liabilities assumed	$6,432	$0	$1,244

Inventories_Details

Inventories (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$73,354	$67,939
Work-in-process	38,930	36,670
Finished goods	16,958	13,749
Inventories	$129,242	$118,358

Assets_Held_For_Sale_Details

Assets Held For Sale (Details) (Building [Member], Swiss Orthopaedic Product Line [Member], Greatbatch Medical [Member], USD $)	Jan. 02, 2015	Jan. 03, 2014
In Thousands, unless otherwise specified
Building [Member] | Swiss Orthopaedic Product Line [Member] | Greatbatch Medical [Member]
Assets Held For Sale Detail [Line Items]
Current assets held-for-sale	$1,635	$0

Assets_Held_For_Sale_Narrative

Assets Held For Sale (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012	Jan. 02, 2015
Assets Held For Sale Detail [Line Items]
Impairment of Long-Lived Assets to be Disposed of	$0.40	$0.90	$3.60
Orthopaedic Facility Optimization [Member]
Assets Held For Sale Detail [Line Items]
Assets Held for Sale (Note 5)				2.1
Impairment of Long-Lived Assets to be Disposed of	$0.40

Property_Plant_and_Equipment_N2

Property, Plant and Equipment, Net (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$358,945	$341,857
Accumulated depreciation	-214,020	-196,084
Total	144,925	145,773	150,893
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	167,173	159,542
Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	89,258	87,359
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	31,725	28,010
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	31,170	31,522
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	14,045	13,889
Land and Land Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	10,816	13,016
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	14,129	7,886
Other Capitalized Property Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$629	$633

Property_Plant_and_Equipment_N3

Property, Plant and Equipment, Net (Depreciation Expense) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Property, Plant and Equipment [Abstract]
Depreciation	$23,320	$22,799	$31,575

Intangible_Assets_Narrative_De

Intangible Assets (Narrative) (Details) (USD $)	12 Months Ended
	Jan. 02, 2015	Jan. 03, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Contingent Liability From Intangible Asset Purchase		$4,000,000
Reversal of Contingent Liability From Intangible Asset Purchase	3,000,000
Goodwill, Impaired, Accumulated Impairment Loss	$0

Intangible_Assets_Amortizing_I

Intangible Assets (Amortizing Intangible Assets) (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$173,167,000	$170,067,000
Accumulated Amortization	-111,973,000	-98,096,000
Foreign Currency Translation	4,143,000	4,151,000
Net Carrying Amount	65,337,000	76,122,000
Purchased Technology And Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	95,776,000	97,376,000
Accumulated Amortization	-75,894,000	-69,026,000
Foreign Currency Translation	1,966,000	1,980,000
Net Carrying Amount	21,848,000	30,330,000
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	72,857,000	68,257,000
Accumulated Amortization	-31,460,000	-24,671,000
Foreign Currency Translation	1,374,000	1,367,000
Net Carrying Amount	42,771,000	44,953,000
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,534,000	4,434,000
Accumulated Amortization	-4,619,000	-4,399,000
Foreign Currency Translation	803,000	804,000
Net Carrying Amount	$718,000	$839,000

Intangible_Assets_Amortization

Intangible Assets (Amortization Expense by categories) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$13,877	$13,167	$14,261
Cost of Sales [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	6,201	6,822	7,489
Selling, General and Administrative Expenses [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	7,009	5,800	6,227
Research and Development Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$667	$545	$545

Intangible_Assets_Future_Amort

Intangible Assets (Future Amortization Expense) (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$12,988
2016	10,676
2017	9,520
2018	7,232
2019	5,431
Thereafter	19,490
Net Carrying Amount	$65,337	$76,122

Intangible_Assets_Change_in_In

Intangible Assets (Change in Indefinite-lived Assets and Goodwill) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-lived intangible assets, beginning	$20,288
Indefinite-lived intangible assets, ending	20,288
Goodwill [Roll Forward]
Goodwill, beginning	346,656
Goodwill acquired	8,296
Foreign currency translation	-559
Goodwill, ending	354,393
Greatbatch Medical [Member]
Goodwill [Roll Forward]
Goodwill, beginning	304,856
Goodwill acquired	0
Foreign currency translation	-559
Goodwill, ending	304,297
QiG [Member]
Goodwill [Roll Forward]
Goodwill, beginning	41,800
Goodwill acquired	8,296
Foreign currency translation	0
Goodwill, ending	50,096
Trademarks and Trade Names [Member]
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-lived intangible assets, beginning		20,288
Indefinite-lived intangible assets, ending	$20,288	$20,288

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014
In Thousands, unless otherwise specified
Accounts Payable and Accrued Liabilities [Abstract]
Salaries and benefits	$20,770	$16,311
Profit sharing and bonuses	18,524	19,808
Warranty	660	1,819
Other	8,430	6,743
Total	$48,384	$44,681

Debt_Schedule_of_LongTerm_Debt

Debt (Schedule of Long-Term Debt) (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]
Term Loan	$187,500	$197,500
Line of Credit Facility, Amount Outstanding	0	0
Long-term Debt	187,500	197,500
Current portion of long-term debt	11,250	0
Long-term debt	$176,250	$197,500

Debt_Credit_Facility_Details_D

Debt (Credit Facility Details) (Details 1) (USD $)	1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Jan. 02, 2015
Line of Credit Facility [Abstract]
Credit Facility, Amendment Date	20-Sep-13
Line of Credit Facility, Maximum Borrowing Capacity	$300
Term Loan, Maximum Borrowing Capacity	200
Letter of Credit Subfacility Maximum Borrowing Capacity	15
Swingline Subfacility Maximum Borrowing Capacity	15
Credit Facility Borrowing Capacity Increase	200
Line of Credit Facility, Expiration Date	20-Sep-18
Line Of Credit Expiration Date Extension	20-Sep-19
Debt Instrument, Maturity Date	20-Sep-19
Debt Instrument, Collateral		The Credit Facility is secured by the Company’s non-realty assets including cash, accounts receivable and inventories.
Interest Margin Above Prime Minimum Credit Facility	0.00%
Interest Margin Above Prime Maximum Credit Facility	0.75%
Interest Margin Above LIBOR Minimum Credit Facility	1.38%
Interest Margin Above LIBOR Maximum Credit Facility	2.75%
Interest Margin Above Prime Minimum Swingline	0.00%
Interest Margin Above Prime Maximum Swingline	0.75%
Line of Credit Facility Commitment Fee Percentage Minimum	0.18%
Line of Credit Facility Commitment Fee Percentage Maximum	0.25%
Credit Facility Aggregate Restricted Activities Limit	300
Credit Facility Maximum Permitted Acquisitions	250
Credit Facility Maximum Other Investment Purchases	100
Credit Facility Maximum Stock Repurchases and Declare Dividends	150
Credit Facility Maximum Foreign Subsidiary Investment	20
Line of Credit, Adjustments to Limitations on Incurrence of Indebtedness, Maximum Leverage Ratio	2.75
Credit Facility Restriction Available		100.00%
Credit Facility Aggregate Restricted Activities Limit Remaining		277
Credit Facility Maximum Permitted Acquisitions Remaining		230
Credit Facility Maximum Oth Investment Purchases Remaining		97
Line of Credit, Adjusted EBITDA to Interest Expense, Ratio Required		3
Line of Credit, Leverage Ratio, Maximum		4.5
Line of Credit, Leverage Ratio, Maximum, As of Covenant Restrictive Effective Date		4.25
Total Leverage Covenant Restriction Effective Date		2-Jan-16
Debt Instrument, Covenant Compliance		As of Janaury 2, 2015, the Company was in compliance with all covenants under the Credit Facility.
Debt, Weighted Average Interest Rate		1.57%
Debt Instrument, Unused Borrowing Capacity, Amount		$300

Debt_Convertible_Notes_and_Int

Debt (Convertible Notes and Interest Rate Swap Details) (Details 2) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
	Feb. 20, 2013	Mar. 31, 2007	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Debt Instruments [Abstract]
Convertible Subordinated Debt		$197,800,000
Debt Discount Percentage		5.00%
Debt Instrument, Interest Rate, Stated Percentage		2.25%
Debt Instrument, Interest Rate During Period		8.50%
Debt Redemption Date	20-Feb-13
Derivative [Line Items]
Interest expense			4,252,000	11,261,000	18,054,000
Interest Rate Swap [Member]
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net			0	0	0
Interest expense			500,000	500,000	0
Interest Rate Swap 1 [Member]
Derivative [Line Items]
Interest Rate Swap Term					3 years
Type of Hedge			Cash flow
Notional Amount			100,000,000		150,000,000
Start Date			20-Feb-13
End Date			22-Feb-16
Derivative, Fixed Interest Rate			0.57%
Derivative, Variable Interest Rate			0.16%
Annual Notional Amortizing Amount			50,000,000
Interest Rate Swap 1 [Member] | Other Liabilities [Member]
Derivative [Line Items]
Fair Value			-125,000
Interest Rate Swap 2 [Member]
Derivative [Line Items]
Type of Hedge			Cash flow
Notional Amount			90,000,000
Start Date			20-Feb-15
End Date			20-Sep-19
Derivative, Fixed Interest Rate			1.92%
Annual Notional Amortizing Amount			10,000,000
Notional amortizing start date			21-Feb-17
Interest Rate Swap 2 [Member] | Other Liabilities [Member]
Derivative [Line Items]
Fair Value			-865,000
Interest Rate Swap 2a [Member]
Derivative [Line Items]
Notional Amount			45,000,000
Start Date			20-Feb-15
Interest Rate Swap 2b [Member]
Derivative [Line Items]
Notional Amount			$45,000,000
Start Date			22-Feb-16

Debt_Contractual_Interest_and_

Debt (Contractual Interest and Discount Amortization) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Interest Costs Incurred [Abstract]
Contractual interest	$0	$634	$4,450
Discount amortization	$0	$5,368	$11,464

Debt_Longterm_Debt_Maturity_Sc

Debt (Long-term Debt Maturity Schedule) (Details 4) (USD $)	Jan. 02, 2015	Jan. 03, 2014
In Thousands, unless otherwise specified
Long-term Debt, Fiscal Year Maturity [Abstract]
2015	$11,250
2016	16,250
2017	20,000
2018	20,000
2019	120,000
Long-term Debt	$187,500	$197,500

Debt_Deferred_Financing_Fees_D

Debt (Deferred Financing Fees) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014
Deferred Finance Costs [Roll Forward]
Deferred Finance Costs, Net, Beginning Balance	$3,860	$2,056
Financing costs deferred		2,802
Write-off during the period		-156
Amortization during the period	-773	-842
Deferred Finance Costs, Net, Ending Balance	$3,087	$3,860

Benefit_Plans_Narrative_Detail

Benefit Plans (Narrative) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Defined Contribution And Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Basis Points	0.50%
Defined Contribution Plan Cash [Member]
Defined Contribution And Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent	35.00%	35.00%	35.00%
Defined Contribution Plan, Maximum Annual Contribution Per Employee, Percent	6.00%	6.00%	6.00%
Defined Contribution Plan, Cost Recognized	$2.20	$2	$2
Defined Contribution Plan Stock [Member]
Defined Contribution And Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent	4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	4.2	4.8	1.9
Shares Held In Employee Stock Plan	602,604
Education Assistance Program [Member]
Defined Contribution And Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Cost Recognized	$1.90	$2	$2.20

Benefit_Plans_Change_in_projec

Benefit Plans (Change in projected benefit obligation) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Projected benefit obligation at beginning of year	$2,422	$16,215
Service cost	203	236
Interest cost	75	138
Prior service cost and plan amendments	0	-45
Plan participants’ contribution	36	134
Actuarial (gain) loss	630	-2
Benefits transferred in, net	155	434
Settlement/curtailment gain	-337	-14,539
Foreign currency translation	-341	-149
Projected benefit obligation at end of year	$2,843	$2,422

Benefit_Plans_Change_in_fair_v

Benefit Plans (Change in fair value of plan assets) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	$731	$12,269
Employer contributions (refund)	-39	150
Plan participants’ contribution	36	134
Actual loss on plan assets	-101	-26
Benefits transferred in, net	198	138
Settlements	-337	-11,780
Foreign currency translation	-51	-154
Fair value of plan assets at end of year	437	731
Projected benefit obligation in excess of plan assets at end of year	2,406	1,691
Defined benefit liability classified as other current liabilities	25	25
Defined benefit liability classified as long-term liabilities	2,381	1,666
Accumulated benefit obligation at end of year	$1,938	$1,684

Benefit_Plans_Amount_recognize

Benefit Plans (Amount recognized in Accumulated Other Comprehensive Income) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Net loss occurring during the year	$736	$25
Amortization of losses	-138	-722
Prior service cost	-2	150
Amortization of prior service cost	-11	33
Foreign currency translation	-76	224
Pre-tax adjustment	509	-290
Taxes	-135	18
Net (gain) loss	$374	($272)	($1,685)

Benefit_Plans_Amortization_to_

Benefit Plans (Amortization to be recognized in Accumulated Other Comprehensive Income) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Amortization of net prior service credit	$11
Amortization of net loss	$45

Benefit_Plans_Net_Pension_Cost

Benefit Plans (Net Pension Costs) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Service cost	$203	$236
Interest cost	75	138
Settlements loss	105	0
Expected return on assets	-3	0
Recognized net actuarial loss (gain)	45	-1,929
Net pension cost (income)	$425	($1,555)

Benefit_Plans_Actuarial_valuat

Benefit Plans (Actuarial valuations) (Details)	12 Months Ended
	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	2.30%	3.40%
Salary growth	3.00%	3.10%
Expected rate of return on assets	2.30%	2.50%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	3.40%	2.10%	2.50%
Salary growth	3.10%	2.40%	2.30%
Expected rate of return on assets	2.50%	0.00%	3.50%

Benefit_Plans_Plan_assets_comp

Benefit Plans (Plan assets components) (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
In Thousands, unless otherwise specified
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$437	$731	$12,269
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	437	731
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Insurance Contract [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	437	731
Insurance Contract [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Insurance Contract [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	437	731
Insurance Contract [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$0	$0

Benefit_Plans_Estimated_benefi

Benefit Plans (Estimated benefit payments over next ten years) (Details) (USD $)	Jan. 02, 2015
In Thousands, unless otherwise specified
Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract]
2015	$47
2016	67
2017	124
2018	113
2019	177
2020-2024	$866

StockBased_Compensation_Narrat

Stock-Based Compensation (Narratives) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum term of share based award	10 years
Closing stock price	$48.66
Unrecognized compensation cost related to non-vested stock options	$2.10
Period for recognition	2 years
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Restricted Stock and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period for recognition	2 years
Tax benefit (expense) from compensation expense	2.3	-0.4	-0.02
Total unrecognized compensation cost	7.7
Fair value of shares vested	$12.50	$4	$1.50
Restricted Stock and Restricted Stock Units [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Potential performance based restricted stock units to be issued based on shareholder return	0
Restricted Stock and Restricted Stock Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Potential performance based restricted stock units to be issued based on shareholder return	716,163
Restricted Stock And Unit Awards [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Two Thousand Five Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	2,450,000
Number of shares available for grant	16,799
Two Thousand Five Plan [Member] | Restricted Stock and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	850,000
Number of shares available for grant	3,625
Two Thousand Nine Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	1,350,000
Number of shares available for grant	316,695
Two Thousand Nine Plan [Member] | Restricted Stock and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	200,000
Number of shares available for grant	26,594
Two Thousand Eleven Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	1,350,000
Number of shares available for grant	575,451

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	$13,186	$14,101	$10,904
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	3,530	3,864	2,620
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	7,923	7,907	7,684
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	1,440	1,194	600
Other Operating Expenses, net [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	293	1,136	0
Employee Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	2,523	3,490	2,786
Restricted Stock And Unit Awards [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	6,417	5,843	6,233
Defined Contribution Plan Stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	$4,246	$4,768	$1,885

StockBased_Compensation_Weight

Stock-Based Compensation (Weighted-Average Fair Value and Assumptions) (Details 1) (USD $)	12 Months Ended
	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant date fair value	$16.43	$8.38	$8.20
Risk-free interest rate	1.73%	0.73%	0.83%
Expected volatility	39.00%	39.00%	40.00%
Expected life (in years)	5 years 3 months 18 days	5 years 3 months 18 days	5 years 3 months 18 days
Expected dividend yield	0.00%	0.00%	0.00%
Annual prevesting forfeiture rate	9.00%	9.00%	9.00%

StockBased_Compensation_TimeVe

Stock-Based Compensation (Time-Vested Stock Option Activity) (Details 2) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Stock Options Time Based [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Stock Options Outstanding, Beginning	1,616,409	1,775,847	1,558,771
Option Grants in Period, Gross	183,571	372,676	395,978
Option Exercises in Period	-295,203	-443,428	-52,683
Option Forfeitures and Expirations in Period	-33,279	-88,686	-126,219
Stock Options Outstanding, Ending	1,471,498	1,616,409	1,775,847
Options Expected to Vest, Number	1,447,519
Options Exercisable, Number	1,278,765
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Exercise Price, Beginning	$22.92	$23.17	$23.42
Option Grants in Period, Weighted Average Exercise Price	$43.84	$23.33	$22.19
Option Exercises in Period, Weighted Average Exercise Price	$23.42	$23.24	$20.77
Option Forfeitures and Expirations in Period, Weighted Average Exercise Price	$27.82	$28.05	$24.21
Options Outstanding, Weighted Average Exercise Price, Ending	$25.32	$22.92	$23.17
Options Expected to Vest, Weighted Average Exercise Price	$25.10
Options Exercisable, Weighted Average Exercise Price	$23.88
Options Outstanding, Weighted Average Remaining Contractual Term	6 years 1 month 6 days
Options Expected to Vest, Weighted Average Remaining Contractual Term	6 years 1 month 6 days
Options Exercisable, Weighted Average Remaining Contractual Term	5 years 9 months 18 days
Options Outstanding, Intrinsic Value	$34.30
Options Expected to Vest, Intrinsic Value	34.1
Options Exercisable, Intrinsic Value	31.7
Stock Options Performance Based [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Stock Options Outstanding, Beginning	177,261	284,925	478,364
Option Exercises in Period	-58,422	-107,664	-7,657
Option Forfeitures and Expirations in Period	0	0	-185,782
Stock Options Outstanding, Ending	118,839	177,261	284,925
Options Expected to Vest, Number	118,839
Options Exercisable, Number	118,839
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Exercise Price, Beginning	$23.27	$23.26	$24.44
Option Exercises in Period, Weighted Average Exercise Price	$23.35	$23.23	$22.04
Option Forfeitures and Expirations in Period, Weighted Average Exercise Price	$0	$0	$26.35
Options Outstanding, Weighted Average Exercise Price, Ending	$23.24	$23.27	$23.26
Options Expected to Vest, Weighted Average Exercise Price	$23.24
Options Exercisable, Weighted Average Exercise Price	$23.24
Options Outstanding, Weighted Average Remaining Contractual Term	3 years 0 months 0 days
Options Expected to Vest, Weighted Average Remaining Contractual Term	3 years 0 months 0 days
Options Exercisable, Weighted Average Remaining Contractual Term	3 years 0 months 0 days
Options Outstanding, Intrinsic Value	3
Options Expected to Vest, Intrinsic Value	3
Options Exercisable, Intrinsic Value	$3

StockBased_Compensation_Exerci

Stock-Based Compensation (Exercise of Stock Option) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Intrinsic value	$7,997	$6,807	$148
Cash received	8,278	12,807	1,263
Tax benefit (expense) realized	$1,704	$727	($132)

StockBased_Compensation_Restri

Stock-Based Compensation (Restricted Stock and Restricted Stock Units)(Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Restricted Stock And Restricted Stock Units Time Based [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested Restricted Stock Units and Awards, Beginning	67,575	80,269	69,942
Restricted Stock Units and Awards Granted	63,817	67,230	92,265
Restricted Stock Units and Awards Vested	-53,568	-74,062	-74,901
Restricted Stock Units and Awards Forfeited	-9,992	-5,862	-7,037
Nonvested Restricted Stock Units and Awards, Ending	67,832	67,575	80,269
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Beginning	$26.37	$23.48	$22.69
Restricted Stock Units and Awards Granted, Weighted Average Fair Value	$44.78	$26.76	$23.49
Restricted Stock Units and Awards Vested, Weighted Average Fair Value	$34.16	$23.93	$22.83
Restricted Stock Units and Awards Forfeited, Weighted Average Fair Value	$35.30	$22.26	$22.56
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Ending	$36.22	$26.37	$23.48
Restricted Stock And Restricted Stock Units Performance Based [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested Restricted Stock Units and Awards, Beginning	779,678	782,446	529,743
Restricted Stock Units and Awards Granted	186,825	318,169	332,918
Restricted Stock Units and Awards Vested	-221,470	-49,139	-15,500
Restricted Stock Units and Awards Forfeited	-28,870	-271,798	-64,715
Nonvested Restricted Stock Units and Awards, Ending	716,163	779,678	782,446
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Beginning	$16.41	$16.02	$16.68
Restricted Stock Units and Awards Granted, Weighted Average Fair Value	$31.33	$15.86	$15.30
Restricted Stock Units and Awards Vested, Weighted Average Fair Value	$18.51	$14.68	$24.64
Restricted Stock Units and Awards Forfeited, Weighted Average Fair Value	$18.42	$14.94	$15.72
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Ending	$19.57	$16.41	$16.02
Restricted Stock and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Tax Benefit (Expense) from Vesting of Restricted Stock and Restricted Stock Units	$2.30	($0.40)	($0.02)

Research_Development_and_Engin2

Research, Development and Engineering Costs (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Research and development expense [Line Items]
Research and Development Expense (Excluding Acquired in Process Cost)	$49,845	$54,077	$52,490
Research, Development, and Engineering Costs [Member]
Research and development expense [Line Items]
Research and Development Expense (Excluding Acquired in Process Cost)	58,974	62,652	62,848
Customer Cost Reimbursements [Member]
Research and development expense [Line Items]
Research and Development Expense (Excluding Acquired in Process Cost)	($9,129)	($8,575)	($10,358)

Other_Operating_Expenses_Net_N

Other Operating Expenses, Net (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
	Jan. 02, 2015	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Restructuring Cost and Reserve [Line Items]
Fair value adjustments		$840,000	$690,000
Impairment of Long-Lived Assets to be Disposed of	400,000		900,000	3,600,000
Indefinite-lived assets written-off (Note 18)			-500,000
Relocation costs		15,297,000	15,790,000	42,346,000
Investments in Capacity and Capabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date		2014
Restructuring And Related Activities Capital Expenditures Incurred To Date		4,000,000
Restructuring and Related Cost, Cost Incurred to Date	8,900,000	8,900,000
Investments in Capacity and Capabilities [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures		25,000,000
Restructuring and Related Cost, Expected Cost	29,000,000	29,000,000
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	7,000,000	7,000,000
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	2,000,000	2,000,000
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	20,000,000	20,000,000
Investments in Capacity and Capabilities [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures		27,000,000
Restructuring and Related Cost, Expected Cost	34,000,000	34,000,000
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	9,000,000	9,000,000
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	3,000,000	3,000,000
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	22,000,000	22,000,000
Operating Unit Realignment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date		2013
Initiatives, Expected Period of Completion		0 months
Restructuring and Related Cost, Cost Incurred to Date	6,600,000	6,600,000
Operating Unit Realignment [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	5,000,000	5,000,000
Operating Unit Realignment [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	1,600,000	1,600,000
Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date		2010
Restructuring and Related Costs, Facility Consolidations		2
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Curtailments			1,900,000
Impairment of Long-Lived Assets to be Disposed of	400,000
Initiatives, Expected Period of Completion		2 years
Restructuring And Related Activities Capital Expenditures Incurred To Date		24,800,000
Restructuring and Related Cost, Cost Incurred to Date	42,500,000	42,500,000
Assets Transferred to Held for Sale		2,100,000
Orthopaedic Facility Optimization [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures		30,000,000
Restructuring and Related Cost, Expected Cost	43,000,000	43,000,000
Orthopaedic Facility Optimization [Member] | Minimum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	11,000,000	11,000,000
Orthopaedic Facility Optimization [Member] | Minimum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	13,000,000	13,000,000
Orthopaedic Facility Optimization [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	19,000,000	19,000,000
Orthopaedic Facility Optimization [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures		35,000,000
Restructuring and Related Cost, Expected Cost	48,000,000	48,000,000
Orthopaedic Facility Optimization [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	24,000,000	24,000,000
Medical Device Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date		2011
Restructuring and Related Costs, Facility Expansions		2
Initiatives, Expected Period of Completion		0 years
Restructuring And Related Activities Capital Expenditures Incurred To Date		12,500,000
Restructuring and Related Cost, Cost Incurred to Date	1,800,000	1,800,000
Medical Device Facility Optimization [Member] | Production Inefficiencies, Moving And Revalidation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	700,000	700,000
Medical Device Facility Optimization [Member] | Personnel [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	600,000	600,000
Medical Device Facility Optimization [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	500,000	500,000
ERP System Upgrade [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date		2011
Initiatives, Expected Period of Completion		0 months
Restructuring And Related Activities Capital Expenditures Incurred To Date		4,000,000
Restructuring and Related Cost, Cost Incurred to Date	5,700,000	5,700,000
ERP System Upgrade [Member] | Training And Consulting Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	3,200,000	3,200,000
ERP System Upgrade [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	2,500,000	2,500,000
Corporate Headquarters Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Relocation costs				1,200,000
In Process Research And Development [Member] | QiG [Member]
Restructuring Cost and Reserve [Line Items]
Indefinite-lived assets written-off (Note 18)			-540,000
Swiss Orthopaedic Product Line [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Impairment of Long-Lived Assets to be Disposed of				3,600,000
Disposal Group, Payments Received			4,700,000
Liabilities Assumed By Third Parties			2,400,000
Assets Held-For-Sale, Expected Gain From Earn-Out Payment		2,700,000
Wireless Sensing [Member] | Greatbatch Medical [Member]
Restructuring Cost and Reserve [Line Items]
Write-off			900,000
Executive Vice President [Member]
Restructuring Cost and Reserve [Line Items]
Severance Costs		$900,000

Other_Operating_Expenses_Net_D

Other Operating Expenses, Net (Details) (USD $)	12 Months Ended
	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Operating Costs and Expenses [Abstract]
Other operating (income) expense, net	$15,297,000	$15,790,000	$42,346,000
Investments in Capacity and Capabilities [Member]
Operating Costs and Expenses [Abstract]
Other operating (income) expense, net	8,925,000	0	0
Operating Unit Realignment [Member]
Operating Costs and Expenses [Abstract]
Other operating (income) expense, net	1,017,000	5,625,000	0
Orthopaedic facility optimization [Member]
Operating Costs and Expenses [Abstract]
Other operating (income) expense, net	1,317,000	8,038,000	32,482,000
Medical device facility optimization [Member]
Operating Costs and Expenses [Abstract]
Other operating (income) expense, net	11,000	312,000	1,525,000
ERP system upgrade [Member]
Operating Costs and Expenses [Abstract]
Other operating (income) expense, net	-82,000	783,000	5,041,000
Integration costs [Member]
Operating Costs and Expenses [Abstract]
Other operating (income) expense, net	3,000	-502,000	1,460,000
Asset dispositions severance and other [Member]
Operating Costs and Expenses [Abstract]
Other operating (income) expense, net	4,106,000	1,534,000	1,838,000
Operating Unit Realignment [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	6,600,000
Orthopaedic Facility Optimization [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	42,500,000
Medical Device Facility Optimization [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	1,800,000
ERP System Upgrade [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	$5,700,000

Other_Operating_Expenses_Net_C

Other Operating Expenses, Net (Changes in Accrued Liabilities) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015
Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	$0
Restructuring charges	8,925
Write-offs	-33
Cash payments	-6,663
Restructuring Reserve, Ending balance	2,229
Operating Unit Realignment [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	1,211
Restructuring charges	1,017
Cash payments	-2,228
Restructuring Reserve, Ending balance	0
Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	857
Restructuring charges	1,317
Write-offs	-400
Cash payments	-1,487
Restructuring Reserve, Ending balance	287
Medical Device Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	11
Cash payments	-11
Restructuring Reserve, Ending balance	0
ERP System Upgrade [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	-82
Cash payments	82
Restructuring Reserve, Ending balance	0
Severance And Retention [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	2,209
Cash payments	-1,046
Restructuring Reserve, Ending balance	1,163
Severance And Retention [Member] | Operating Unit Realignment [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	465
Restructuring charges	849
Cash payments	-1,314
Restructuring Reserve, Ending balance	0
Severance And Retention [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	0
Write-offs	0
Cash payments	0
Restructuring Reserve, Ending balance	0
Production Inefficiencies, Moving And Revalidation [Member] | Medical Device Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	0
Cash payments	0
Restructuring Reserve, Ending balance	0
Training And Consulting Costs [Member] | ERP System Upgrade [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	-82
Cash payments	82
Restructuring Reserve, Ending balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	33
Write-offs	-33
Cash payments	0
Restructuring Reserve, Ending balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	-2,255
Write-offs	-400
Cash payments	2,655
Restructuring Reserve, Ending balance	0
Accelerated Depreciation And Asset Write Offs [Member] | ERP System Upgrade [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	0
Cash payments	0
Restructuring Reserve, Ending balance	0
Personnel [Member] | Medical Device Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	1
Cash payments	-1
Restructuring Reserve, Ending balance	0
Other Restructuring [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	6,683
Cash payments	-5,617
Restructuring Reserve, Ending balance	1,066
Other Restructuring [Member] | Operating Unit Realignment [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	746
Restructuring charges	168
Cash payments	-914
Restructuring Reserve, Ending balance	0
Other Restructuring [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	857
Restructuring charges	3,572
Write-offs	0
Cash payments	-4,142
Restructuring Reserve, Ending balance	287
Other Restructuring [Member] | Medical Device Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	10
Cash payments	-10
Restructuring Reserve, Ending balance	$0

Income_Taxes_Narratives_Detail

Income Taxes (Narratives) (Details) (USD $)	Jan. 02, 2015
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]
Reasonably possible reduction within next 12 months	$1
Unrecognized tax benefit	$2.10

Income_Taxes_Income_Before_Inc

Income Taxes (Income Before Income Tax Domestic And Foreign) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Income Tax Disclosure [Line Items]
Income (loss) from continuing operations before income taxes	$76,579	$48,838	$6,730
UNITED STATES [Member]
Income Tax Disclosure [Line Items]
Income (loss) from continuing operations before income taxes	56,801	42,392	36,057
International [Member]
Income Tax Disclosure [Line Items]
Income (loss) from continuing operations before income taxes	$19,778	$6,446	($29,327)

Income_Taxes_Provision_Benefit

Income Taxes (Provision Benefit of Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Current:
Federal	$16,293	$39,353	$4,747
State	1,299	1,604	381
International	2,998	1,470	668
Total	20,590	42,427	5,796
Deferred:
Federal	1,211	-28,678	6,615
State	-310	427	175
International	-370	-1,605	-1,057
Total	531	-29,856	5,733
Provision for income taxes	$21,121	$12,571	$11,529

Income_Taxes_Effect_Tax_Rate_R

Income Taxes (Effect Tax Rate Reconciliation) (Details)	12 Months Ended
	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Income Tax Disclosure [Abstract]
Statutory rate	35.00%	35.00%	35.00%
Federal tax credits	-2.10%	-7.50%	0.00%
Foreign rate differential	-4.30%	-0.70%	50.70%
Uncertain tax positions	0.60%	1.70%	-10.10%
State taxes, net of federal benefit	0.70%	2.30%	4.90%
Change in tax rate - loss of Swiss tax holiday	0.00%	0.00%	25.60%
Change in foreign tax rates	-0.60%	-3.70%	0.00%
Valuation allowance	-0.40%	0.40%	67.60%
Other	-1.30%	-1.80%	-2.40%
Effective tax rate	27.60%	25.70%	171.30%

Income_Taxes_Deferred_Tax_Asse

Income Taxes (Deferred Tax Assets and Liabilities) (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014
In Thousands, unless otherwise specified
Components of Deferred Tax Assets and Liabilities [Abstract]
Tax credits	$5,828	$6,624
Net operating loss carryforwards	6,721	9,161
Inventories	3,335	4,202
Accrued expenses	4,338	4,303
Stock-based compensation	9,341	9,194
Other	1,659	573
Gross deferred tax assets	31,222	34,057
Less valuation allowance	-10,709	-11,661
Net deferred tax assets	20,513	22,396
Property, plant and equipment	-2,646	-2,254
Intangible assets	-57,850	-57,648
Convertible subordinated notes	-5,006	-6,178
Gross deferred tax liabilities	-65,502	-66,080
Net deferred tax liability	($44,989)	($43,684)

Income_Taxes_Deferred_Tax_Asse1

Income Taxes (Deferred Tax Assets and Liabilities Current Noncurrent) (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014
In Thousands, unless otherwise specified
Components of Deferred Tax Assets and Liabilities [Abstract]
Current deferred tax asset	$6,168	$6,008
Current deferred tax liability	-588	-613
Noncurrent deferred tax asset	2,626	2,933
Noncurrent deferred tax liability	-53,195	-52,012
Net deferred tax liability	($44,989)	($43,684)

Income_Taxes_Income_Tax_Carry_

Income Taxes (Income Tax Carry Forward) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jan. 02, 2015
International [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$48	[1]
Operating Loss Carryforwards, Expiration Dates	1-Jan-15
State [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	37.6	[1]
Research Tax Credit Carryforward [Member] | US and State [Member]
Operating Loss Carryforwards [Line Items]
Tax Credit Carryforward, Amount	0.7	[1]
Investment Tax Credit Carryforward [Member] | State [Member]
Operating Loss Carryforwards [Line Items]
Tax Credit Carryforward, Amount	$5.30
[1]	The utilization of certain net operating losses and credits is subject to an annual limitation under Internal Revenue Code Section 382.

Income_Taxes_Unrecognized_Tax_

Income Taxes (Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, beginning of year	$1,858	$970	$1,580
Additions based upon tax positions related to the current year	268	325	0
Additions related to prior period tax positions	510	651	210
Reductions relating to settlements with tax authorities	-225	-88	-522
Reductions as a result of a lapse of applicable statute of limitations	0	0	-298
Balance, end of year	$2,411	$1,858	$970

Commitments_and_Contingencies_1

Commitments and Contingencies (Narratives) (Details) (USD $)	0 Months Ended	12 Months Ended			0 Months Ended
	Dec. 03, 2014	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012	Dec. 21, 2012	Jan. 29, 2015
Loss Contingencies [Line Items]
Loss Contingency, Date of Dismissal	3-Dec-14
Loss contingency, opinion of counsel		The Company has not recorded a reserve in connection with this matter since any potential loss is not probable.
Direct Operating Costs [Abstract]
Direct operating cost, royalty expense		$3,300,000	$3,500,000	$3,100,000
Standard Product Warranty Disclosure [Abstract]
Standard product warranty description		Product Warranties – The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Maximum loss per associate under stop loss insurance		225,000
Accrued self insured medical plan liability		1,800,000	1,600,000
Purchase commitment, description		Purchase Commitments – Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing needs and are fulfilled by its vendors within short time horizons. The Company enters into blanket orders with vendors that have preferred pricing and terms, however these orders are normally cancelable by us without penalty. As of January 2, 2015, the total contractual obligation related to such expenditures is approximately $36.4 million and will primarily be financed by existing cash and cash equivalents, cash generated from operations, or the Credit Facility. The Company also enters into contracts for outsourced services; however, the obligations under these contracts were not significant and the contracts generally contain clauses allowing for cancellation without significant penalty.
Purchase obligation		36,400,000
Litigation One [Member]
Loss Contingencies [Line Items]
Loss contingency, lawsuit filing date					December 21, 2012
Customer Product Liability Insurance Coverage		5,000,000
Product Liability Insurance Coverage		$10,000,000
Subsequent Event [Member]
Loss Contingencies [Line Items]
Loss Contingency, Settlement Agreement, Date						29-Jan-15

Commitments_and_Contingencies_2

Commitments and Contingencies (Change in product warranty liability) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$1,819	$2,626
Additions to warranty reserve	953	1,624
Warranty claims paid	-2,112	-2,431
Ending balance	$660	$1,819

Commitments_and_Contingencies_3

Commitments and Contingencies (Operating Lease Expenses) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Commitments and Contingencies Disclosure [Abstract]
Operating lease expense	$4,281	$4,379	$4,024

Commitments_and_Contingencies_4

Commitments and Contingencies (Minimum future estimated annual operating lease expense) (Details) (USD $)	Jan. 02, 2015
In Thousands, unless otherwise specified
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	$5,797
2016	5,952
2017	3,908
2018	3,489
2019	3,418
Thereafter	13,938
Total estimated operating lease expense	$36,502

Commitments_and_Contingencies_5

Commitments and Contingencies (Foreign currency contracts) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Foreign Currency Cash Flow Hedges [Abstract]
Reduction in Cost of Sales	($168)	($1,154)	($79)
Ineffective portion of change in fair value	0	0	0
FX Contract 1 [Member]
Derivative [Line Items]
Derivative, Type of Instrument	FX Contract
Aggregate Notional Amount	16,880
Start Date	1-Jan-15
End Date	31-Dec-15
$/Peso	0.0734
Foreign Currency Cash Flow Hedge Liability at Fair Value	$1,568
Balance Sheet Location	Accrued Expenses

Earnings_Loss_Per_Share_Detail

Earnings (Loss) Per Share (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jan. 02, 2015	Oct. 03, 2014	Jul. 04, 2014	Apr. 04, 2014	Jan. 03, 2014	Sep. 27, 2013	Jun. 28, 2013	Mar. 29, 2013	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Numerator for basic EPS:
Net income (loss)									$55,458	$36,267	($4,799)
Denominator for basic EPS:
Weighted average shares outstanding									24,825	23,991	23,584
Effect of dilutive securities stock options, restricted stock and restricted stock units									1,150	1,332	0
Denominator for diluted EPS									25,975	25,323	23,584
Basic (in dollars per share)	$0.57	$0.56	$0.50	$0.61	$0.40	$0.46	$0.41	$0.24	$2.23	$1.51	($0.20)
Diluted (in dollars per share)	$0.54	$0.54	$0.48	$0.58	$0.38	$0.44	$0.39	$0.23	$2.14	$1.43	($0.20)

Earnings_Loss_Per_Share_Antidi

Earnings (Loss) Per Share (Antidilutive Securities) (Details)	12 Months Ended
	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]
Time-vested stock options, restricted stock and restricted stock units	175,549	18,480	2,142,000
Performance-vested stock options and restricted stock units	0	0	781,000
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities			0

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax, [Abstract]
Defined Benefit Plan Liability, Beginning	($672)	($962)
Net defined benefit plan liability adjustments	-509	290
Defined Benefit Plan Liability, Ending	-1,181	-672	-962
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax [Abstract]
Cash Flow Hedges, Beginning	-468	120
Unrealized gain (loss) on cash flow hedges	-2,372	58
Realized Gain (Loss) On Foreign Currency Contracts Before Tax	-168	-1,154
Realized Gain (Loss) On Interest Rate Swaps Before Tax	450	508
Cash Flow Hedges, End	-2,558	-468	120
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax [Abstract]
Foreign Currency Translation Adjustment, Beginning	14,952	13,431
Net foreign currency translation gain (loss)	-3,502	1,521
Foreign Currency Translation Adjustment, End	11,450	14,952	13,431
Other Comprehensive Income (Loss), before Tax [Abstract]
Total Pre-Tax Amount, Beginning	13,812	12,589
Unrealized gain (loss) on cash flow hedges	-2,372	58
Realized Gain (Loss) On Foreign Currency Contracts Before Tax	-168	-1,154
Realized Gain (Loss) On Interest Rate Swaps Before Tax	450	508
Net defined benefit plan liability adjustments	-509	290
Net foreign currency translation gain (loss)	-3,502	1,521
Total Pre-Tax Amount, End	7,711	13,812	12,589
Other Comprehensive Income (Loss), Tax [Abstract]
Tax, Beginning	546	358
Unrealized gain (loss) on cash flow hedges	829	-20
Other Comprehensive Income Realized Gain Loss On Foreign Currency Hedges Tax	59	404
Realized Gain (Loss) On Interest Rate Swaps Tax	-157	-178
Net defined benefit plan liability adjustments	135	-18
Net foreign currency translation gain (loss)	0	0
Tax, End	1,412	546	358
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Net-of-Tax Amount, Beginning	14,358	12,947
Unrealized gain (loss) on cash flow hedges, net of tax	-1,543	38
Realized Gain (Loss) On Foreign Currency Contracts Net Of Tax	-109	-750
Realized Gain (Loss) On Interest Rate Swaps Net Of Tax	293	330
Net defined benefit plan liability adjustments	-374	272	1,685
Foreign currency translation gain (loss)	-3,502	1,521	1,905
Net-of-Tax Amount, End	$9,123	$14,358	$12,947

Fair_Value_Measurement_Narrati

Fair Value Measurement (Narratives) (Details) (USD $)	3 Months Ended	12 Months Ended
	Jan. 02, 2015	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Foreign currency cash flow hedge gain (loss) to be reclassified during next 12 months	$1,600,000	$1,600,000
Contingent consideration liability	0	0	840,000	1,530,000
Cost and equity method investments aggregate carrying amount	14,500,000	14,500,000	12,300,000
Cost-method investments, realized gains		3,200,000
Income (Loss) from Equity Method Investments		1,200,000	-200,000	-300,000
Impairment of Long-Lived Assets to be Disposed of	400,000		900,000	3,600,000
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)			500,000
Fair Value, Inputs, Level 2 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent consideration liability			0
Cost and equity method investments other than temporary impairment		0	500,000	100,000
Financial Milestones [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent consideration liability	0	0
Development Milestones [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent consideration liability	$0	$0
Chinese Venture Capital Fund [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Equity Method Investment, Ownership Percentage	7.40%	7.40%

Fair_Value_Measurement_Accrued

Fair Value Measurement (Accrued Contingent Consideration) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014
Contingent Consideration Liability [Roll Forward]
Contingent consideration liability, beginning balance	$840	$1,530
Fair value adjustments	-840	-690
Contingent consideration liability, ending balance	$0	$840

Fair_Value_Measurement_Assets_

Fair Value Measurement (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	$0	$840,000	$1,530,000
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	1,568,000	140,000
Interest rate swap	990,000	328,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability		0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	0	0
Interest rate swap	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability		0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	1,568,000	140,000
Interest rate swap	990,000	328,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability		840,000
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	0	0
Interest rate swap	$0	$0

Fair_Value_Measurements_Assets

Fair Value Measurements (Assets and Liabilities Measured on Non-recurring Basis) (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014
In Thousands, unless otherwise specified
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	$1,568	$140
Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held for Sale (Note 5)	1,635	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held for Sale (Note 5)		0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	1,568	140
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held for Sale (Note 5)	1,635
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held for Sale (Note 5)		$0

Business_Segment_Geographic_an2

Business Segment, Geographic and Concentration Risk Information (Narrative) (Details)	12 Months Ended
	Jan. 02, 2015
	Segment
Noncontrolling Interest [Line Items]
Number of Reportable Segments	2
QiG [Member]
Noncontrolling Interest [Line Items]
Controlling Interest, Number of Ownership Interests	3
Controlling Interest, Liability of Expenses Incurred, Percentage	100.00%
CE Approval Date	17-Jun-14
QiG [Member] | Minimum [Member]
Noncontrolling Interest [Line Items]
Controlling Interest, Ownership Percentage	89.00%
QiG [Member] | Maximum [Member]
Noncontrolling Interest [Line Items]
Controlling Interest, Ownership Percentage	100.00%

Recovered_Sheet1

Business Segment, Geographic And Concentration Risk Information (Sales by Product Lines) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Oct. 03, 2014	Jul. 04, 2014	Apr. 04, 2014	Jan. 03, 2014	Sep. 27, 2013	Jun. 28, 2013	Mar. 29, 2013	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	$169,726	$171,699	$172,081	$174,281	$176,619	$167,730	$171,331	$148,265	$687,787	$663,945	$646,177
Greatbatch Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									678,285	660,902	643,722
Greatbatch Medical [Member] | Cardiac Neuromodulation [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									321,419	325,412	306,669
Greatbatch Medical [Member] | Orthopaedic [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									147,296	130,247	122,061
Greatbatch Medical [Member] | Portable Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									69,043	78,743	81,659
Greatbatch Medical [Member] | Vascular [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									58,770	48,357	51,980
Greatbatch Medical [Member] | Energy [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									81,757	78,143	81,353
QiG [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									$9,502	$3,043	$2,455

Recovered_Sheet2

Business Segment, Geographic And Concentration Risk Information (Reconciliation of Segment Information) (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Segment Reporting Information [Line Items]
Operating income as reported	$75,654	$61,339	$25,821
Unallocated other income (expense), net	925	-12,501	-19,091
Income before provision for income taxes	76,579	48,838	6,730
Depreciation And Amortization Including Noncash Debt Amortization	38,230	42,332	58,925
Segment Reporting Information, Expenditures for Additions to Long-Lived Assets	25,646	18,174	41,166
Total assets	956,009	890,703	889,875
Greatbatch Medical [Member]
Segment Reporting Information [Line Items]
Operating income as reported	126,312	111,805	79,093
Depreciation And Amortization Including Noncash Debt Amortization	31,906	31,112	39,820
Segment Reporting Information, Expenditures for Additions to Long-Lived Assets	19,006	13,242	33,249
Total assets	761,225	758,369	779,890
QiG [Member]
Segment Reporting Information [Line Items]
Operating income as reported	-23,256	-30,484	-32,554
Depreciation And Amortization Including Noncash Debt Amortization	2,101	1,539	630
Segment Reporting Information, Expenditures for Additions to Long-Lived Assets	1,453	2,134	3,208
Total assets	76,529	56,245	57,750
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income as reported	103,056	81,321	46,539
Depreciation And Amortization Including Noncash Debt Amortization	34,007	32,651	40,450
Segment Reporting Information, Expenditures for Additions to Long-Lived Assets	20,459	15,376	36,457
Total assets	837,754	814,614	837,640
Unallocated Amount to Segment [Member]
Segment Reporting Information [Line Items]
Operating income as reported	-27,402	-19,982	-20,718
Depreciation And Amortization Including Noncash Debt Amortization	4,223	9,681	18,475
Segment Reporting Information, Expenditures for Additions to Long-Lived Assets	5,187	2,798	4,709
Total assets	$118,255	$76,089	$52,235

Recovered_Sheet3

Business Segment, Geographic And Concentration Risk Information (Sales by Geographic Information) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015	Oct. 03, 2014	Jul. 04, 2014	Apr. 04, 2014	Jan. 03, 2014	Sep. 27, 2013	Jun. 28, 2013	Mar. 29, 2013	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	$169,726	$171,699	$172,081	$174,281	$176,619	$167,730	$171,331	$148,265	$687,787	$663,945	$646,177
UNITED STATES [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									312,539	325,090	330,537
PUERTO RICO [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									127,702	117,961	105,731
BELGIUM [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									65,308	67,155	58,043
Rest Of World [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net									$182,238	$153,739	$151,866

Business_Segment_Geographic_An3

Business Segment, Geographic And Concentration Risk Information (Long lived Tangible Assets by Region) (Details) (USD $)	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
In Thousands, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	$144,925	$145,773	$150,893
UNITED STATES [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	113,851	116,484	123,104
Rest Of World [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	$31,074	$29,289	$27,789

Business_Segment_Geographic_An4

Business Segment, Geographic And Concentration Risk Information (Significant Customers) (Details)	12 Months Ended
	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	54.00%	56.00%	52.00%
Entity Wide Accounts Receivable, Major Customer, Percentage	47.00%	46.00%
Customer A [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	18.00%	20.00%	19.00%
Entity Wide Accounts Receivable, Major Customer, Percentage	4.00%	8.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	18.00%	16.00%	16.00%
Entity Wide Accounts Receivable, Major Customer, Percentage	23.00%	19.00%
Customer C [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	12.00%	13.00%	11.00%
Entity Wide Accounts Receivable, Major Customer, Percentage	8.00%	8.00%
Customer D [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	6.00%	7.00%	6.00%
Entity Wide Accounts Receivable, Major Customer, Percentage	12.00%	11.00%

Quarterly_Sales_and_Earnings_D2

Quarterly Sales and Earnings Data - Unaudited (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jan. 02, 2015	Oct. 03, 2014	Jul. 04, 2014	Apr. 04, 2014	Jan. 03, 2014	Sep. 27, 2013	Jun. 28, 2013	Mar. 29, 2013	Jan. 02, 2015	Jan. 03, 2014	Dec. 28, 2012
Quarterly Financial Information Disclosure [Abstract]
Sales	$169,726	$171,699	$172,081	$174,281	$176,619	$167,730	$171,331	$148,265	$687,787	$663,945	$646,177
Gross profit	57,214	58,118	58,470	57,596	57,385	55,877	57,302	48,749	231,398	219,313	201,649
Net income	$14,176	$14,012	$12,348	$14,922	$9,781	$11,071	$9,752	$5,663	$55,458	$36,267	($4,799)
Earnings Per Share, Basic (in dollars per share)	$0.57	$0.56	$0.50	$0.61	$0.40	$0.46	$0.41	$0.24	$2.23	$1.51	($0.20)
Earnings Per Share, Diluted (in dollars per share)	$0.54	$0.54	$0.48	$0.58	$0.38	$0.44	$0.39	$0.23	$2.14	$1.43	($0.20)

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015		Jan. 03, 2014		Dec. 28, 2012
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$2,001		$2,372		$1,930
Charged to Cost and Expenses	98		-93		484
Charged to Other Accounts	14	[1],[2]	-15	[1]	71	[1],[2]
Deductions	-702	[3]	-263	[3]	-113	[3]
Balance at End of Period	1,411		2,001		2,372
Valuation Allowance of Deferred Tax Assets [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	11,661		12,768		7,775
Charged to Cost and Expenses	-729	[4]	-1,263	[4]	5,145	[4]
Charged to Other Accounts	0	[1]	32	[1]	124	[1]
Deductions	-223	[4],[5]	124	[4]	-276	[5]
Balance at End of Period	$10,709		$11,661		$12,768
[1]	Includes foreign currency translation effect.
[2]	Balance recorded as a part of our 2014 acquisition of Centro de Construcción de Cardioestimuladores del Uruguay and our 2012 acquisition of NeuroNexus Technologies, Inc.
[3]	Accounts written off.
[4]	Valuation allowance recorded in the provision for income taxes for certain net operating losses and tax credits. The net decrease in allowance in 2014 and 2013 primarily relates to the use of net operating loss carryforwards.
[5]	Primarily relates to return to provision adjustments for prior years.